Annual Report

MEDPLUS HEALTH SERVICES PRIVATE LIMITED
Standalone Financial Statements for period 01/04/2016 to 31/03/2017
[400100] Disclosure of general information about company

Unless otherwise specified, all monetary values are in INR
01/04/2016 01/04/2015
to to
31/03/2017 31/03/2016
MEDPLUS HEALTH SERVICES
Name of company PRIVATE LIMITED
Corporate identity number U85110TG2006PTC051845
Permanent account number of entity AAECM9412H
707, 7th Floor,
5-9-13 Taramandal
Address of registered office of company Commercial Complex,
Saifabad Hyderabad Hyderabad Telangana 500004 India
Commercial and
Type of industry Industrial
Date of board meeting when final accounts were approved 30/05/2017
Period covered by financial statements 01-04-2016 To 31-03-2017 01-04-2015 To 31-03-2016
Date of start of reporting period 01/04/2016 01/04/2015
Date of end of reporting period 31/03/2017 31/03/2016
Nature of report standalone consolidated Standalone
Content of report Financial Statements
Description of presentation currency INR
Level of rounding used in financial statements Actual
Type of cash flow statement Indirect Method
Whether company is maintaining books of account and other
No
relevant books and papers in electronic form
Disclosure of principal product or services [Table] ..(1)

Types of principal product or services [Axis] Column 1
01/04/2016
to
31/03/2017
Disclosure of general information about company [Abstract]
Disclosure of principal product or services [Abstract]
Disclosure of principal product or services [LineItems]
Product or service category (ITC 4 digit) code 9993
Medical laboratory
Description of product or service category services
Turnover of product or service category 2,16,48,642
Highest turnover contributing product or service (ITC 8 digit) code 99931950
Medical laboratory
Description of product or service services
Turnover of highest contributing product or service 2,16,48,642
MEDPLUS HEALTH SERVICES PRIVATE LIMITED Standalone Financial Statements for period 01/04/2016 to 31/03/2017
[400400] Disclosures - Directors report
Details of directors signing board report [Table] ..(1)

Directors signing board report [Axis] Column 1 Column 2
01/04/2016 01/04/2016
to to
31/03/2017 31/03/2017
Details of signatories of board report [Abstract]
Details of directors signing board report [LineItems]
Name of director signing board report [Abstract]
First name of director GANGADI CHERUKUPALLI
Middle name of director MADHUKAR BHASKAR
Last name of director REDDY REDDY
Designation of director Managing Director Director
Director identification number of director 00098097 00926550
Date of signing board report 31/12/2017 31/12/2017
2

01/04/2016
to
31/03/2017
Textual information (1)
Disclosure in board of directors report explanatory [TextBlock] [See below]
Description of state of companies affair [See below]
5 TRANSFER TO
RESERVES: The Company
doesn’t have any profits
as on 31st March, 2017, the
Disclosure relating to amounts if any which is proposed to carry to any directors have
reserves transferred the loss
component after tax to
reserves during the
financial year under
review.
4 DIVIDEND: Your
Directors doesn’t
Disclosures relating to amount recommended to be paid as dividend propose any dividend
during the financial year
under review.
Details regarding energy conservation [See below]
Details regarding technology absorption [See below]
Details regarding foreign exchange earnings and outgo [See below]
Disclosures in director’s responsibility statement [See below]
Details of material changes and commitment occurred during period Textual information (7)
affecting financial position of company [See below]
Particulars of loans guarantee investment under section 186 [TextBlock] [See below]
Particulars of contracts/arrangements with related parties under section Textual information (9)
188(1) [TextBlock] [See below]
Whether there are contracts/arrangements/transactions not at arm's
No
length basis
Whether there are material contracts/arrangements/transactions at
No
arm's length basis
Disclosure of extract of annual return as provided under section 92(3) Textual information (10)
[TextBlock] [See below]
Disclosure of statement on declaration given by independent directors Textual information (11)
under section 149(6) [TextBlock] [See below]
Disclosure for companies covered under section 178(1) on
directors appointment and remuneration including other matters [See below]
provided under section 178(3) [TextBlock]
Disclosure of statement on development and implementation of risk Textual information (13)
management policy [TextBlock] [See below]
Details on policy development and implementation by company on
corporate social responsibility initiatives taken during year NA
[TextBlock]
Disclosure as per rule 8(5) of companies accounts rules 2014 [TextBlock]
Disclosure of financial summary or highlights [TextBlock] [See below]
Disclosure of change in nature of business [TextBlock] [See below]
Details of directors or key managerial personnels who were Textual information (16)
appointed or have resigned during year [TextBlock] [See below]
Disclosure of companies which have become or ceased to be its
subsidiaries, joint ventures or associate companies during NA
year [TextBlock]
Details relating to deposits covered under chapter v of companies act Textual information (17)
t h e
details of deposits which
are not in compliance with
Details of deposits which are not in compliance with requirements
the requirements of
of chapter v of act [TextBlock] Chapter V of the
A c t :
Nil.
3
Details of significant and material orders passed by

regulators or courts or tribunals impacting going concern [See below]
status and company’s operations in future [TextBlock]
Details regarding adequacy of internal financial controls with Textual information (19)
reference to financial statements [TextBlock] [See below]
Disclosure of appointment and remuneration of managerial personnels Textual information (20)
Number of meetings of board [pure] 0
4
Disclosure in board of directors report explanatory [Text Block]

Board’s report
To
The Members
MedPlus Health Services Private Limited
Hyderabad.
Your Directors have pleasure in presenting the Annual Report together with the Financial Statement for the financial year from 1st April, 2016 to
31st March, 2017 along with the Report of Directors including annexure thereto and Report of Auditor's thereon.
1. STATEMENT OF AFFAIRS:
The Company’s financial performance for the financial year ended as on 31st March, 2017 is summarized below:
Amount (In Rs)
Particulars 31st March, 2017 31st March, 2016
Income from Operations (Including other Income) 21,648,642 22,439,160
Total Expenses 44,875,208 75,536,193
Profit/Loss before Tax (19,498,545) (43,035,759)
Profit/Loss after Tax (19,498,545) (43,035,759)
Balance carried to Balance sheet (19,498,545) (43,035,759)
5
1.1 PERFORMANCE AND FINANCIAL HIGHLIGHTS:
During the financial year ended as on 31st March, 2017, the Company recorded a total revenue of 2016.49 Lakhs (Previous financial year
224.39 Lakhs) and recorded net loss (after considering an amount towards depreciation in accordance with provisions of Schedule II of the
Companies Act, 2013) of 194.99 Lakhs (Previous Year loss of 430.36 Lakhs).
1.2 FUTURE OUTLOOK:
The Company has made significant progress in terms of revenue. The revenue has reached Rs. 21,648,642/- from Rs. 22,439,160/-. The losses
have declined considerably since the last financial year.
Your Company is considering expanding its capacities from the existing level to further improve the performance.
2 EVENTS SUBSEQUENT TO THE DATE OF FINANCIAL STATEMENTS TILL THE DATE OF DIRECTORS REPORT:
There are no significant material changes and commitments affecting financial position between 31st March, 2017 and the date of Board’s Report
except an investment of Rs. 7.00 Crores (Approx) in the Equity shares of the Company on 15th December, 2017.
3 CHANGE IN THE NATURE OF BUSINESS, IF ANY:
Your Company has not changed the nature of Business during the financial year under review.
4 DIVIDEND:
Your Directors doesn’t propose any dividend during the financial year under review.
5 TRANSFER TO RESERVES:
The Company doesn’t have any profits as on 31st March, 2017, the directors have transferred the loss component after tax to reserves during the
financial year under review.
6
6 BOARD MEETINGS:
5 (Five) Board Meetings were held during the year, the details of the same are given below:
S. No. Date of Board Meetings
1. 22nd April, 2016
2. 28th May, 2016
3. 06th September, 2016
4. 14th November, 2016
5. 14th March, 2017
Number of Board Meetings attended by each Director during the financial year 2016 - 17:
S. No. Name of Director Designation No. of Board Meetings attended
1. Mr. G. Madhukar Reddy Managing Director 5
2. Mr. Cherukupalli Bhaskar Reddy Director 5
3. Mr. Roy Edwin Campbell II Nominee Director 1
4. Ms. Sudha Ravi Nominee Director 2
7
7 COMMITTEE MEETINGS:
The following is the Committee constituted by the Company:
Audit Committee: Audit Committee of the Company has met thrice on 28th May, 2016, 6th September, 2016 & 14th November, 2016.
Composition Designation No. of Meetings entitled to attend No. of Meetings attended
Mr. G. Madhukar Reddy Member 3 3
Mr. Roy Edwin Campbell II Member 3 1
Ms. Sudha Ravi Member 3 2
*Mr. C. Bhaskar Reddy Member 1 1
* Mr. C. Bhaskar Reddy was inducted as the member of the Audit Committee with effect from 14th November, 2016.
8 DIRECTORS AND KEY MANAGERIAL PERSONNEL:
Following are the Directors and Key Managerial Personnel of the Company as on date:
S. No. Name of Director Designation
i. Mr. G. Madhukar Reddy Managing Director
8
ii. Mr. Cherukupalli Bhaskar Reddy Director
iii. Mr. Roy Edwin Campbell II Nominee Director
iv. Ms. Sudha Ravi Nominee Director
v. Mr. Atul Kumar Agarwal Chief Financial Officer
vi. Mr. Parag Kumar Jain Company Secretary
Appointment :
There were no appointments in the Company during the financial year 2016 – 17.
Resignation :
There were no resignations from the Company during the financial year 2016 – 17.
9 STATEMENT ON DECLARATION GIVEN BY THE INDEPENDENT DIRECTORS:
Since the Company is a Listed Private Company, appointment of Independent directors as per sub section (4) of section 149 of the Companies
Act, 2013, is not mandatory to your Company.
10 CHANGES IN SHARE CAPITAL:
During the year under review, your company has not issued any shares and there were no allotments.
11 DIRECTOR’S RESPONSIBILITY STATEMENT:
9
Pursuant to Section134 (5) of the Companies Act, 2013, the Directors confirm that:
i. In the preparation of the annual accounts for the year ended 31st March, 2017 the applicable accounting standards had been followed
along with proper explanation relating to material departures;
ii. the directors had selected such accounting policies and applied them consistently and made judgments and estimates that are
reasonable and prudent so as to give a true and fair view of the state of affairs of the company at the end of the financial year 31st March, 2017
and of the profits of the company for that period;
iii. the directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the
provisions of this Act for safeguarding the assets of the company and for preventing and detecting fraud and other irregularities;
iv. the directors had prepared the annual accounts for the period ended 31st March, 2017 on a going concern basis.
v. that the directors have laid down internal controls to be followed by the Company and that such internal financial controls are adequate
and were operating effectively;
vi. the directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were
adequate and operating effectively.
12 NAMES OF THE SUBSIDIARIES/ASSOCIATES/JOINT VENTURES:
The following are the Subsidiaries of your Company:
· Optival Health Solutions Private Limited
· Ritemed Pharma Retail Private Limited
· MHS Pharmaceuticals Private Limited
10
· PanIndia Pharma Distributors Private Limited
· Ritecure Pharma Private Limited
· Medsupply Distributors Private Limited
The following are the step subsidiaries of your Company:
· Sai Sridhar Pharma Private Limited
· Venkata Krishna Enterprises Private Limited
· Shri Banashankari Pharma Private Limited
· Deccan Medisales Private Limited
· Sidson Pharma Distributors Private Limited
13 PERFORMANCE & FINANCIAL POSITION OF SUBSIDIARIES:
M/s. Optival Health Solutions Private Limited: The following table indicates the financial position of the Company:
Amount (In Rs)
Income from Operations (Including other Income) 19,152,390,881 16,670,419,101
Total Expenses 18,864,748,682 16,561,873,212
Profit/Loss before Tax 287,642,199 108,545,889
Profit/Loss after Tax 181,584,341 59,094,882
Balance carried to Balance sheet 181,584,341 59,094,882
11
M/s. Ritemed Pharma Retail Private Limited: The following table indicates the financial position of the Company:
Amount (In Rs)
Total Expenses 4,942,805,924 4,254,332,190
M/s. MHS Pharmaceuticals Private Limited: The following table indicates the financial position of the Company:
Amount (In Rs)
Total Expenses 507,236,416 348,332,411
12
M/s. PanIndia Pharma Distributors Private Limited: The following table indicates the financial position of the Company:
Amount (In Rs)
Income from Operations (Including other Income) 8,347 187,715
Total Expenses 40,243 289,945
Profit/Loss before Tax (31,806) (102,230)
Profit/Loss after Tax (31,993) (140,485)
Balance carried to Balance sheet (31,993) (140,485)
M/s. Ritecure Pharma Private Limited: The following table indicates the financial position of the Company:
Amount (In Rs)
Income from Operations (Including other Income) - -
Total Expenses 36034 33,704
Profit/Loss before Tax (36034) (33,704)
Profit/Loss after Tax (36034) (33,704)
Balance carried to Balance sheet (36034) (33,704)
13
M/s. Medsupply Distributors Private Limited: The following table indicates the financial position of the Company:
Amount (In Rs)
Income from Operations (Including other Income) 41,618 1,042,789
Total Expenses 412,105 1,662,093
Profit/Loss before Tax (370,487) (619,304)
Profit/Loss after Tax (370,487) (619,304)
Balance carried to Balance sheet (370,487) (619,304)
M/s. Sai Sridhar Pharma Private Limited: The following table indicates the financial position of the Company:
Amount (In Rs)
Total Expenses 1,309,054,042 1,120,511,580
Profit before Tax 7,749,248 11,637,785
Profit after Tax 4,951,281 7,523,849
Balance carried to Balance Sheet 4,951,281 7,523,849
M/s. Venkata Krishna Enterprises Private Limited: The following table indicates the financial position of the Company:
14
Amount (In Rs)
Total Expenses 1,699,524,527 1,397,771,352
Profit after Tax 7,606,795 6,639,441
M/s. Shri Banashankari Pharma Private Limited: The following table indicates the financial position of the Company:
Amount (In Rs)
Total Expenses 263,199,924 136,640,612
Profit before Tax 1,014,904 (1724)
Profit after Tax 887,102 (1724)
Balance carried to Balance Sheet 887,102 (1724)
M/s. Deccan Medisales Private Limited: The following table indicates the financial position of the Company:
Amount (In Rs)
15
Income from Operations (Including other Income) 1,094,811,584 769,080,522
Total Expenses 1,085,132,342 761,608,535
Profit after Tax 6,664,637 5,090,501
M/s. Sidson Pharma Distributors Private Limited: The following table indicates the financial position of the Company:
Amount (In Rs)
Total Expenses 387,340,012 230,602,629
Profit before Tax (5421950) (9,624,148)
Profit after Tax (5421950) (9,624,148)
Balance carried to Balance sheet (5421950) (9,624,148)
14 EXTRACT OF ANNUAL RETURN:
As required pursuant to Section 92(3) of the Companies Act, 2013 and rule 12(1) of the Companies (Management and Administration) Rules,
2014, an extract of Annual Return in Form MGT-9 as a part of this Report is annexed to this report as ( Annexure - I).
16
15 CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION AND FOREIGN EXCHANGE EARNINGS &OUTGO:
As required by the provisions of Companies Act, 2013, the relevant information pertaining to conservation of energy, technology absorption and
foreign exchange earnings and outgo are given under:
15.1 CONSERVATION OF ENERGY:
· Steps taken on Conservation of Energy and impact thereof: Conservation of energy is an ongoing process in the Company. Every effort is
made towards optimum utilization of energy. Efforts are also directed towards eliminating wastage in all areas of operations.
· Steps taken by the company for utilizing alternate sources of energy: Nil.
· Capital investment on energy conservation equipment: There are no substantial additional investments and proposals for reduction in
energy consumption at present. The same will be undertaken as and when necessary by the Company.
15.2 TECHNOLOGY ABSORPTION:
i) Efforts were made towards technology absorption: Nil
ii) benefits derived as a result of the above efforts, e.g. product improvement, cost reduction, product development, import substitution: Nil
iii) In case of imported technology (imported during the last 3 years reckoned from the beginning of the financial year), following information
may be furnished:
a) Details of technology imported - Nil
b) Year of import - Nil
c) Whether the technology been fully absorbed - Nil
d) If not fully absorbed, areas where absorption has not taken
e) place, and the reasons therefore - Nil
iv) Expenditure incurred on Research and Development - Nil
15.3 FOREIGN EXCHANGE EARNINGS & OUTGO:
During the year under review, the Company has the following Foreign Exchange Earnings & Outgo:
17
(Amount in Rs)
S. No. Particulars As on 31st March, 2017 As on 31st March, 2016
1. Foreign Exchange Earnings Nil Nil
2. Foreign Exchange Outgo Nil Nil
16 DETAILS RELATING TO DEPOSITS:
The Company doesn’t have any deposits as covered under chapter V of the Companies Act, 2013, following are the disclosures:
· Deposits accepted during the year : Nil
· remained unpaid or unclaimed as at the end of the year : Nil
· whether there has been any default in repayment of deposits or payment of interest thereon during the year and if so, number of such cases
and the total amount involved -
(i) at the beginning of the year; Nil
(ii) maximum during the year; Nil
(iii) at the end of the year; Nil
the details of deposits which are not in compliance with the requirements of Chapter V of the Act : Nil.
17 EXPLANATIONS OR COMMENTS BY THE BOARD ON EVERY QUALIFICATION, RESERVATION OR ADVERSE REMARK

OR DISCLAIMER MADE BY THE AUDITOR IN HIS REPORT:
1. Auditor’s Comments:
In our opinion and according to the information and explanation given to us, the Company has utilised the money raised by way of term loans
during the previous year 2014-15 for the purposes for which they were raised, except for:
18
Amount Subsequently rectified

Nature of Fund Raised Details of Default (Reason/Delay)
(Rs.) (Yes/No) and details
Term Loans - raised in the form of Funds used for working capital requirements
55,662,608 No
non- convertible debentures /funding of losses of the Company.
Also idle/ surplus funds which were not required for immediate utilization have been gainfully invested in liquid investments payable on demand.
The maximum amount of idle/surplus funds invested during the year was Rs. 17,267,483, of which Rs. 2,607,402 (lying in current accounts) was
outstanding at the end of the year. According to the information and explanations given by the management, the Company has not raised any
money way of initial public offer / further public offer.
Management’s Reply: Because of non-availability of funds, the Company was compelled to utilise the
funds meant for investment purpose in order to manage the day to day operations of the Company.
18 DETAILS IN RESPECT OF FRAUDS REPORTED BY AUDITORS UNDER SUB - SECTION (12) OF SECTION 143:
The Auditors have not reported any offence involving fraud committed against the Company by the officers or employees of the Company under
sub section (12) of section 143 to the Audit Committee or the Board.
19 SIGNIFICANT & MATERIAL ORDERS PASSED BY THE REGULATORS, COURTS AND TRIBUNALS IMPACTING THE
GOING CONCERN STATUS AND COMPANY’S OPERATIONS IN FUTURE:
There are no significant and material orders that were passed by the regulators or courts or tribunals against your Company.
20 ADEQUACY OF INTERNAL FINANCIAL CONTROLS WITH REFERNECE TO THE FINANCIAL STATEMENTS:
Your Company has effective ‘internal financial controls’ that ensure an orderly and efficient conduct of its business, including adherence to
company’s policies, safeguarding of its assets, prevention and detection of frauds and errors, accuracy and completeness of the accounting
records, and timely preparation of reliable financial information.
While these controls have been effective through-out the year, these are reviewed on a periodic basis for any changes/ modifications to align to
business needs.
19
21 CRITERIA FOR DETERMINING QUALIFICATIONS, POSITIVE ATTRIBUTES AND INDEPENDENCY OF A DIRECTOR:
Since no Independent Directors are on Board of the Company, the aforesaid statement is not applicable.
21.1 APPOINTMENT AND QUALIFICATIONS:
The general terms of appointment of Directors, KMP and Senior Managerial personnel is provided hereunder:
The Remuneration Committee identifies and ascertains the integrity, qualification, expertise and experience of the person for appointment as
Director, KMP or at Senior Management level and recommend to the Board for his / her appointment.
The Remuneration Committee has discretion to decide whether qualification, expertise and experience possessed by a person are sufficient /
satisfactory for the concerned position.
21.2 TERM/TENURE:
v Managing Director/Whole-Time Director/Manager (Managerial Person):
The Company has a policy not to appoint or re-appoint any person as Managerial Person for a term exceeding 5 years at a time.
21.3 REMUNERATION:
The Company’s Remuneration Strategy is designed to attract and retain quality talent that gives its business a competitive advantage and enables
the Company to achieve its objectives. The Company’s Remuneration Strategy, whilst focusing on remuneration and related aspects of
performance management, is aligned with and reinforces the employee value proposition of a superior quality of work life, that includes an
enabling work environment, an empowering and engaging work culture and opportunities to learn and grow. The Compensation approach
endeavours to align each employee with the Company’s goals.
v Remuneration to Key Managerial Personnel (“KMP”):
20
a) Remuneration of KMP is determined, recommended by the Remuneration Committee and is approved by the Board. Remuneration of the
Managing Director / Whole time Director is also subject to the approval of the shareholders.
b) Remuneration is reviewed and revised periodically, when such a revision is warranted by the market.
c) Apart from fixed elements of remuneration and benefits, the KMP are also eligible for Variable Pay / Performance Bonus which is linked to
their individual performance and the overall performance of the Company.
v Remuneration of employees other than KMP:
a) Remuneration of employees other than KMP is approved by the Board.
b) Remuneration is reviewed and revised periodically, when such a revision is warranted by the market. The quantum of revision is linked to
market trends, the competitive context of the Company’s business, as well as the track record of the individual employee.
22 ANNUAL EVALUATION OF PERFORMANCE BY THE BOARD:
Pursuant to the provisions of the Companies Act, 2013, evaluation of all Board members, annual performance evaluation of its own performance,
as well as the evaluation of the working of its Committees of the Board is led by the Chairman of the Board with specific focus on the
performance and effective functioning of the Board.
The evaluation process also considers the time spent by each of the Board members, core competencies, personal characteristics, accomplishment
of specific responsibilities and expertise.
23 RATIO OF REMUNERATION OF EACH OF THE DIRECTOR TO THE MEDIAN EMPLOYEE’S REMUNERATION:
As per Annexure.
24 PARTICULARS OF LOANS, GUARANTEES OR INVESTMENTS MADE BY THE COMPANY:
21
Particulars relating to loan or guarantee to any person or body corporate made by the Company during the Financial Year pursuant to Section 186
of Companies Act, 2013 is as follows:
Investment in Equity shares of its Subsidiaries
(Rs. In Millions)
S. No. Name of the Subsidiary 31st March, 2017 31st March, 2016
1. Optival Health Solutions Private Limited 1,499.45 1,499.45
2. Ritemed Pharma Retail Private Limited 230.00 230.00
3. MHS Pharmaceuticals Private Limited 0.099 0.099
4. PanIndia Pharma Distributors Private Limited 43.60 43.60
5. Ritecure Pharma Private Limited 0.10 0.10
6. Medsupply Distributors Private Limited 125.77 90.77
7. Sai Sridhar Pharma Private Limited (through its Subsidiary) 0.24 0.24
8. Venkata Krishna Enterprises Private Limited (through its Subsidiary) 0.18 0.18
9. Shri Banashankari Pharma Private Limited (through its Subsidiary) 2.10 -
10. Deccan Medisales Private Limited (through its Subsidiary) 2.10 2.10
11. Sidson Pharma Distributors Private Limited 2 .01 2 .01
Loans given
22
The Company has not given any loan during this financial year.
Corporate Guarantee given
(Rs. In Millions)
2. Optival Health Solutions Private Limited 1050.00 1050.00
25 RISK MANAGEMENT:
As a diversified enterprise, your Company continues to focus on a system-based approach to business risk management. The management of risk
is embedded in the corporate strategies of developing a portfolio of world-class businesses that best match organizational capability with market
opportunities, focusing on building distributed leadership and succession planning processes, nurturing specialism and enhancing organisational
capabilities through timely developmental inputs.
The Company has initiated procedure for risk assessment and its minimization.
26 PARTICULARS OF EMPLOYEES:
Pursuant to Rule 5 pursuant to the Companies (Appointment and Remuneration Managerial Personnel) Rule, 2014 of the Companies Act, 2013,
there are no employees who are in receipt of remuneration exceeding Rs. 1,02,00,000/- or more per annum or Rs. 8,50,000/ or more per month or
where employed for a part of the year during the financial year under review.
27 SECRETARIAL AUDITORS:
The Board has appointed M/s R & A Associates, a firm of practicing Company Secretaries, Hyderabad as the Secretarial Auditor to conduct
Secretarial Audit of the Company for the financial year ended 31st March, 2017 in compliance with the provisions of Section 204 of the
Companies Act, 2013.
23
The report of the Secretarial Audit Report by M/s. R & A Associates, in Form MR-3 is enclosed as ( Annexure - II) to this Report.
28 STATUTORY AUDITORS:
M/s. S. R. Batliboi & Associates LLP, (FRN: 101049W) Chartered Accountants are the Statutory Auditors of the Company. As per the provisions
of the Companies Act, 2013, it is recommended to ratify the appointment of auditor till the conclusion of next Annual General Meeting of the
Company.
29 RELATED PARTY TRANSACTIONS:
The contracts/arrangements with related parties as specified in sub section (1) of section 188 of the Companies Act, 2013 during the financial year
2014-15, is attached as Form AOC-2 to this report as ( Annexure - III).
30 ANNUAL DISCLOSURE AS PER DEBENTURE LISTING AGREEMENT:
S. No. Particulars Amount
1. Loans and advances in the nature of loans to subsidiaries Nil
2. Loans and advances in the nature of loans to Associates Nil
3. Loans and advances in the nature of loans to Firm/Companies in which directors are interested Nil
31 DISCLOSURE UNDER THE SEXUAL HARASSMENT OF WOMAN AT WORKPLACE (PREVENTION, PROHIBITION AND
REDRESSAL) ACT, 2013:
As required under the Harassment Act, the following is a summary of sexual harassment during the financial year 2016 - 2017:
24
S. No. Particulars Remarks
1. Number of sexual harassment complaints received in a year. Nil
2. Number of complaints disposed off during the year. Nil
3. Number of cases pending for more than 90 days. Nil
4. Number of awareness programs or workshops against sexual harassment conducted during the year. Nil
5. Nature of action taken by the employer or district officer with respect to the cases. Nil
32 CHANGE IN DEPRECIATION ACCOUNTING POLICY IN ACCORDANCE WITH COMPANIES ACT, 2013.
There was a change in the depreciation accounting policy of the Company due to implementation of Companies Act, 2013.
33 VIGIL MECHANISM/WHISTLE BLOWER POLICY:
The Board of Directors of the Company have adopted Whistle Blower Policy. This policy is formulated to provide an opportunity to employees
and an avenue to raise concerns and to access in good faith the Audit Committee, to the highest possible standards of ethical, moral and legal
business conduct and its commitment to open communication, in case they observe unethical and improper practices or any other wrongful
conduct in the Company, to provide necessary safeguards for protection of employees from reprisals or victimization and to prohibit managerial
personnel from taking any adverse personnel action against those employees.
34 DETAILS OF ADEQUACY OF INTERNAL FINANCIAL CONTROLS
The Company has in place adequate internal financial controls with reference to financial statements. During the year, such controls were tested
and no reportable material weakness in the design or operation were observed
35 CHANGE IN THE NATURE OF BUSINESS
There has been no change in the nature of business of the Company during the financial year under review.
25
36 DECLARATION WITH THE COMPLIANCE WITH THE CODE OF CONDUCT BY MEMBERS OF THE BOARD AND SENIOR
MANAGEMENT PERSONNEL
The Company has complied with the requirements about code of conduct for Board members and Sr. Management Personnel .
37 ACKNOWLEDGEMENTS:
The Board wishes to place on record its grateful thanks for the assistance and support extended by all Government Authorities, Banks,
shareholders and consultants of the Company.
Your directors express their appreciation for the dedicated and sincere services rendered by the employees of the Company.
BY ORDER OF THE BOARD
CIN: U85110AP2006PTC051845
Place: Hyderabad G. Madhukar Reddy C. Bhaskar Reddy
Date : 31/12/2017 Director Director
DIN: 00098097 DIN: 00926550
26
Description of state of companies affair

1.1 PERFORMANCE AND FINANCIAL HIGHLIGHTS: During the financial year ended as on 31st March, 2017, the Company recorded a total
revenue of 2016.49 Lakhs (Previous financial year 224.39 Lakhs) and recorded net loss (after considering an amount towards depreciation in
accordance with provisions of Schedule II of the Companies Act, 2013) of 194.99 Lakhs (Previous Year loss of 430.36 Lakhs). 1.2 FUTURE
OUTLOOK: The Company has made significant progress in terms of revenue. The revenue has reached Rs. 21,648,642/- from Rs. 22,439,160/-.
The losses have declined considerably since the last financial year. Your Company is considering expanding its capacities from the existing level
to further improve the performance.
Details regarding energy conservation

15.1 CONSERVATION OF ENERGY: • Steps taken on Conservation of Energy and impact thereof: Conservation of energy is an ongoing
process in the Company. Every effort is made towards optimum utilization of energy. Efforts are also directed towards eliminating wastage in all
areas of operations. • Steps taken by the company for utilizing alternate sources of energy: Nil. • Capital investment on energy conservation
equipment: There are no substantial additional investments and proposals for reduction in energy consumption at present. The same will be
undertaken as and when necessary by the Company.
Details regarding technology absorption

15.2 TECHNOLOGY ABSORPTION: i) Efforts were made towards technology absorption: Nil ii) benefits derived as a result of the above
efforts, e.g. product improvement, cost reduction, product development, import substitution: Nil iii) In case of imported technology (imported
during the last 3 years reckoned from the beginning of the financial year), following information may be furnished: a) Details of technology
imported - Nil b) Year of import - Nil c) Whether the technology been fully absorbed - Nil d) If not fully absorbed, areas where absorption has not
taken e) place, and the reasons therefore - Nil iv) Expenditure incurred on Research and Development - Nil
Details regarding foreign exchange earnings and outgo

15.3 FOREIGN EXCHANGE EARNINGS & OUTGO: During the year under review, the Company has the following Foreign Exchange
Earnings & Outgo: (Amount in Rs) S. No. Particulars As on 31st March, 2017 As on 31st March, 2016 1. Foreign Exchange Earnings Nil Nil 2.
Foreign Exchange Outgo Nil Nil
Disclosures in director’s responsibility statement

11 DIRECTOR’S RESPONSIBILITY STATEMENT: Pursuant to Section134 (5) of the Companies Act, 2013, the Directors confirm that: i. In
the preparation of the annual accounts for the year ended 31st March, 2017 the applicable accounting standards had been followed along with
proper explanation relating to material departures; ii. the directors had selected such accounting policies and applied them consistently and made
judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the company at the end of the
financial year 31st March, 2017 and of the profits of the company for that period; iii. the directors had taken proper and sufficient care for the
maintenance of adequate accounting records in accordance with the provisions of this Act for safeguarding the assets of the company and for
preventing and detecting fraud and other irregularities; iv. the directors had prepared the annual accounts for the period ended 31st March, 2017
on a going concern basis. v. that the directors have laid down internal controls to be followed by the Company and that such internal financial
controls are adequate and were operating effectively; vi. the directors had devised proper systems to ensure compliance with the provisions of all
applicable laws and that such systems were adequate and operating effectively.
27
Details of material changes and commitment occurred during period affecting financial position of company
2 EVENTS SUBSEQUENT TO THE DATE OF FINANCIAL STATEMENTS TILL THE DATE OF DIRECTORS REPORT: There are no
significant material changes and commitments affecting financial position between 31st March, 2017 and the date of Board’s Report except an
investment of Rs. 7.00 Crores (Approx) in the Equity shares of the Company on 15th December, 2017.
28
Particulars of loans guarantee investment under section 186 [Text Block]

1 PARTICULARS OF LOANS, GUARANTEES OR INVESTMENTS MADE BY THE COMPANY:
Particulars relating to loan or guarantee to any person or body corporate made by the Company during the Financial Year pursuant to Section 186
of Companies Act, 2013 is as follows:
Investment in Equity shares of its Subsidiaries
(Rs. In Millions)
1. Optival Health Solutions Private Limited 1,499.45 1,499.45
3. MHS Pharmaceuticals Private Limited 0.099 0.099
4. PanIndia Pharma Distributors Private Limited 43.60 43.60
5. Ritecure Pharma Private Limited 0.10 0.10
6. Medsupply Distributors Private Limited 125.77 90.77
7. Sai Sridhar Pharma Private Limited (through its Subsidiary) 0.24 0.24
8. Venkata Krishna Enterprises Private Limited (through its Subsidiary) 0.18 0.18
9. Shri Banashankari Pharma Private Limited (through its Subsidiary) 2.10 -
10. Deccan Medisales Private Limited (through its Subsidiary) 2.10 2.10
11. Sidson Pharma Distributors Private Limited 2 .01 2 .01
29
Loans given
The Company has not given any loan during this financial year.
Corporate Guarantee given
(Rs. In Millions)
2. Optival Health Solutions Private Limited 1050.00 1050.00
30
Particulars of contracts/arrangements with related parties under section 188(1) [Text Block]
Form No. AOC-2
(Pursuant to clause (h) of sub-section (3) of section 134 of the Act and Rule 8(2) of the Companies
(Accounts) Rules, 2014)
Form for disclosure of particulars of con tracts/arrangements entered into by the company with related parties referred to in sub-section (1) of
section 188 of the Companies Act, 2013 including certain arms length transactions under third proviso thereto
1. Details of contracts or arrangements or transactions not at arm’s length basis
Date on
which the
special
resolution
Justification
Salient terms of was
Name(s) of Duration of for entering Date(s)
the contracts or Amount passed in
the related Nature of contracts the contracts into such of
arrangements paid as general
SN party and /arrangements/trans / contracts or approval
or transactions advances, meeting
nature of actions arrangements arrangements by the
including the if any as
relationship / transactions or Board
value, if any required
transactions
under first
proviso to
Section
188
Nil
2. Details of material contracts or arrangement or transactions at arm’s length basis
Nature of Duration of the Salient terms of the contracts Date(s) of Amount

Name(s) of the
contracts / contracts / or arrangements or approval by paid as
SN related party and
arrangements / arrangements / transactions including the the Board, if advances,
nature of relationship
transactions transactions value, if any any if any
31
Optival Health
Management
Solutions Private Providing stewardship
1 services Ongoing - Nil
Limited (Subsidiary activities.
rendered
Company)
Ritemed Pharma
Management
Retail Private Limited - Providing stewardship
2 services Ongoing - Nil
(Subsidiary activities -
rendered
Company)
MHS Management
- Providing stewardship
3 Pharmaceuticals services Ongoing - Nil
activities
Private Limited rendered
32
Disclosure of extract of annual return as provided under section 92(3) [Text Block]
Form No. MGT-9
EXTRACT OF ANNUAL RETURN
as on the financial year ended on 31st

March, 2017
[Pursuant to section 92(3) of the

Companies Act, 2013 and rule 12(1) of the
Companies (Management and

Administration) Rules, 2014]
I. REGISTRATION AND OTHER

DETAILS:
i. CIN :
Registration date
ii. :
Name of the Company

iii. :
Category/Sub Category of the Company

iv. :
Address of the Registered Office and Contact details

v. :
vi.
Whether Listed Company :
Name, Address and contact details of Registrar and Transfer

vii. :
Agent, if any
II. PRINCIPAL BUSINESS ACTIVITIES OF THE COMPANY:
All the business activities contributing 10%

or more of the total turnover of the
Company shall be stated:
33
NIC Code of the Product/

SI. No. Name and Description of main products / services
service
1. Pathological Laboratories Testing and Hospital and Medical Care 86905
PARTICULARS OF HOLDING, SUBSIDIARY AND ASSOCIATE

III.
COMPANIES:
S. No Name and address of the Company CIN/GLN
Optival Health Solutions Private Limited

Address: H. No: 11-6-56, Survey No: 257 & 258/1, Opp:IDPL
1 U85110TG2005PTC046821
Railway Siding Road,(Moosapet),Kukatpally, Hyderabad,
Telangana - 500037.
Ritemed Pharma Retail Private Limited

2 U52399TG2009PTC064130
Telangana - 500037.
MHS Pharmaceuticals Private Limited

3 U24233TG2008PTC059624
Telangana - 500037.
PanIndia Pharma Distributors Private Limited

4 Address: D. No.8-3-166/1/A, Ground and First Floor, Erragadda, U24232TG2007PTC055895
Telangana - 500018.
Ritecure Pharma Private Limited

5 U24232TG2008PTC058385
Telangana - 500037.
Medsupply Distributors Private Limited

Address: Ground Floor,12-7-20/64/2, Survey No. 793, Goods
6 U24239TG2007PTC052676
Shed Road, Moosapet, Kukatpally, Hyderabad, Telangana -
500018.
Sai Sridhar Pharma Private Limited

7 Address: D. No.8-3-166/1/A, Ground and First Floor, Erragadda, U24232TG2007PTC055902
Telangana – 500 018.
Venkata Krishna Enterprises Private Limited

8 Address: H. No.1-1-650/17, Gandhi Nagar, New Bakaram, U51909TG2010PTC071012
Hyderabad – 500 080.
Deccan Medisales Private Limited

Address: M. No: 562/105/1, Portion I, 1st Main Road, S R
9 U51397KA2011PTC059204
Compound, South City Road, Bannerughatta Road,
Bangalore,560076.
Shri Banashankari Pharma Private Limited

Address: M. No: 562/105/1, Portion II, 1st Main Road, S R
10 U74900KA2014PTC074302
Compound, South City Road, Bannerughatta Road,
Bangalore,560076.
Sidson Pharma Distributors Private Limited

11 Address: Plot No:5,First Floor,Opp:IDPL Company Balanagar U74900TG2014PTC092145
Hyderabad, 500037.
34
IV. SHARE HOLDING PATTERN (Equity Share Capital Breakup as

percentage of Total Equity)
i) Category-wise Share Holding
No. of Shares held at the

Category of Shareholders No. of Shares held at the beginning of the year
end of the year
Demat Physical Total
A.Promoters
(1) Indian
a) Individual/HUF 21945 11,335
b) Central Govt. 0 0
c) State Govt. 0 0
d)Bodies Corporate 0 0
e)Bank/FI's 0 0
f) Any Other 0 0
Sub-Total (A)(1):- 21,945 11,335
(2) Foreign
a) NRI's-Individuals 0 0
b) Other Individuals 0 0
c)Bodies Corporate 0 0
d)Bank/FI's 0 0
e) Any Other 0 0
Sub-Total (A)(2):- 0 0
Total Shareholding of Promoter (A)=

(A)(1)+(A)(2)
21,945 11,335 33,280
B) Public Shareholding
1. Institutions
a) Mutual Funds 0
b) Banks/FI's 0
c) Central Govt. 0
d) State Govt. 0
e) Ventrure Capital Funds 0
f) Insurance Companies 0
g) FII's 0
35
h) Foreiegn Venture Capital 0
i)Others (Specify) 0
Sub-Total (B)(1):- 0
2. Non-Institutions
a) Bodies Corporate
i) Indian 18834
ii) Overseas 87340
b) Individuals 1132
i) Individual Shareholders holding nominal

0 15,496
share capital in upto Rs. 1 Lakh
ii) Individual Shareholders holding nominal

0 0
share capital in excess of Rs. 1 Lakh
c) Others (specify) 0 4599
Sub-Total (B)(2):- 107,306 37,320
Total Public Shareholding

107,306 37,320
(B)=(B)(1)+(B)(2)
C. Shares held by Custodians for ADR's &

0 0
GDR's
Grand Total
129,251 48,655
(A+B+C)
ii) Shareholding of Promoters
Shareholding
Shareholding
Shareholder's at the
S.No. at the end of
Name beginning of
the year
the year
% of Shares % of Shares
% of total
% of total Shares of Pledged / No. of Pledged /
No. of Shares Shares of the
the company encumbered Shares encumbered
company
to total to total
G. Madhukar
1 33,280 18.71 0.00 33,280
Reddy
2 C. Bhaskar Reddy 0 0.00 0.00 0
Total 33,280 18.71 0.00 33,280
(iii) Change in Promoters' Shareholding (

please specify, if there is no change)
Shareholding Cumulative
at the Shareholding
S.No.
beginning of during the
the year year
36
% of Total % of Total
No. of Shares of No. of Shares of
Shares the Shares the
Company Company
At the beginning of NO
1
the year CHANGE
Date wise Increase

/ Decrease in
Promoters
Shareholding
2
during the year
(specifying the
reasons for
increase/decrease
At the end of the

3
year
Total
(iv) Shareholding Pattern of top ten

Shareholders (other than Directors, Promoters
and Holders of GDRs and ADRs):
Shareholder's at the Shareholding
S.No.
Name beginning of during the
the year year
MKCP Direct
1 Investments
(Mauritius) IV Ltd
Company Company
At the beginning of
87340 49.09 87340 49.09
the year
Date wise Increase

/ Decrease in
Promoters
Shareholding
- - - -
during the year
(specifying the
reasons for
increase/decrease
At the end of the

- - 87340 49.09
year
Total 87340 49.09

S.No.
the year year
IL & FS Trust
Company Limited
2 (As trustee of TVS
Sriram Growth
Company Company
Fund I)
37
At the beginning of
18834 10.59 18834 10.59
the year
Date wise Increase

/ Decrease in
Promoters
Shareholding
- - - -
during the year
(specifying the
reasons for
increase/decrease
At the end of the

- - 18834 10.59
year
Total 18834 10.59

S.No.
the year year
IL & FS Trust
Company Limited
3 (As trustee of India
Venture Trust -
Company Company
Fund-1)
At the beginning of
16173 9.09 16173 9.09
the year
Date wise Increase

/ Decrease in
Promoters
Shareholding
- - - -
during the year
(specifying the
reasons for
increase/decrease
At the end of the

- - 16173 9.09
year
Total 16173 9.09

S.No.
the year year
G.Madhukar Reddy
( As trustee of
4 MedPlus
Employees Benefit
Company Company
Fund)
At the beginning of
9673 5.44 9673 5.44
the year
38
Date wise Increase

/ Decrease in
Promoters
Shareholding
- - - -
during the year
(specifying the
reasons for
increase/decrease
At the end of the

- - 9673 5.44
year
Total 9673 5.44

S.No.
the year year
Varalakshmi No. of Shares of No. of Shares of
5
Koppolu Shares the Shares the
Company Company
At the beginning of
5823 3.27 5823 3.27
the year
Date wise Increase

/ Decrease in
Promoters
Shareholding
- - - -
during the year
(specifying the
reasons for
increase/decrease
At the end of the

- - 5823 3.27
year
Total 5823 3.27

S.No.
the year year
Regal Corporate No. of Shares of No. of Shares of
6
Advisors Pvt Ltd Shares the Shares the
Company Company
At the beginning of
714 0.40 714 0.40
the year
Date wise Increase

/ Decrease in
Promoters
Shareholding
39
during the year
- - - -
40
(specifying the
reasons for
increase/decrease
At the end of the

- - 714 0.40
year
Total 714 0.40

S.No.
the year year
Vivek Mundra ( No. of Shares of No. of Shares of
7
HUF) Shares the Shares the
Company Company
At the beginning of
714 0.40 714 0.40
the year
Date wise Increase

/ Decrease in
Promoters
Shareholding
- - - -
during the year
(specifying the
reasons for
increase/decrease
At the end of the

- - 714 0.40
year
Total 714 0.40

S.No.
the year year
8 Sridhar Kotagiri
Company Company
At the beginning of
593 0.33 593 0.33
the year
Date wise Increase

/ Decrease in
Promoters
Shareholding
- - - -
during the year
(specifying the
reasons for
increase/decrease
At the end of the
41
year - - 593 0.33
Total 593 0.33

S.No.
the year year
9 N.Lakshminarayana
Company Company
At the beginning of
539 0.30 539 0.30
the year
Date wise Increase

/ Decrease in
Promoters
Shareholding
- - - -
during the year
(specifying the
reasons for
increase/decrease
At the end of the

- - 539 0.30
year
Total 539 0.30

S.No.
the year year
10 J.Kondal Rayudu
Company Company
At the beginning of
420 0.24 420 0.24
the year
Date wise Increase

/ Decrease in
Promoters
Shareholding
- - - -
during the year
(specifying the
reasons for
increase/decrease
At the end of the

- - 420 0.24
year
Total 420 0.24
42

S.No.
the year year
11 Tera Padmamma
Company Company
At the beginning of
420 0.24 420 0.24
the year
Date wise Increase

/ Decrease in
Promoters
Shareholding
- - - -
during the year
(specifying the
reasons for
increase/decrease
At the end of the

- - 420 0.24
year
Total 420 0.24

S.No.
the year year
12 Ajay Kumar Bannai
Company Company
At the beginning of
359 0.20 359 0.20
the year
Date wise Increase

/ Decrease in
Promoters
Shareholding
- - - -
during the year
(specifying the
reasons for
increase/decrease
At the end of the

- - 359 0.20
year
Total 359 0.20
(v) Shareholding of Directors and Key

Managerial Personnel:
43
S.No. Name beginning of during the

the year year
G. Madhukar No. of Shares of No. of Shares of
1
Reddy Shares the Shares the
Company Company
At the beginning of
33280 18.71 33280 18.71
the year
Date wise Increase

/ Decrease in
Promoters
Shareholding
- - - -
during the year
(specifying the
reasons for
increase/decrease
At the end of the

3 - - 33280 18.71
year

S.No.
the year year
2 C. Bhaskar Reddy
Company Company
At the beginning of
0 0.00 0 0.00
the year
Date wise Increase

/ Decrease in
Promoters
Shareholding
- - - -
during the year
(specifying the
reasons for
increase/decrease
At the end of the

3 - - 0 0.00
year

S.No.
the year year
Roy Edwin No. of Shares of No. of Shares of
3
Campbell II Shares the Shares the
Company Company
At the beginning of
- - - -
the year
44
Date wise Increase

/ Decrease in
Promoters
Shareholding - - - -
during the year
(specifying the
reasons for
increase/decrease
At the end of the

3 - - - -
year

S.No.
the year year
4 Sudha Ravi
Company Company
At the beginning of
- - - -
the year
Date wise Increase

/ Decrease in
Promoters
Shareholding
- - - -
during the year
(specifying the
reasons for
increase/decrease
At the end of the

3 - - - -
year

S.No.
the year year
5 Atul Kumar Agarwal
Company Company
At the beginning of
- - - -
the year
Date wise Increase

/ Decrease in
Promoters
Shareholding
- - - -
during the year
(specifying the
reasons for
increase/decrease
At the end of the

3 - - - -
year
45

S.No.
the year year
6 Parag Kumar Jain
Company Company
At the beginning of
- - - -
the year
Date wise Increase

/ Decrease in
Promoters
Shareholding
- - - -
during the year
(specifying the
reasons for
increase/decrease
At the end of the

3 - - - -
year
V. INDEBTNESS
Indebtedness of the Company including

interest outstanding/accrued but not due for
payment
Secured Loans Unsecured Total

Deposits
excluding deposits Loans (NCD) Indebtedness
Indebtedness at the beginning of the financial

year
i) Principal Amount 0 430,270,000 0 430,270,000
ii) Interest due but not paid 0 0 0 0
iii) Interest accrued but not due 0 0 0 0
Total (i+ii+iii) 430,270,000 430,270,000
Changes in Indebtedness during the year
Addition 0 0 0 0
Reduction 0 0 0 0
Net Change 0 0 0 0
Indebtedness at the end of the financial year
i) Principal Amount 0 430,270,000 0 430,270,000
ii) Interest due but not paid 0 0 0 0
iii) Interest accrued but not due 0 0 0 0
Total (i+ii+iii) 0 430,270,000 0 430,270,000
46
VI. REMUNERATION TO DIRECTORS AND

KEY MANAGERIAL PERSONNEL:
A. Remuneration to Managing Director,

Whole-Time Director and/or Manager:
Particulars of Name of Total

S.No.
Remuneration Director Amount
G. Madhukar Reddy
1 Gross salary 4000000 4000000
(a) Salary as per

provisions
contained in section
17(1) of the
Income-tax Act,
1961
(b) Value of
perquisites u/s
17(2) Income-tax
Act, 1961
(c) Profits in lieu of

salary under
section 17(3)
Income-tax Act,
1961
2 Stock Option
Sweat Equity
3
Shares
4 Commission
- as %
-others
5 Others
Total (A) 4000000 4000000
Ceiling as per the

N/A N/A N/A
Act
B. Remuneration to other Directors:
Particulars of Name of Total

S.No.
Remuneration Director Amount
C. Bhaskar
Reddy
Independent
1 - -
Directors
•Fee for attending

Board Committee - -
Meetings
•Commission - -
•Others - -
47
Total (1) - -
Other
2 Non-Executive - -
Directors
•Fee for attending

Board Committee - -
Meetings
•Commission - -
•Others 5,939,590 5,939,590
Total (2) -
Total (B)(1)+(2) -
Total Managerial
Remuneration (A + 5,939,590 5,939,590
B)
Overall Ceiling as
N/A
per the Act
C. Remuneration to Key Managerial

Personnel Other than MD/MANAGER/WTD
Name of Key
Particulars of Total
S.No. Managerial
Remuneration Amount
Person
Mr. Atul Kumar

Mr. Parag Jain [CS]
Agarwal [CFO]
1 Gross salary
(a) Salary as per

provisions
contained in section
17(1) of the
Income-tax Act,
1961
(b) Value of
perquisites u/s
17(2) Income-tax
Act, 1961
(c) Profits in lieu of

salary under
section 17(3)
Income-tax Act,
1961
2 Stock Option
Sweat Equity
3
Shares
4 Commission
- as %
-others
5 Others
48
Total
VII.
PENALITIES/PUNISHMENT/COMPOUNDING
OF OFFENCES: Nil
Section of The Brief Details of Appeals

Type
Companies Act Description Authority Made
Penalty/Punishment/ Compounding of Fees

[RD/NCLT/Court]
Imposed
A. COMPANY
Penalty - - - - -
Punishment - - - -
Compounding - - - -
B. DIRECTORS
Penalty - - - - -
Punishment - - - - -
Compounding - - - - -
C. OTHER OFFICERS IN DEFAULT
Penalty - - - - -
Punishment - - - - -
Compounding - - - - -
G. Madhukar C. Bhaskar
Reddy Reddy
Managing
Director
Director
DIN: DIN:
00098097 00926550
Disclosure of statement on declaration given by independent directors under section 149(6) [Text Block]
1 STATEMENT ON DECLARATION GIVEN BY THE INDEPENDENT DIRECTORS:
Since the Company is a Listed Private Company, appointment of Independent directors as per sub section (4) of section 149 of the Companies
Act, 2013, is not mandatory to your Company.
49
Disclosure for companies covered under section 178(1) on directors appointment and remuneration including other
matters provided under section 178(3) [Text Block]
Appointment :
Resignation :
50
Disclosure of statement on development and implementation of risk management policy [Text Block]
1 RISK MANAGEMENT:
As a diversified enterprise, your Company continues to focus on a system-based approach to business risk management. The management of risk
is embedded in the corporate strategies of developing a portfolio of world-class businesses that best match organizational capability with market
opportunities, focusing on building distributed leadership and succession planning processes, nurturing specialism and enhancing organisational
capabilities through timely developmental inputs.
The Company has initiated procedure for risk assessment and its minimization.
Disclosure of financial summary or highlights [Text Block]

1. STATEMENT OF AFFAIRS:
The Company’s financial performance for the financial year ended as on 31st March, 2017 is summarized below:
Amount (In Rs)
Total Expenses 44,875,208 75,536,193
Profit/Loss before Tax (19,498,545) (43,035,759)
Profit/Loss after Tax (19,498,545) (43,035,759)
Balance carried to Balance sheet (19,498,545) (43,035,759)
51
Disclosure of change in nature of business [Text Block]

1 CHANGE IN THE NATURE OF BUSINESS, IF ANY:
Your Company has not changed the nature of Business during the financial year under review
52
Details of directors or key managerial personnels who were appointed or have resigned during year [Text Block]
Appointment :
Resignation :
53
Details relating to deposits covered under chapter v of companies act [Text Block]
1 DETAILS RELATING TO DEPOSITS:
The Company doesn’t have any deposits as covered under chapter V of the Companies Act, 2013, following are the disclosures:
· Deposits accepted during the year : Nil
· remained unpaid or unclaimed as at the end of the year : Nil
· whether there has been any default in repayment of deposits or payment of interest thereon during the year and if so, number of such cases
and the total amount involved -
(i) at the beginning of the year; Nil
(ii) maximum during the year; Nil
(iii) at the end of the year; Nil
Details of significant and material orders passed by regulators or courts or tribunals impacting going concern status
and company’s operations in future [Text Block]
1 SIGNIFICANT & MATERIAL ORDERS PASSED BY THE REGULATORS, COURTS AND TRIBUNALS IMPACTING THE
GOING CONCERN STATUS AND COMPANY’S OPERATIONS IN FUTURE:
There are no significant and material orders that were passed by the regulators or courts or tribunals against your Company.
Details regarding adequacy of internal financial controls with reference to financial statements [Text Block]
1 ADEQUACY OF INTERNAL FINANCIAL CONTROLS WITH REFERNECE TO THE FINANCIAL STATEMENTS:
Your Company has effective ‘internal financial controls’ that ensure an orderly and efficient conduct of its business, including adherence to
company’s policies, safeguarding of its assets, prevention and detection of frauds and errors, accuracy and completeness of the accounting
records, and timely preparation of reliable financial information.
While these controls have been effective through-out the year, these are reviewed on a periodic basis for any changes/ modifications to align to
business needs.
54
Disclosure of appointment and remuneration of managerial personnels [Text Block]

Appointment :
Resignation :
55
[400200] Disclosures - Auditors report
Details regarding auditors [Table] ..(1)

Auditors [Axis] Column 1
01/04/2016
to
31/03/2017
Details regarding auditors [Abstract]
Details regarding auditors [LineItems]
Category of auditor Auditors firm
S.R.Batliboi & Co.
Name of audit firm LLP
NAVNEETRAI
Name of auditor signing report GOPALRAI
KABRA
Firms registration number of audit firm 101049W
Membership number of auditor 102328
PLOT NO 18 OVAL
OFFICE ILABS C E
N T R E
SOFTWARE
Address of auditors UNITS LAYOUT
HITEC CITY
MADHAPUR
HYDERABAD
500081 INDIA
Permanent account number of auditor or auditor's firm ABSFS4151K
SRN of form ADT-1 C26270124
Date of signing audit report by auditors 30/05/2017
Date of signing of balance sheet by auditors 30/05/2017
56
Disclosure of auditor's qualification(s), reservation(s) or adverse remark(s) in auditors' report [Table] ..(1)
Auditor's
Auditor's qualification(s), reservation(s) or adverse remark(s) in auditors' report [Axis] favourable remark
[Member]
01/04/2016
to
31/03/2017
Disclosure of auditor's qualification(s), reservation(s) or adverse remark(s) in auditors' report [Abstract]
Disclosure of auditor's qualification(s), reservation(s) or adverse remark(s) in auditors' report
[LineItems]
Disclosure in auditors report relating to fixed assets Favourable Remark
(i) (a) The company
has maintained
proper records
showing full
Disclosure relating to quantitative details of fixed assets particulars including
quantitative details
and situation of
Property, Plants and
equipments.
Textual information
Disclosure relating to physical verification and material discrepancies of fixed assets (21) [See below]
Textual information
Disclosure relating to title deeds of immovable properties (22) [See below]
(ii) The Management
has conducted
physical verification
of inventory at
reasonable intervals
Disclosure in auditors report relating to inventories during the year and
no material
discrepancies were
noticed on such
physical verification.
Textual information
Disclosure in auditors report relating to loans (23) [See below]
Textual information
Disclosure in auditors report relating to compliance with Section 185 and 186 of Companies Act, 2013 (24) [See below]
(v) The Company
has not accepted any
Disclosure in auditors report relating to deposits accepted deposits from the
Public.
Textual information
Disclosure in auditors report relating to maintenance of cost records (25) [See below]
Textual information
Disclosure in auditors report relating to statutory dues [TextBlock] (26) [See below]
Textual information
Disclosure in auditors report relating to default in repayment of financial dues (27) [See below]
Disclosure in auditors report relating to public offer and term loans used for purpose for which Textual information
those were raised (28) [See below]
Disclosure in auditors report relating to fraud by the company or on the company by its officers Textual information
or its employees reported during period (29) [See below]
Textual information
Disclosure in auditors report relating to managerial remuneration (30) [See below]
(xii) In our opinion,
the company is not a
nidhi company.
Therefore, the
provisions of clause
Disclosure in auditors report relating to Nidhi Company 3 (xii) of the order
are not applicable to
the company and
hence not
commented upon.
Textual information
Disclosure in auditors report relating to transactions with related parties (31) [See below]
Disclosure in auditors report relating to preferential allotment or private placement of shares or Textual information
convertible debentures (32) [See below]
Disclosure in auditors report relating to non-cash transactions with directors or persons connected Textual information
with him (33) [See below]
57
(xvi) According to
the information and
explanations given
to us, the provisions
Disclosure in auditors report relating to registration under section 45-IA of Reserve Bank of India
of section 45-IA of
Act, 1934 the Reserve Bank of
India Act, 1934 are
not applicable to the
Company.

01/04/2016
to
31/03/2017
Disclosure in auditor’s report explanatory [TextBlock] [See below]
Whether companies auditors report order is applicable on company Yes
Whether auditors' report has been qualified or has any reservations or
No
contains adverse remarks
Disclosure relating to physical verification and material discrepancies of fixed assets

(b) All Property, Plants and Equipment have not been physically verified by the management during the year and there is a regular program of
verification which, in our opinion, is reasonable having regard to the size of the company and the nature of its assets. No material discrepancies
were noticed on such verification.
Disclosure relating to title deeds of immovable properties

(c) According to the information and explanations given by the management, there are no Immovable properties, included in property, plant and
equipment of the company and accordingly, the requirements under paragraph 3(i)(c) of the Order are not applicable to the Company.
Disclosure in auditors report relating to loans

(iii) according to the information and explanations given to us,the company has not granted any loans , secured or unsecured to companies, firms.
Limited liability partnerships or other parties covered in the register maintained under section 189 of the Companies Act, 2013, Accordingly, the
provisions of clause 3(iii) (a), (b) and (c) of the order are not applicable to the Company and hence not commented upon.
Disclosure in auditors report relating to compliance with Section 185 and 186 of Companies Act, 2013
(iv) In our opinion and according to the information and explanations given to us, provisions of section 185 and 186 of the Companies Act, 2013
in respect of loans and advances given, investments made and, guarantees, and securities given have been complied with by the company.
Disclosure in auditors report relating to maintenance of cost records

(vi) To the best of our knowledge and as explained, the Central Government has not specified the maintenance of cost records under clause 148(1)
of the companies Act, 2013, for the services of the Company.
58
Disclosure in auditors report relating to statutory dues [Text Block]

(i) (a) The company is regular in depositing with appropriate authorities undisputed
Statutory dues including provident fund , employees’ State insurance. Income tax
, service tax., cess and other material statutory dues applicable to it . the
provisions relating to sales –tax, value added tax, duty of custom and duty of exercise are not applicable to the company.
(b) according to the information and explanations given to us, no disputed amounts payable in respect of provident fund , employees’ State
insurance. Income tax
, service tax., cess and other material statutory dues were outstanding, at the year
end, for a period of more than six months from the date they became payable . the
(c) according to the information and explanations given to us , there are no dues of income tax, service tax and cess which have not been
deposited on account of any dispute. The provisions relating to sales-tax, value added tax, duty of custom and duty of excise are not applicable to
the company.
Disclosure in auditors report relating to default in repayment of financial dues

(viii) Based on our audit procedures and according to the information and explanations given by the management, we are of the opinion that the
company has not defaulted in repayment of dues to debenture holders. The Company did not have any outstanding dues in respect of financial
institution, bank or government during the year.
Disclosure in auditors report relating to public offer and term loans used for purpose for which those were raised
(ix) In our opinion and according to the information and explanations given to us, the company has utilized the money raised by way of the term
loans during the previous year 2014-15 for the purposes for which they were raised, except for: Nature of the Fund Raised Details of default
(Reason/delay) Amount (Rs.) Subsequently rectified (Yes/No) and Details Term Loans – raised in the form of non-convertible debentures. Funds
used for working capital requirements/funding of losses of the Company 55,662,608 No. Also idle/surplus funds which were not required for
immediate utilization have been gainfully invested in liquid investments payable on demand, The maximum amount of idle/surplus funds invested
during the year was Rs.17,267,483, of which Rs,2,607,402 (lying in current accounts) was outstanding at the end of the year. According to the
information and explanations given by the management, the company has not raised any money way of initial public offer/further public offer.
Disclosure in auditors report relating to fraud by the company or on the company by its officers or its employees
reported during period
(x) Based upon the audit procedures performed for the purpose of reporting the true and fair view of the financial statements and according to the
information and explanations given by the management, we report that no fraud by the company or on the company by the officers and employees
of the company has been noticed or reported during the year.
59
Disclosure in auditors report relating to managerial remuneration

(xi) According to the information and explanations given by the management, the provisions of section 197 read with Schedule V of the Act is not
applicable to the company and hence reporting under clause 3(xi) are not applicable and hence not commented upon.
Disclosure in auditors report relating to transactions with related parties

(xiii) According to the information and explanation given by the management, transactions with the related parties are in compliance with section
177 and 188 of companies Act, 2013 where applicable and the details have been disclosed in the notes to the financial statements, as required by
the applicable accounting standards.
Disclosure in auditors report relating to preferential allotment or private placement of shares or convertible
debentures
(xiv) According to the information and explanations given to us and on an overall examination of the balance sheet, the company has not made
any preferential allotment or private placement of shares or fully or partly convertible debentures during the year under review and hence,
reporting requirements under clause 3(xiv) are not applicable to the company and,not commented upon.
Disclosure in auditors report relating to non-cash transactions with directors or persons connected with him
(xv) According to the information and explanations given by the management, the company has not entered into any non-cash transactions with
directors or persons connected with him as referred to in section 192 of companies Act, 2013.
60
Disclosure in auditor’s report explanatory [Text Block]
INDEPENDENT AUDITOR’S REPORT
To the Members of Medplus Health Services Private Limited
Report on the Financial Statements:
We have audited the accompanying financial statements of Medplus Health Services Private Limited (“the Company”), which comprise the
Balance Sheet as at March 31, 2017, the Statement of Profit and Loss and the Cash Flow Statement for the period then ended, and a summary of
significant accounting policies and other explanatory information.
Management’s Responsibility for the Financial Statements:
The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Companies Act, 2013 ("the Act") with respect to
the preparation of these financial statements that give a true and fair view of the financial position, financial performance and cash flows of the
Company in accordance with accounting principles generally accepted in India, including the Accounting Standards specified under Section 133
of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014 and the companies (Accounting Standards) Amendment Rules,2016. This
responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the
assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting
policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal
financial control that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation
and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.
Auditor’s Responsibility:
61
Our responsibility is to express an opinion on these financial statements based on our audit. We have taken into account the provisions of the Act,
the accounting and auditing standards and matters which are required to be included in the audit report under the provisions of the Act and the
Rules made thereunder. We conducted our audit in accordance with the Standards on Auditing,issued by the Institute of Chartered Accountants of
India as specified under section 143(10) of the Act.. Those Standards require that we comply with ethical requirements and plan and perform the
audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.
An audit involves performing audit procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The
procedures selected depend on the auditor’s judgment, including the assessment of the risks of material misstatement of the financial statements,
whether due to fraud or error. In making those risk assessments, the auditor considers internal financial control relevant to the Company’s
preparation of the financial statement that give true and fair view in order to design audit procedures that are appropriate in the circumstances. An
audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of the accounting estimates made by
Company’s Directors, as well as evaluating the overall presentation of the financial statements.
We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the financial
statements.
Opinion:
In our opinion and to the best of our information and according to the explanations given to us, the Standalone Financial statements give the
information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally
accepted in India of the State of affairs of the Company as at March 31, 2017, its loss, and its cash flows for the year ended on that date:
Report on Other Legal and Regulatory Requirements:
1. As required by the Companies (Auditor’s Report) Order, 2016 (“the Order”) issued by the Central Government of India in terms of sub-section
(11) of section 143 of the Act, we give in the Annexure-1 a statement on the matters specified in the paragraphs 3 and 4 of the Order.
2. As required by section 143(3) of the Act, we report that:
a. we have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the
purpose of our audit;
62
b. in our opinion proper books of account as required by law have been kept by the Company so far as it appears from our examination of
those books;
c. the Balance Sheet, and Statement of Profit and Loss and Cash Flow Statement dealt with by this Report are in agreement with the books of
account and the Companies (Accounting Standards) Amendments Rules 2016;
d. in our opinion, the aforesaid Standalone Financial Statements comply with the Accounting Standards specified under section 133 of the
Companies Act, 2013 read with rule 7 of the Companies (Accounts)Rules,2014.
e. on the basis of written representations received from the directors as on March 31, 2017, and taken on record by the Board of Directors,
none of the directors is disqualified as on March 31, 2017, from being appointed as a director in terms of section 164(2) of Act.
f. With respect to the adequacy internal financial controls system over financial reporting of the company and the operating effectiveness of
such controls, refer to our separate report in ‘ Annexure 2” to this report.
g. With respect to the other matters to be included in auditor’s report in accordance with Rule 11 of Companies (Audit and Auditors),Rules
2014, in our opinion and to the best of our information and according to the explanation given to us;
i. The Company does not have any pending litigation of its financial position in its financial Position
ii. The Company did not have any long term contracts including derivative contracts for which there were any material
foreseeable losses.
iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the
Company; and
iv. The Company has provided requisite disclosure in Note 31 to these Standalone financial statements as to the holding
of Specified Bank Notes (SBNs) on November 8,2016 and December 30,2016 as well as dealing in Specified Bank Notes during the period From
November 8,2016 to December 30,2016. Based on our audit procedures and relying on management representations, except for the segregation
between SBNs and other denominations as more fully described in Note 31 to these Standalone financial statements upon which are unable to
comment on in the absence of necessary details, we report that the amounts disclosed in the said notes is in accordance with the books of account
maintained by the company and produced to us for verification.
63
For S.R. Batliboi & Associates LLP
Chartered Accountants
ICAI Firm Registration Number: 101049W/E30004
Per Navneet Rai Kabra
Partner
Membership Number : 102328
Place of Signature: Hyderabad
Date : May 30, 2017
Annexure 1 referred to in our report of even date
Re: Medplus Health Seevices Private Limited (“ the Company”)
(i) (a) The company has maintained proper records showing full particulars including quantitative details and situation of Property,
Plants and equipments.
64
(b) All Property, Plants and Equipment have not been physically verified by the management during the year and there is a regular program of
verification which, in our opinion, is reasonable having regard to the size of the company and the nature of its assets. No material discrepancies
were noticed on such verification.
(c) According to the information and explanations given by the management, there are no Immovable properties, included in property, plant and
equipment of the company and accordingly, the requirements under paragraph 3(i)(c) of the Order are not applicable to the Company.
(ii) The Management has conducted physical verification of inventory at reasonable intervals during the year and no material
discrepancies were noticed on such physical verification.
(iii) according to the information and explanations given to us,the company has not granted any loans , secured or unsecured to
companies, firms. Limited liability partnerships or other parties covered in the register maintained under section 189 of the Companies Act, 2013,
Accordingly, the provisions of clause 3(iii) (a), (b) and (c) of the order are not applicable to the Company and hence not commented upon.
(iv) In our opinion and according to the information and explanations given to us, provisions of section 185 and 186 of the Companies
Act, 2013 in respect of loans and advances given, investments made and, guarantees, and securities given have been complied with by the
company.
(v) The Company has not accepted any deposits from the Public.
(vi) To the best of our knowledge and as explained, the Central Government has not specified the maintenance of cost records under
clause 148(1) of the companies Act, 2013, for the services of the Company.
(vii) (a) The company is regular in depositing with appropriate authorities undisputed
Statutory dues including provident fund , employees’ State insurance. Income tax
, service tax., cess and other material statutory dues applicable to it . the
(b) according to the information and explanations given to us, no disputed amounts payable in respect of provident fund , employees’ State
insurance. Income tax
, service tax., cess and other material statutory dues were outstanding, at the year
end, for a period of more than six months from the date they became payable . the
(c) according to the information and explanations given to us , there are no dues of income tax, service tax and cess which have not been
deposited on account of any dispute. The provisions relating to sales-tax, value added tax, duty of custom and duty of excise are not applicable to
the company.
65
(viii) Based on our audit procedures and according to the information and explanations given by the management, we are of the opinion that
the company has not defaulted in repayment of dues to debenture holders. The Company did not have any outstanding dues in respect of financial
institution, bank or government during the year.
(ix) In our opinion and according to the information and explanations given to us, the company has utilized the money raised by way of
the term loans during the previous year 2014-15 for the purposes for which they were raised, except for:
Amount Subsequently rectified

Nature of the Fund Raised Details of default (Reason/delay)
(Rs.) (Yes/No) and Details
Term Loans – raised in the form of Funds used for working capital
55,662,608 No.
non-convertible debentures. requirements/funding of losses of the Company
Also idle/surplus funds which were not required for immediate utilization have been gainfully invested in liquid investments payable on demand,
The maximum amount of idle/surplus funds invested during the year was Rs.17,267,483, of which Rs,2,607,402 (lying in current accounts) was
outstanding at the end of the year. According to the information and explanations given by the management, the company has not raised any
money way of initial public offer/further public offer.
(x) Based upon the audit procedures performed for the purpose of reporting the true and fair view of the financial statements and
according to the information and explanations given by the management, we report that no fraud by the company or on the company by the
officers and employees of the company has been noticed or reported during the year.
(xi) According to the information and explanations given by the management, the provisions of section 197 read with Schedule V of the
Act is not applicable to the company and hence reporting under clause 3(xi) are not applicable and hence not commented upon.
(xii) In our opinion, the company is not a nidhi company. Therefore, the provisions of clause 3 (xii) of the order are not applicable to the
company and hence not commented upon.
(xiii) According to the information and explanation given by the management, transactions with the related parties are in compliance with
section 177 and 188 of companies Act, 2013 where applicable and the details have been disclosed in the notes to the financial statements, as
required by the applicable accounting standards.
(xiv) According to the information and explanations given to us and on an overall examination of the balance sheet, the company has not
made any preferential allotment or private placement of shares or fully or partly convertible debentures during the year under review and hence,
reporting requirements under clause 3(xiv) are not applicable to the company and,not commented upon.
(xv) According to the information and explanations given by the management, the company has not entered into any non-cash transactions
with directors or persons connected with him as referred to in section 192 of companies Act, 2013.
(xvi) According to the information and explanations given to us, the provisions of section 45-IA of the Reserve Bank of India Act, 1934 are
not applicable to the Company.
66
Partner
Date : May 30, 2017
ANNEXURE 2 TO THE INDEPENDENT AUDITOR’S REPORT OF EVEN DATE ON THE STADALONE FINANCIAL STATEMENTS OF
Report on the Internal Financial Control under Clause (i) of Sub-section 3 of section 143 of the Companies Act, 2013 (“the Act”)
we have audited the Internal financial controls over financial reporting of Medplus Health Services Private Limited (“ the company”) as of March
31,2017 in conjunction with our audit of the Standalone financial statements of the company for the year ended on that date.
Management’s Respnsibility for Internal Financial Controls
The Company’s Management is responsible for establishing and maintaining internal financial controls based on the internal control over
financial reporting criteria established by the company considering the essential components of internal control stated in the Guidance Note on
Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India. These responsibilities
includes the design, implementations and maintenance of adequate internal financial controls that were operating effectively for ensuring the
orderly and efficient conduct of its business, including adherence to the company’s policies, the safeguarding of its assets, the prevention and
detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial
information, as required under the Companies Act,2013.
67
Auditor’s Responsibility
Our responsibility is to express an opinion on the Company’s internal financial controls over financial reporting based on our audit. We conducted
our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the “ Guidance Note”) and the
standards on Auditing as specified under section 143(10) of the companies Act,2013, to the extent applicable to an audit of internal financial
controls, both applicable to an audit of Internal Financial Controls and both issued by the institute of Chartered Accountants of India. Those
Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance
about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated
effectively in all material respects.
Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial
reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of
internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and
operating effectiveness of internal control based on the assessed risk of Material misstatement of the financial statements, whether due to fraud or
error.
We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the internal financial
controls system over financial reporting.
Meaning of Internal Financial Controls over Financial Reporting
A Company’s internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of
financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.
A company’s internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of
records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide
reasonable assurance of transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted
accounting principles , and that receipts and expenditures of the company are being made only in accordance with authorizations of management
and directors of the company ; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or
dispositions of the company’s assets that could have a material effect on the financial statements.
Inherent Limitations of Internal Financial Controls over Financing Reporting
Because of the Inherent Limitations of Internal financial controls over financial reporting, including the possibility of collusion or improper
management override of controls, Material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation
of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial
reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may
deteriorate.
Opinion
68
In our opinion, the company has, in all material respects , an adequate internal financial controls system over financial reporting and such internal
financial controls over financial reporting were operating effectively as at March 31,2017, based on the internal control over financial reporting
criteria established by the company considering the essential components of internal control stated in the Guidance Note on Audit of Internal
Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India.
Partner
Date : May 30, 2017
69
[400500] Disclosures - Secretarial audit report
Details of signatories of secretarial audit report [Table] ..(1)

Signatories of secretarial audit report [Axis] Column 1
01/04/2016
to
31/03/2017
Details of signatories of secretarial audit report [Abstract]
Details of signatories of secretarial audit report [LineItems]
Secretarial auditors
Category of secretarial auditor firm
Name of secretarial audit firm R & A Associates
RAGHU BABU
Name of secretarial auditor signing report GUNTURU
Certificate of practice number of secretarial auditor 2820
Flat # 101, Sapthagi
r i Residency,
1-10-98/A, Chikoti
Address of secretarial auditors Gardens, Begumpet,
Hyderabad,
Telangana-500016
Permanent account number of secretarial auditor or secretarial auditors firm AADFR7405F
Date of signing secretarial audit report 01/12/2017

01/04/2016
to
31/03/2017
Disclosure in secretarial audit report explanatory [TextBlock] [See below]
Whether secretarial audit report is applicable on company Yes
Whether secretarial audit report has been qualified or has any
No
observation or other remarks
70
Disclosure in secretarial audit report explanatory [Text Block]

FORM NO. MR-3
SECRETARIAL AUDIT REPORT
FOR THE FINANCIAL YEAR ENDED MARCH 31, 2017
[Pursuant to section 204(1) of the Companies Act, 2013 and rule no.9 of the Companies (Appointment and Remuneration of Managerial
Personnel) Rules, 2014]
To
M/s. MedPlus Health Services Private Limited
707, 7th Floor, # 5-9-13,
Taramandal Commercial Complex, Saifabad,
Hyderabad, Telangana – 500 004.
We have conducted the secretarial audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by
M/s. MedPlus Health Services Private Limited (hereinafter called the “Company”) (CIN: U85110TG2006PTC051845 ). Secretarial Audit was
conducted in amanner that provided us a reasonable basis for evaluating thecorporate conducts/statutory compliances and expressing ouropinion
thereon.
Based on our verification of the Company’s books, papers, minute books, forms andreturns filed and other records maintained by the Company
andalso the information provided by the Company, its officers, agentsand authorized representatives during the conduct of secretarial audit, we
hereby report that in our opinion, the Companyhas, during the audit period covering the financial year ended on March 31, 2017 complied with
the statutory provisions listed hereunder and also that the Company has proper Board-processes and compliance-mechanism in place to the extent,
in the mannerand subject to the reporting made hereinafter:
We have examined the books, papers, minute books, forms andreturns filed and other records maintained by the Company for the financial year
ended on March 31, 2017 according to the provisions of:
i. The Companies Act, 2013 (the Act) and the rules madethereunder;
ii. The Securities Contracts (Regulation) Act, 1956 (‘SCRA’) and the rules made thereunder;(Not applicable to the Company during the
Audit Period);
iii. The Depositories Act, 1996 and the Regulations and Bye-lawsframed thereunder;
71
iv. Foreign Exchange Management Act, 1999 and the rules andregulations made thereunder to the extent of Foreign DirectInvestment;
v. The Securities Exchange Board of India (Issue and Listing of Debt Securities), Regulations, 2008/The Securities Exchange Board of
India (Listing Obligation and Disclosure Requirements) Regulations, 2015 ;
vi. Other Regulations and Guidelines prescribed under theSecurities and Exchange Board of India Act, 1992 (‘SEBI Act’):(Not applicable
to the Company during the Audit Period).
We have also examined compliance with the applicable clauses ofthe following:
i. Secretarial Standards issued by The Institute of Company Secretaries of India
ii. The Debt Listing Agreement entered into by the Company with BSE Limited.
During the period under review, the Company has complied with the provisions of the Act, Rules, Regulations, Guidelines, Standards, etc.,
mentioned above.
We further report that the Board of Directors of the Company is duly constituted withproper balance of Executive Directors and Non-Executive
Directors. The changes in the composition of the Board of Directors that took place during the period under reviewwere carried out in compliance
with the provisions of the Act.
Adequate notice was given to all Directors at least seven days in advance to schedule the Board Meetings. Agenda and detailed notes on agenda
were sent in advance, and a system exists for seeking andobtaining further information and clarifications on the agendaitems before the meeting
and for meaningful participation at themeeting. Consent of directors was obtained for the board meetings called with shorter notices.
All decisions at Board Meetings are carried out unanimously as recorded in the minutes of the meetings of the Board of Directors or Committee
of the Board, as the case may be.
We further report that the Company is engaged in the business of pathological laboratory testing and the following laws are applicable
specifically to the Company:
(a) Andhra Pradesh Private Medical Care Establishments (Registration & Regulation) Act, 2002.
(b) Bio-Medical Waste (Management and Handling) Rules, 1998.
During the period under review, the Company has complied with the provisions of the Act and Rules mentioned above.
We further report that there are adequate systems andprocesses in the Companycommensurate with the size andoperations of the Company to
monitor and ensure compliance with applicable laws, rules, regulations and guidelines.
We further report that during the audit period there were no other specific events/actions having a major bearing on the Company’s affairs in
pursuance of the above referred laws, rules, guidelines and standards except the above referred events.
R & A Associates
(G. Raghu Babu)
Partner
72
Date : FCS No.: 4448
Place : Hyderabad C P No.: 2820
This report is to be read with our letter of even date, which is annexed as “Annexure – A” attached herewith and forms an integral part of this
report.
Annexure – A”
To
M/s. MedPlus Health Services Private Limited
707, 7th Floor, # 5-9-13,
Taramandal Commercial Complex, Saifabad,
Hyderabad, Telangana – 500 004.
Our report of even date is to be read along with this letter:
1. Maintenance of secretarial records is the responsibility of the management of M/s. MedPlus Health Services Private Limited (“the
Company”). Our responsibility is to express an opinion on these secretarial records based on our audit.
2. We have followed the audit practices and processes as were appropriate to obtain reasonable assurance about the correctness of the contents
of the Secretarial records. The verification was done on the random test basis to ensure that correct facts are reflected in secretarial records. We
believe that the processes and practices, we followed provide a reasonable basis for our opinion.
3. We have not verified the correctness and appropriateness of financial records and Books of Accounts of the Company.
4. The compliance of the provisions of Corporate and other applicable laws, rules, regulations, standards is the responsibility of management.
Our examination was limited to the verification of procedures on random test basis.
5. The Secretarial Audit report is neither an assurance as to the future viability of the Company nor of the efficacy or effectiveness with which
the management has conducted the affairs of the Company.
R & A Associates
73
(G. Raghu Babu)
Partner
Date : FCS No.: 4448
Place : Hyderabad C P No.: 2820
[100100] Balance sheet

31/03/2017 31/03/2016 31/03/2015
Balance sheet [Abstract]
Equity and liabilities [Abstract]
Shareholders' funds [Abstract]
Share capital 12,40,13,510 12,40,13,510 12,40,13,510
Reserves and surplus 88,31,97,732 108,24,85,425
Total shareholders' funds 100,72,11,242 120,64,98,935
Share application money pending allotment 0 0
Non-current liabilities [Abstract]
Long-term borrowings 43,02,70,000 43,02,70,000
Other long-term liabilities 37,77,16,054 19,79,26,906
Long-term provisions 3,56,600 4,06,601
Total non-current liabilities 80,83,42,654 62,86,03,507
Current liabilities [Abstract]
Short-term borrowings 0 0
Trade payables (A) 69,37,071 (B) 67,66,653

Other current liabilities 12,49,915 10,67,453
Short-term provisions 24,63,118 23,70,381
Total current liabilities 1,06,50,104 1,02,04,487
Total equity and liabilities 182,62,04,000 184,53,06,929
Assets [Abstract]
Non-current assets [Abstract]
Fixed assets [Abstract]
Tangible assets 36,58,569 72,93,487 72,93,487
Intangible assets 0 0
Total fixed assets 36,58,569 72,93,487
Non-current investments 177,31,51,280 177,31,51,280
Long-term loans and advances 4,35,99,107 4,15,00,339
Other non-current assets 75,000 75,000
Total non-current assets 182,04,83,956 182,20,20,106
Current assets [Abstract]
Current investments 0 0
Inventories 13,19,968 13,01,792
Trade receivables 8,42,053 17,96,940
Cash and bank balances 26,72,677 1,74,52,153
Short-term loans and advances 8,02,415 26,23,886
Other current assets 82,931 1,12,052
Total current assets 57,20,044 2,32,86,823
Total assets 182,62,04,000 184,53,06,929
74
Footnotes
(A) ?? -Total outstanding dues of creditors other than micro enterprises and small enterprises
(B) Trade payables ?? -Total outstanding dues of micro enterprises and small enterprisesRs.0.00 ?? -Total outstanding dues of creditors
other than micro enterprises . and small enterprises Rs.6766653
[400300] Disclosures - Signatories of financial statements
Details of directors signing financial statements [Table] ..(1)

Directors signing financial statements [Axis] Column 1 Column 2
01/04/2016 01/04/2016
to to
31/03/2017 31/03/2017
Details of signatories of financial statements [Abstract]
Details of directors signing financial statements [Abstract]
Details of directors signing financial statements [LineItems]
Name of director signing financial statements [Abstract]
First name of director GANGADI CHERUKUPALLI
Middle name of director MADHUKAR BHASKAR
Last name of director REDDY REDDY
Designation of director Managing Director Director
Director identification number of director 00098097 00926550
Date of signing of financial statements by director 30/05/2017 30/05/2017
75
[100400] Cash flow statement, indirect

01/04/2016 01/04/2015
to to 31/03/2015
31/03/2017 31/03/2016
Statement of cash flows [Abstract]
Whether cash flow statement is applicable on company Yes Yes
Cash flows from used in operating activities [Abstract]
Profit before extraordinary items and tax -1,94,98,545 -4,30,35,759
Adjustments for reconcile profit (loss) [Abstract]
Adjustments to profit (loss) [Abstract]
Adjustments for depreciation and amortisation expense 39,01,848 28,55,139
Adjustments for impairment loss reversal of impairment loss
0 4,951
recognised in profit or loss
Other adjustments for non-cash items 47,989
(A) 11,482
Total adjustments to profit (loss) 39,49,837 28,71,572
Adjustments for working capital [Abstract]
Adjustments for decrease (increase) in inventories -18,176 -3,08,122
Adjustments for decrease (increase) in trade receivables 6,08,572 -1,45,655
Adjustments for decrease (increase) in other current assets 3,67,846 -94,464
Adjustments for increase (decrease) in trade payables 22,40,103 8,03,107
Adjustments for increase (decrease) in other current liabilities 4,46,505 1,74,001
Adjustments for provisions 5,87,421 1,31,51,492
Total adjustments for working capital 42,32,271 1,35,80,359
Total adjustments for reconcile profit (loss) 81,82,108 1,64,51,931
Net cash flows from (used in) operations -1,13,16,437 -2,65,83,828
Interest paid -430 -430
Interest received -5,59,072 -87,19,181
Income taxes paid (refund) 23,27,232 61,30,124
Other inflows (outflows) of cash -28,32,098 -6,14,043
Net cash flows from (used in) operating activities before extraordinary
-1,70,34,409 -4,20,46,746
items
Net cash flows from (used in) operating activities -1,70,34,409 -4,20,46,746
Cash flows from used in investing activities [Abstract]
Proceeds from sales of tangible assets 0 12,686
Purchase of tangible assets 2,66,930 15,51,629
Interest received 5,88,193 91,58,734
Other inflows (outflows) of cash 19,34,100 -24,88,79,525
Net cash flows from (used in) investing activities before extraordinary
22,55,363 -24,12,59,734
items
Net cash flows from (used in) investing activities 22,55,363 -24,12,59,734
Cash flows from used in financing activities [Abstract]
Proceeds from issuing shares 0 0
Proceeds from borrowings 0 0
Repayments of borrowings 0 0
Interest paid 430 430
Net cash flows from (used in) financing activities before extraordinary
-430 -430
items
Net cash flows from (used in) financing activities -430 -430
Net increase (decrease) in cash and cash equivalents before effect of
-1,47,79,476 -28,33,06,910
exchange rate changes
Net increase (decrease) in cash and cash equivalents -1,47,79,476 -28,33,06,910
Cash and cash equivalents cash flow statement at end of period 26,72,677 1,74,52,153 30,07,59,063
Footnotes
(A) Advances/debts written off
76
[200100] Notes - Share capital
Disclosure of classes of share capital [Table] ..(1)

Equity shares
Classes of share capital [Axis] Share capital [Member]
[Member]
01/04/2016 01/04/2015 01/04/2016
to to 31/03/2015 to
31/03/2017 31/03/2016 31/03/2017
Disclosure of classes of share capital [Abstract]
Disclosure of classes of share capital [LineItems]
Number of shares authorised [shares] 1,24,20,000 [shares] 1,24,20,000 [shares] 1,85,000
Value of shares authorised 12,42,00,000 12,42,00,000 18,50,000
Number of shares issued [shares] 1,24,01,351 [shares] 1,24,01,351 [shares] 1,68,233
Value of shares issued 12,40,13,510 12,40,13,510 16,82,330
Number of shares subscribed and fully paid [shares] 1,24,01,351 [shares] 1,24,01,351 [shares] 1,68,233
Value of shares subscribed and fully paid 12,40,13,510 12,40,13,510 16,82,330
Number of shares subscribed but not fully paid [shares] 0 [shares] 0 [shares] 0
Value of shares subscribed but not fully paid 0 0 0
Total number of shares subscribed [shares] 1,24,01,351 [shares] 1,24,01,351 [shares] 1,68,233
Total value of shares subscribed 12,40,13,510 12,40,13,510 16,82,330
Value of shares paid-up [Abstract]
Number of shares paid-up [shares] 1,24,01,351 [shares] 1,24,01,351 [shares] 1,68,233
Value of shares called 12,40,13,510 12,40,13,510 16,82,330
Value of shares paid-up 12,40,13,510 12,40,13,510 16,82,330
Reconciliation of number of shares outstanding
[Abstract]
Changes in number of shares outstanding
[Abstract]
Increase in number of shares outstanding
[Abstract]
Number of shares issued in public offering [shares] 0 [shares] 0 [shares] 0
Number of shares issued as bonus shares [shares] 0 [shares] 0 [shares] 0
Number of shares issued as rights [shares] 0 [shares] 0 [shares] 0
Number of shares issued in private
placement arising out of conversion of
[shares] 0 [shares] 0 [shares] 0
debentures preference shares during
period
Number of shares issued in other private
placement
Number of shares issued as preferential
allotment arising out of conversion of
period
Number of shares issued as other
preferential allotment
Number of shares allotted for
contracts without payment received [shares] 0 [shares] 0 [shares] 0
in cash
Number of shares issued under scheme of
amalgamation
Number of other issues of shares [shares] 0 [shares] 0 [shares] 0
Number of shares issued under employee
stock option plan
Number of other issue of shares
arising out of conversion of [shares] 0 [shares] 0 [shares] 0
securities
Total aggregate number of shares issued
during period
Decrease in number of shares during period
[Abstract]
Number of shares redeemed [shares] 0 [shares] 0
Number of shares bought back [shares] 0 [shares] 0 [shares] 0
Other decrease in number of shares [shares] 9,673 [shares] 9,673 [shares] 9,673
77
Total decrease in number of shares during

[shares] 9,673 [shares] 9,673 [shares] 9,673
period
Total increase (decrease) in number of
[shares] -9,673 [shares] -9,673 [shares] -9,673
shares outstanding
Number of shares outstanding at end of period [shares] 1,24,01,351 [shares] 1,24,01,351 [shares] 1,24,11,024 [shares] 1,77,906
Reconciliation of value of shares outstanding
[Abstract]
Changes in share capital [Abstract]
Increase in share capital during period
[Abstract]
Amount of public issue during period 0 0 0
Amount of bonus issue during period 0 0 0
Amount of rights issue during period 0 0 0
Amount of private placement issue
arising out of conversion of debentures 0 0 0
preference shares during period
Amount of other private placement issue
0 0 0
during period
Amount of preferential allotment issue
Amount of other preferential allotment
0 0 0
issue during period
Amount of issue allotted for
contracts without payment 0 0 0
received in cash during period
Amount of issue under scheme of
0 0 0
amalgamation during period
Amount of other issues during period 0 0 0
Amount of employee stock option plan
0 0 0
issued during period
Amount of other issue arising out of
conversion of securities during 0 0 0
period
Total aggregate amount of increase in
0 0 0
share capital during period
Decrease in share capital during period
[Abstract]
Decrease in amount of shares redeemed 0 0
Decrease in amount of shares bought back 0 0 0
Other decrease in amount of shares 96,730 96,730 96,730
Total decrease in share capital during
96,730 96,730 96,730
period
Total increase (decrease) in share capital -96,730 -96,730 -96,730
Share capital at end of period 12,40,13,510 12,40,13,510 12,40,13,510 16,82,330
Details of application money received for
allotment of securities and due for refund and
interest accrued thereon [Abstract]
Application money received for allotment of
securities and due for refund and interest
accrued thereon [Abstract]
Application money received for
allotment of securities and due for 0 0 0
refund, principal
refund, interest accrued
Total application money received for
allotment of securities and due for refund 0 0 0
and interest accrued thereon
78

Classes of share capital [Axis] Equity shares [Member] Equity shares 1 [Member]
01/04/2015 01/04/2016 01/04/2015
to 31/03/2015 to to
31/03/2016 31/03/2017 31/03/2016
Type of share Equity Share Capital Equity Share Capital
Number of shares authorised [shares] 1,85,000 [shares] 1,85,000 [shares] 1,85,000
Value of shares authorised 18,50,000 18,50,000 18,50,000
Number of shares issued [shares] 1,68,233 [shares] 1,68,233 [shares] 1,68,233
Value of shares issued 16,82,330 16,82,330 16,82,330
Number of shares subscribed and fully paid [shares] 1,68,233 [shares] 1,68,233 [shares] 1,68,233
Value of shares subscribed and fully paid 16,82,330 16,82,330 16,82,330
Number of shares subscribed but not fully paid [shares] 0 [shares] 0 [shares] 0
Value of shares subscribed but not fully paid 0 0 0
Total number of shares subscribed [shares] 1,68,233 [shares] 1,68,233 [shares] 1,68,233
Total value of shares subscribed 16,82,330 16,82,330 16,82,330
Number of shares paid-up [shares] 1,68,233 [shares] 1,68,233 [shares] 1,68,233
Value of shares called 16,82,330 16,82,330 16,82,330
Value of shares paid-up 16,82,330 16,82,330 16,82,330
Par value per share [INR/shares] 10 [INR/shares] 10
Amount per share called in case shares not fully
[INR/shares] 0 [INR/shares] 0
called
[Abstract]
[Abstract]
[Abstract]
Number of shares issued in public offering [shares] 0 [shares] 0 [shares] 0
Number of shares issued as bonus shares [shares] 0 [shares] 0 [shares] 0
Number of shares issued as rights [shares] 0 [shares] 0 [shares] 0
period
placement
period
contracts without payment received [shares] 0 [shares] 0 [shares] 0
in cash
amalgamation
Number of other issues of shares [shares] 0 [shares] 0 [shares] 0
stock option plan
arising out of conversion of [shares] 0 [shares] 0 [shares] 0
securities
during period
[Abstract]
Number of shares bought back [shares] 0 [shares] 0 [shares] 0
Other decrease in number of shares [shares] 9,673 [shares] 9,673 [shares] 9,673
[shares] 9,673 [shares] 9,673 [shares] 9,673
period
79

[shares] -9,673 [shares] -9,673 [shares] -9,673
shares outstanding
Number of shares outstanding at end of period [shares] 1,77,906 [shares] 1,77,906 [shares] 1,77,906 [shares] 1,77,906
[Abstract]
[Abstract]
Amount of public issue during period 0 0 0
Amount of bonus issue during period 0 0 0
Amount of rights issue during period 0 0 0
0 0 0
during period
0 0 0
issue during period
contracts without payment 0 0 0
0 0 0
Amount of other issues during period 0 0 0
0 0 0
conversion of securities during 0 0 0
period
0 0 0
[Abstract]
Decrease in amount of shares bought back 0 0 0
Other decrease in amount of shares 96,730 96,730 96,730
96,730 96,730 96,730
period
Total increase (decrease) in share capital -96,730 -96,730 -96,730
Share capital at end of period 16,82,330 17,79,060 16,82,330 16,82,330
refund, principal
allotment of securities and due for refund 0 0 0
80

Equity shares 1
Classes of share capital [Axis] Preference shares [Member]
[Member]
01/04/2016 01/04/2015
31/03/2015 to to 31/03/2015
31/03/2017 31/03/2016
Number of shares authorised [shares] 1,22,35,000 [shares] 1,22,35,000
Value of shares authorised 12,23,50,000 12,23,50,000
Number of shares issued [shares] 1,22,33,118 [shares] 1,22,33,118
Value of shares issued 12,23,31,180 12,23,31,180
Number of shares subscribed and fully paid [shares] 1,22,33,118 [shares] 1,22,33,118
Value of shares subscribed and fully paid 12,23,31,180 12,23,31,180
Number of shares subscribed but not fully paid [shares] 0 [shares] 0
Value of shares subscribed but not fully paid 0 0
Total number of shares subscribed [shares] 1,22,33,118 [shares] 1,22,33,118
Total value of shares subscribed 12,23,31,180 12,23,31,180
Number of shares paid-up [shares] 1,22,33,118 [shares] 1,22,33,118
Value of shares called 12,23,31,180 12,23,31,180
Value of shares paid-up 12,23,31,180 12,23,31,180
[Abstract]
[Abstract]
[Abstract]
Number of shares issued in public offering [shares] 0 [shares] 0
Number of shares issued as bonus shares [shares] 0 [shares] 0
[shares] 0 [shares] 0
period
placement
period
contracts without payment received [shares] 0 [shares] 0
in cash
amalgamation
Number of other issues of shares [shares] 0 [shares] 0
stock option plan
arising out of conversion of [shares] 0 [shares] 0
securities
during period
[Abstract]
Number of shares bought back [shares] 0 [shares] 0
Other decrease in number of shares [shares] 0 [shares] 0
period
shares outstanding
Number of shares outstanding at end of period [shares] 1,77,906 [shares] 1,22,33,118 [shares] 1,22,33,118 [shares] 1,22,33,118
81

[Abstract]
[Abstract]
Amount of public issue during period 0 0
Amount of bonus issue during period 0 0
arising out of conversion of debentures 0 0
0 0
during period
arising out of conversion of debentures 0 0
0 0
issue during period
contracts without payment 0 0
0 0
Amount of other issues during period 0 0
0 0
conversion of securities during 0 0
period
0 0
[Abstract]
Decrease in amount of shares bought back 0 0
Other decrease in amount of shares 0 0
0 0
period
Total increase (decrease) in share capital 0 0
Share capital at end of period 17,79,060 12,23,31,180 12,23,31,180 12,23,31,180
allotment of securities and due for 0 0
refund, principal
allotment of securities and due for 0 0
allotment of securities and due for refund 0 0
82

Classes of share capital [Axis] Preference shares 1 [Member]
01/04/2016 01/04/2015
to to 31/03/2015
31/03/2017 31/03/2016
Redeemable Preference Redeemable Preference
Type of share Shares Shares
Number of shares authorised [shares] 1,22,35,000 [shares] 1,22,35,000
Value of shares authorised 12,23,50,000 12,23,50,000
Number of shares issued [shares] 1,22,33,118 [shares] 1,22,33,118
Value of shares issued 12,23,31,180 12,23,31,180
Number of shares subscribed and fully paid [shares] 1,22,33,118 [shares] 1,22,33,118
Value of shares subscribed and fully paid 12,23,31,180 12,23,31,180
Number of shares subscribed but not fully paid [shares] 0 [shares] 0
Value of shares subscribed but not fully paid 0 0
Total number of shares subscribed [shares] 1,22,33,118 [shares] 1,22,33,118
Total value of shares subscribed 12,23,31,180 12,23,31,180
Number of shares paid-up [shares] 1,22,33,118 [shares] 1,22,33,118
Value of shares called 12,23,31,180 12,23,31,180
Value of shares paid-up 12,23,31,180 12,23,31,180
Par value per share [INR/shares] 10 [INR/shares] 10
Amount per share called in case shares not fully called [INR/shares] 0 [INR/shares] 0
Reconciliation of number of shares outstanding [Abstract]
Changes in number of shares outstanding [Abstract]
Increase in number of shares outstanding [Abstract]
Number of shares issued in public offering [shares] 0 [shares] 0
Number of shares issued as bonus shares [shares] 0 [shares] 0
Number of shares issued in private placement
arising out of conversion of debentures [shares] 0 [shares] 0
Number of shares issued in other private placement [shares] 0 [shares] 0
Number of shares issued as preferential allotment
arising out of conversion of debentures [shares] 0 [shares] 0
Number of shares issued as other preferential allotment [shares] 0 [shares] 0
Number of shares allotted for contracts without payment
received in cash
Number of shares issued under scheme of amalgamation [shares] 0 [shares] 0
Number of other issues of shares [shares] 0 [shares] 0
Number of shares issued under employee stock option plan [shares] 0 [shares] 0
Number of other issue of shares arising out of conversion
of securities
Total aggregate number of shares issued during period [shares] 0 [shares] 0
Decrease in number of shares during period [Abstract]
Number of shares bought back [shares] 0 [shares] 0
Other decrease in number of shares [shares] 0 [shares] 0
Total decrease in number of shares during period [shares] 0 [shares] 0
Total increase (decrease) in number of shares outstanding [shares] 0 [shares] 0
[shares]
Number of shares outstanding at end of period [shares] 1,22,33,118 [shares] 1,22,33,118
1,22,33,118
Reconciliation of value of shares outstanding [Abstract]
Increase in share capital during period [Abstract]
Amount of public issue during period 0 0
Amount of bonus issue during period 0 0
Amount of private placement issue arising out of
conversion of debentures preference shares during 0 0
period
Amount of other private placement issue during period 0 0
83
Amount of preferential allotment issue arising out

of conversion of debentures preference shares 0 0
during period
Amount of other preferential allotment issue during period 0 0
Amount of issue allotted for contracts without payment
0 0
Amount of issue under scheme of amalgamation during period 0 0
Amount of other issues during period 0 0
Amount of employee stock option plan issued during period 0 0
Amount of other issue arising out of conversion of
0 0
securities during period
Total aggregate amount of increase in share capital during
0 0
period
Decrease in share capital during period [Abstract]
Decrease in amount of shares bought back 0 0
Other decrease in amount of shares 0 0
Total decrease in share capital during period 0 0
Total increase (decrease) in share capital 0 0
Share capital at end of period 12,23,31,180 12,23,31,180 12,23,31,180
Details of application money received for allotment of
securities and due for refund and interest accrued thereon
[Abstract]
Application money received for allotment of securities
and due for refund and interest accrued thereon [Abstract]
Application money received for allotment of securities and
0 0
due for refund, principal
Application money received for allotment of securities
0 0
and due for refund, interest accrued
Total application money received for allotment of
securities and due for refund and interest accrued 0 0
thereon
Disclosure of shareholding more than five per cent in company [Table] ..(1)
Classes of share capital [Axis] Equity shares 1 [Member]
Name of shareholder [Axis] Shareholder 1 [Member] Shareholder 2 [Member]
01/04/2016 01/04/2015 01/04/2016 01/04/2015
to to to to
31/03/2017 31/03/2016 31/03/2017 31/03/2016
Disclosure of shareholding more than five per cent in
company [Abstract]
Disclosure of shareholding more than five per cent
in company [LineItems]
Type of share Equity Share Capital Equity Share Capital Equity Share Capital Equity Share Capital
MKCP Direct MKCP Direct
Name of shareholder Investments Investments G.Madhukar Reddy G.Madhukar Reddy
(Mauritius) IV Ltd (Mauritius) IV Ltd
PAN of shareholder AJEPG8481E AJEPG8481E
Country of incorporation or residence of
MAURITIUS MAURITIUS India India
shareholder
Number of shares held in company [shares] 87,340 [shares] 87,340 [shares] 33,280 [shares] 33,280
Percentage of shareholding in company 49.09% 49.09% 18.71% 18.71%
84
Classes of share capital [Axis] Equity shares 1 [Member]
01/04/2016 01/04/2015 01/04/2016 01/04/2015
to to to to
31/03/2017 31/03/2016 31/03/2017 31/03/2016
company [Abstract]
Type of share Equity Share Capital Equity Share Capital Equity Share Capital Equity Share Capital
IL & FS Trust IL & FS Trust IL & FS Trust
IL & FS Trust
Company Limited Company Limited (As Company Limited
Company Limited (As
Name of shareholder (As trustee of India trustee of India (As trustee of TVS
trustee of TVS Sriram
Venture Trust - Venture Trust - Fund- Sriram Growth Fund
Growth Fund I)
Fund- I) I) I)
PAN of shareholder AAATI6554P AAATI6554P AABTT5582H AABTT5582H
India India India India
shareholder
Number of shares held in company [shares] 16,173 [shares] 16,173 [shares] 18,834 [shares] 18,834
Classes of share capital [Axis] Equity shares 1 [Member] Preference shares 1 [Member]
01/04/2016 01/04/2015 01/04/2016 01/04/2015
to to to to
31/03/2017 31/03/2016 31/03/2017 31/03/2016
company [Abstract]
Redeemable Redeemable Redeemable
Type of share Equity Share Capital
preference shares
preference shares preference shares
IL & FS Trust IL & FS Trust
G.Madhukar Reddy G.Madhukar Reddy
Company Limited Company Limited (As
(As trustee of (As trustee of
Name of shareholder MedPlus Employees MedPlus Employees
(As trustee of TVS trustee of TVS
Shriram Growth Shriram Growth Fund
Benefit Trust) Benefit Trust)
Fund I) I)
PAN of shareholder AJEPG8481E AJEPG8481E AAATI6554P AAATI6554P
shareholder
Number of shares held in company [shares] 9,673 [shares] 9,673 [shares] 40,00,000 [shares] 40,00,000
85
Classes of share capital [Axis] Preference shares 1 [Member]
01/04/2016 01/04/2015 01/04/2016 01/04/2015
to to to to
31/03/2017 31/03/2016 31/03/2017 31/03/2016
company [Abstract]
Redeemable Redeemable Redeemable Redeemable
Type of share preference shares preference shares preference shares preference shares
IL & FS Trust IL & FS Trust IL & FS Trust IL & FS Trust
Company Limited Company Limited (As Company Limited Company Limited (As
Name of shareholder (As trustee of India trustee of India (As trustee of India trustee of India
Venture Trust – Venture Trust – Fund Venture Trust – Venture Trust – Fund
Fund I) I) Fund II) II)
PAN of shareholder AABTT5582H AABTT5582H AABTI1118C AABTI1118C
shareholder
Number of shares held in company [shares] 40,00,000 [shares] 40,00,000 [shares] 40,00,000 [shares] 40,00,000

01/04/2016 01/04/2015
to to
31/03/2017 31/03/2016
Disclosure of notes on share capital explanatory [TextBlock]
Whether there are any shareholders holding more than five per cent
Yes Yes
shares in company
Whether money raised from public offering during year No No
Amount raised from public offering during year 0 0
Amount utilised towards specified purposes for public offering 0 0
Amount remaining unutilised received in respect of public offering 0 0
[200200] Notes - Reserves and surplus
Statement of changes in reserves [Table] ..(1)

Capital reserves
Components of reserves [Axis] Reserves [Member]
[Member]
01/04/2016 01/04/2015 01/04/2016
to to 31/03/2015 to
31/03/2017 31/03/2016 31/03/2017
Statement of changes in reserves [Abstract]
Statement of changes in reserves [LineItems]
Changes in reserves [Abstract]
Additions to reserves [Abstract]
Profit (loss) for period -1,94,98,545 -4,30,35,759 -4,30,35,759
Other additions to reserves 0 2,73,82,408 2,73,82,408 0
Total additions to reserves -1,94,98,545 -1,56,53,351 -1,56,53,351 0
Deductions to reserves [Abstract]
Other deductions to reserves 17,97,89,148 23,72,38,993 23,72,38,993
Total deductions to reserves 17,97,89,148 23,72,38,993 23,72,38,993
Total changes in reserves -19,92,87,693 -25,28,92,344 0
Reserves at end of period 88,31,97,732 108,24,85,425 108,24,85,425 2,86,41,912
86

Employee stock
Components of reserves [Axis] Securities premium account [Member] options outstanding
[Member]
01/04/2016 01/04/2015 01/04/2016
to to 31/03/2015 to
31/03/2017 31/03/2016 31/03/2017
Other additions to reserves 0 0
Total additions to reserves 0 0
Other deductions to reserves 17,97,89,148 22,29,18,037 22,29,18,037 0
Total deductions to reserves 17,97,89,148 22,29,18,037 22,29,18,037 0
Total changes in reserves -17,97,89,148 -22,29,18,037 0

Employee stock options outstanding
Components of reserves [Axis] Other reserves [Member]
[Member]
01/04/2015 01/04/2015
to 31/03/2015 to 31/03/2015
31/03/2016 31/03/2016
Other additions to reserves 1,30,61,452 1,30,61,452 1,43,20,956 1,43,20,956
Total additions to reserves 1,30,61,452 1,30,61,452 1,43,20,956 1,43,20,956
Other deductions to reserves 1,43,20,956 1,43,20,956
Total deductions to reserves 1,43,20,956 1,43,20,956
Total changes in reserves -12,59,504 1,43,20,956

Components of reserves [Axis] General reserve [Member] Surplus [Member]
01/04/2015 01/04/2016 01/04/2015
to 31/03/2015 to to
31/03/2016 31/03/2017 31/03/2016
Profit (loss) for period -1,94,98,545 -4,30,35,759
Other additions to reserves 1,43,20,956 1,43,20,956
Total additions to reserves 1,43,20,956 1,43,20,956 -1,94,98,545 -4,30,35,759
Total changes in reserves 1,43,20,956 -1,94,98,545 -4,30,35,759
Reserves at end of period 2,86,41,912 2,86,41,912 -68,02,70,804 -66,07,72,259
87

Components of reserves [Axis] Surplus [Member]
31/03/2015
Profit (loss) for period -4,30,35,759
Total additions to reserves -4,30,35,759
Reserves at end of period -66,07,72,259
[200300] Notes - Borrowings
Classification of borrowings [Table] ..(1)

Classification based on time period [Axis] Long-term [Member]
Other loans and
Classification of borrowings [Axis] Borrowings [Member]
advances [Member]
Unsecured
Subclassification of borrowings [Axis] Unsecured borrowings [Member] borrowings
[Member]
31/03/2017 31/03/2016 31/03/2015 31/03/2017
Borrowings notes [Abstract]
Details of borrowings [Abstract]
Details of borrowings [LineItems]
Borrowings 43,02,70,000 43,02,70,000 43,02,70,000 43,02,70,000
Details on loans guaranteed [Abstract]
Aggregate amount of loans guaranteed by
0 0 0 0
directors
0 0 0 0
others
Details on defaults on borrowings [Abstract]
Outstanding amount of continuing default
0 0 0
principal
0 0 0 0
interest

Other loans and advances, others
Classification of borrowings [Axis] Other loans and advances [Member]
[Member]
Subclassification of borrowings [Axis] Unsecured borrowings [Member] Unsecured borrowings [Member]
31/03/2016 31/03/2015 31/03/2017 31/03/2016
Borrowings 43,02,70,000 43,02,70,000 43,02,70,000 43,02,70,000
0 0 0 0
directors
0 0 0 0
others
0 0 0
principal
0 0 0 0
interest
88

Long-term
Classification based on time period [Axis]
[Member]
Other loans and
Classification of borrowings [Axis] advances, others
[Member]
Unsecured
Subclassification of borrowings [Axis] borrowings
[Member]
31/03/2015
Borrowings 43,02,70,000
Aggregate amount of loans guaranteed by directors 0
Aggregate amount of loans guaranteed by others 0
Outstanding amount of continuing default interest 0
89
[201000] Notes - Tangible assets
Disclosure of tangible assets [Table] ..(1)

Classes of tangible assets [Axis] Company total tangible assets [Member]
Sub classes of tangible assets [Axis] Owned and leased assets [Member]
Carrying amount accumulated depreciation and gross
Carrying amount [Member] Gross carrying amount [Member]
carrying amount [Axis]
01/04/2016 01/04/2015 01/04/2016 01/04/2015
to to 31/03/2015 to to 31/03/2015
31/03/2017 31/03/2016 31/03/2017 31/03/2016
Disclosure of tangible assets [Abstract]
Disclosure of tangible assets
[LineItems]
Reconciliation of changes in
tangible assets [Abstract]
Changes in tangible assets
[Abstract]
Additions other than through
business combinations tangible 2,66,930 15,51,629 15,51,629 2,66,930 15,51,629 15,51,629
assets
Acquisitions through
business combinations 0 0 0 0 0 0
tangible assets
Depreciation tangible assets -39,01,848 -28,55,139 -28,55,139
Impairment loss
recognised in profit or 0 0 0
loss tangible assets
Reversal of impairment loss
recognised in profit or loss 0 0 0
tangible assets
Revaluation increase
0 0 0 0 0 0
(decrease) tangible assets
Disposals tangible assets
[Abstract]
0 0 0 0 0 0
through demergers
Disposals tangible assets,
0 17,637 17,637 0 34,87,186 34,87,186
others
Total disposals tangible
0 17,637 17,637 0 34,87,186 34,87,186
assets
Other adjustments tangible
assets [Abstract]
Increase (decrease) through
net exchange differences 0 0 0 0 0 0
tangible assets
0 0 0 0 0 0
assets, others
Total other adjustments
0 0 0 0 0 0
tangible assets
Total changes in tangible
-36,34,918 -13,21,147 -13,21,147 2,66,930 -19,35,557 -19,35,557
assets
Tangible assets at end of period 36,58,569 72,93,487 72,93,487 1,97,01,726 1,94,34,796 1,94,34,796
90

Sub classes of tangible assets [Axis] Owned and leased assets [Member] Owned assets [Member]
Carrying amount accumulated depreciation and gross Accumulated depreciation and impairment
Carrying amount [Member]
carrying amount [Axis] [Member]
01/04/2016 01/04/2015 01/04/2016 01/04/2015
to to 31/03/2015 to to 31/03/2015
31/03/2017 31/03/2016 31/03/2017 31/03/2016
[LineItems]
[Abstract]
business combinations tangible 2,66,930 15,51,629 15,51,629
assets
business combinations 0 0 0
tangible assets
Depreciation tangible assets 39,01,848 28,55,139 28,55,139 -39,01,848 -28,55,139 -28,55,139
Impairment loss
recognised in profit or 0 0 0 0 0 0
recognised in profit or loss 0 0 0 0 0 0
tangible assets
0 0 0
[Abstract]
0 0 0 0 0 0
through demergers
0 34,69,549 34,69,549 0 17,637 17,637
others
0 34,69,549 34,69,549 0 17,637 17,637
assets
assets [Abstract]
net exchange differences 0 0 0
tangible assets
0 0 0 0 0 0
assets, others
0 0 0 0 0 0
tangible assets
39,01,848 -6,14,410 -6,14,410 -36,34,918 -13,21,147 -13,21,147
assets
Tangible assets at end of period 1,60,43,157 1,21,41,309 1,21,41,309 36,58,569 72,93,487 72,93,487
91

Sub classes of tangible assets [Axis] Owned assets [Member]
Gross carrying amount [Member]
01/04/2016 01/04/2015 01/04/2016 01/04/2015
to to 31/03/2015 to to 31/03/2015
31/03/2017 31/03/2016 31/03/2017 31/03/2016
[LineItems]
[Abstract]
assets
tangible assets
Depreciation tangible assets 39,01,848 28,55,139 28,55,139
Impairment loss
tangible assets
0 0 0
[Abstract]
0 0 0 0 0 0
through demergers
0 34,87,186 34,87,186 0 34,69,549 34,69,549
others
0 34,87,186 34,87,186 0 34,69,549 34,69,549
assets
assets [Abstract]
tangible assets
0 0 0 0 0 0
assets, others
0 0 0 0 0 0
tangible assets
2,66,930 -19,35,557 -19,35,557 39,01,848 -6,14,410 -6,14,410
assets
Tangible assets at end of period 1,97,01,726 1,94,34,796 1,94,34,796 1,60,43,157 1,21,41,309 1,21,41,309
92

Classes of tangible assets [Axis] Plant and equipment [Member]
01/04/2016 01/04/2015 01/04/2016 01/04/2015
to to 31/03/2015 to to 31/03/2015
31/03/2017 31/03/2016 31/03/2017 31/03/2016
[LineItems]
[Abstract]
business combinations tangible 2,31,000 9,05,189 9,05,189 2,31,000 9,05,189 9,05,189
assets
tangible assets
Impairment loss
tangible assets
0 0 0 0 0 0
[Abstract]
0 0 0 0 0 0
through demergers
0 0 0 0 0 0
others
0 0 0 0 0 0
assets
assets [Abstract]
tangible assets
0 0 0 0 0 0
assets, others
0 0 0 0 0 0
tangible assets
-28,04,147 -12,71,280 -12,71,280 2,31,000 9,05,189 9,05,189
assets
Tangible assets at end of period 26,24,572 54,28,719 54,28,719 1,44,22,097 1,41,91,097 1,41,91,097
93

Classes of tangible assets [Axis] Plant and equipment [Member] Other plant and equipment [Member]
Sub classes of tangible assets [Axis] Owned assets [Member] Owned assets [Member]
01/04/2016 01/04/2015 01/04/2016 01/04/2015
to to 31/03/2015 to to 31/03/2015
31/03/2017 31/03/2016 31/03/2017 31/03/2016
[LineItems]
[Abstract]
assets
tangible assets
Depreciation tangible assets 30,35,147 21,76,469 21,76,469 -30,35,147 -21,76,469 -21,76,469
Impairment loss
tangible assets
0 0 0
[Abstract]
0 0 0 0 0 0
through demergers
0 0 0 0 0 0
others
0 0 0 0 0 0
assets
assets [Abstract]
tangible assets
0 0 0 0 0 0
assets, others
0 0 0 0 0 0
tangible assets
30,35,147 21,76,469 21,76,469 -28,04,147 -12,71,280 -12,71,280
assets
Tangible assets at end of period 1,17,97,525 87,62,378 87,62,378 26,24,572 54,28,719 54,28,719
94

Classes of tangible assets [Axis] Other plant and equipment [Member]
01/04/2016 01/04/2015 01/04/2016 01/04/2015
to to 31/03/2015 to to 31/03/2015
31/03/2017 31/03/2016 31/03/2017 31/03/2016
[LineItems]
[Abstract]
assets
tangible assets
Depreciation tangible assets 30,35,147 21,76,469 21,76,469
Impairment loss
tangible assets
0 0 0
[Abstract]
0 0 0 0 0 0
through demergers
0 0 0 0 0 0
others
0 0 0 0 0 0
assets
assets [Abstract]
tangible assets
0 0 0 0 0 0
assets, others
0 0 0 0 0 0
tangible assets
2,31,000 9,05,189 9,05,189 30,35,147 21,76,469 21,76,469
assets
Tangible assets at end of period 1,44,22,097 1,41,91,097 1,41,91,097 1,17,97,525 87,62,378 87,62,378
95

Classes of tangible assets [Axis] Furniture and fixtures [Member]
01/04/2016 01/04/2015 01/04/2016 01/04/2015
to to 31/03/2015 to to 31/03/2015
31/03/2017 31/03/2016 31/03/2017 31/03/2016
[LineItems]
[Abstract]
business combinations tangible 35,930 0 0 35,930 0 0
assets
tangible assets
Impairment loss
tangible assets
0 0 0 0 0 0
[Abstract]
0 0 0 0 0 0
through demergers
0 0 0 0 0 0
others
0 0 0 0 0 0
assets
assets [Abstract]
tangible assets
0 0 0 0 0 0
assets, others
0 0 0 0 0 0
tangible assets
-6,31,918 -5,32,149 -5,32,149 35,930 0 0
assets
Tangible assets at end of period 3,84,719 10,16,637 10,16,637 27,68,394 27,32,464 27,32,464
96

Classes of tangible assets [Axis] Furniture and fixtures [Member] Vehicles [Member]
01/04/2016 01/04/2015 01/04/2016 01/04/2015
to to 31/03/2015 to to 31/03/2015
31/03/2017 31/03/2016 31/03/2017 31/03/2016
[LineItems]
[Abstract]
business combinations tangible 0 0 0
assets
tangible assets
Depreciation tangible assets 6,67,848 5,32,149 5,32,149 -62,744 -66,559 -66,559
Impairment loss
tangible assets
0 0 0
[Abstract]
0 0 0 0 0 0
through demergers
0 0 0 0 17,637 17,637
others
0 0 0 0 17,637 17,637
assets
assets [Abstract]
tangible assets
0 0 0 0 0 0
assets, others
0 0 0 0 0 0
tangible assets
6,67,848 5,32,149 5,32,149 -62,744 -84,196 -84,196
assets
97

Classes of tangible assets [Axis] Vehicles [Member]
01/04/2016 01/04/2015 01/04/2016 01/04/2015
to to 31/03/2015 to to 31/03/2015
31/03/2017 31/03/2016 31/03/2017 31/03/2016
[LineItems]
[Abstract]
business combinations tangible 0 0 0
assets
tangible assets
Depreciation tangible assets 62,744 66,559 66,559
Impairment loss
tangible assets
0 0 0
[Abstract]
0 0 0 0 0 0
through demergers
0 37,783 37,783 0 20,146 20,146
others
0 37,783 37,783 0 20,146 20,146
assets
assets [Abstract]
tangible assets
0 0 0 0 0 0
assets, others
0 0 0 0 0 0
tangible assets
0 -37,783 -37,783 62,744 46,413 46,413
assets
98

Classes of tangible assets [Axis] Motor vehicles [Member]
01/04/2016 01/04/2015 01/04/2016 01/04/2015
to to 31/03/2015 to to 31/03/2015
31/03/2017 31/03/2016 31/03/2017 31/03/2016
[LineItems]
[Abstract]
business combinations tangible 0 0 0 0 0 0
assets
tangible assets
Depreciation tangible assets -62,744 -66,559 -66,559
Impairment loss
tangible assets
0 0 0 0 0 0
[Abstract]
0 0 0 0 0 0
through demergers
0 17,637 17,637 0 37,783 37,783
others
0 17,637 17,637 0 37,783 37,783
assets
assets [Abstract]
tangible assets
0 0 0 0 0 0
assets, others
0 0 0 0 0 0
tangible assets
-62,744 -84,196 -84,196 0 -37,783 -37,783
assets
99

Classes of tangible assets [Axis] Motor vehicles [Member] Leasehold improvements [Member]
01/04/2016 01/04/2015 01/04/2016 01/04/2015
to to 31/03/2015 to to 31/03/2015
31/03/2017 31/03/2016 31/03/2017 31/03/2016
[LineItems]
[Abstract]
business combinations tangible 0 6,15,840 6,15,840
assets
tangible assets
Depreciation tangible assets 62,744 66,559 66,559 -1,23,168 -53,316 -53,316
Impairment loss
tangible assets
0 0 0
[Abstract]
0 0 0 0 0 0
through demergers
0 20,146 20,146 0 0 0
others
0 20,146 20,146 0 0 0
assets
assets [Abstract]
tangible assets
0 0 0 0 0 0
assets, others
0 0 0 0 0 0
tangible assets
62,744 46,413 46,413 -1,23,168 5,62,524 5,62,524
assets
100

Classes of tangible assets [Axis] Leasehold improvements [Member]
01/04/2016 01/04/2015 01/04/2016 01/04/2015
to to 31/03/2015 to to 31/03/2015
31/03/2017 31/03/2016 31/03/2017 31/03/2016
[LineItems]
[Abstract]
business combinations tangible 0 6,15,840 6,15,840
assets
tangible assets
Depreciation tangible assets 1,23,168 53,316 53,316
Impairment loss
tangible assets
0 0 0
[Abstract]
0 0 0 0 0 0
through demergers
0 34,49,403 34,49,403 0 34,49,403 34,49,403
others
0 34,49,403 34,49,403 0 34,49,403 34,49,403
assets
assets [Abstract]
tangible assets
0 0 0 0 0 0
assets, others
0 0 0 0 0 0
tangible assets
0 -28,33,563 -28,33,563 1,23,168 -33,96,087 -33,96,087
assets
Tangible assets at end of period 6,15,840 6,15,840 6,15,840 1,76,484 53,316 53,316
101

Classes of tangible assets [Axis] Other tangible assets [Member]
01/04/2016 01/04/2015 01/04/2016 01/04/2015
to to 31/03/2015 to to 31/03/2015
31/03/2017 31/03/2016 31/03/2017 31/03/2016
[LineItems]
[Abstract]
business combinations tangible 0 30,600 30,600 0 30,600 30,600
assets
tangible assets
Depreciation tangible assets -12,941 -26,646 -26,646
Impairment loss
tangible assets
0 0 0 0 0 0
[Abstract]
0 0 0 0 0 0
through demergers
0 0 0 0 0 0
others
0 0 0 0 0 0
assets
assets [Abstract]
tangible assets
0 0 0 0 0 0
assets, others
0 0 0 0 0 0
tangible assets
-12,941 3,954 3,954 0 30,600 30,600
assets
Tangible assets at end of period 12,917 25,858 25,858 13,33,055 13,33,055 13,33,055
102

Classes of tangible assets [Axis] Other tangible assets [Member] Other tangible assets, others [Member]
01/04/2016 01/04/2015 01/04/2016 01/04/2015
to to 31/03/2015 to to 31/03/2015
31/03/2017 31/03/2016 31/03/2017 31/03/2016
[LineItems]
Data processing Data processing Data processing
Nature of other tangible assets equipment equipment equipment
[Abstract]
business combinations tangible 0 30,600 30,600
assets
tangible assets
Depreciation tangible assets 12,941 26,646 26,646 -12,941 -26,646 -26,646
Impairment loss
tangible assets
0 0 0
[Abstract]
0 0 0 0 0 0
through demergers
0 0 0 0 0 0
others
0 0 0 0 0 0
assets
assets [Abstract]
tangible assets
0 0 0 0 0 0
assets, others
0 0 0 0 0 0
tangible assets
12,941 26,646 26,646 -12,941 3,954 3,954
assets
Tangible assets at end of period 13,20,138 13,07,197 13,07,197 12,917 25,858 25,858
103

Classes of tangible assets [Axis] Other tangible assets, others [Member]
01/04/2016 01/04/2015 01/04/2016 01/04/2015
to to 31/03/2015 to to 31/03/2015
31/03/2017 31/03/2016 31/03/2017 31/03/2016
[LineItems]
Data processing Data processing Data processing Data processing Data processing Data processing
Nature of other tangible assets equipment equipment equipment equipment equipment equipment
[Abstract]
business combinations tangible 0 30,600 30,600
assets
tangible assets
Depreciation tangible assets 12,941 26,646 26,646
Impairment loss
tangible assets
0 0 0
[Abstract]
0 0 0 0 0 0
through demergers
0 0 0 0 0 0
others
0 0 0 0 0 0
assets
assets [Abstract]
tangible assets
0 0 0 0 0 0
assets, others
0 0 0 0 0 0
tangible assets
0 30,600 30,600 12,941 26,646 26,646
assets
104
Disclosure of additional information tangible assets [Table] ..(1)

Company total tangible assets Other plant and equipment Furniture and fixtures
Classes of tangible assets [Axis]
[Member] [Member] [Member]
Sub classes of tangible assets [Axis] Owned assets [Member] Owned assets [Member] Owned assets [Member]
01/04/2016 01/04/2015 01/04/2016 01/04/2015 01/04/2016 01/04/2015
to to to to to to
31/03/2017 31/03/2016 31/03/2017 31/03/2016 31/03/2017 31/03/2016
Disclosure of additional information
tangible assets [LineItems]
straight-line
Depreciation method tangible assets straight-line basis straight-line basis straight-line basis straight-line basis straight-line basis
basis
lives prescribed lives prescribed lives prescribed lives prescribed lives prescribed lives prescribed
under the under the under the under the under the under the
Useful lives or depreciation rates
schedule II to the schedule II to the schedule II to the schedule II to the schedule II to the schedule II to
tangible assets Companies Act, Companies Act, Companies Act, Companies Act, Companies Act, the Companies
2013. 2013. 2013. 2013. 2013. Act, 2013.
Disclosure of additional information tangible assets [Table] ..(2)

Leasehold improvements Other tangible assets, others
Classes of tangible assets [Axis] Motor vehicles [Member]
[Member] [Member]
Sub classes of tangible assets [Axis] Owned assets [Member] Owned assets [Member] Owned assets [Member]
01/04/2016 01/04/2015 01/04/2016 01/04/2015 01/04/2016 01/04/2015
to to to to to to
31/03/2017 31/03/2016 31/03/2017 31/03/2016 31/03/2017 31/03/2016
tangible assets [LineItems]
Depreciation on Depreciation on
leasehold leasehold
improvements is improvements is straight-line
Depreciation method tangible assets straight-line basis straight-line basis
provided over the provided over the
straight-line basis
basis
lease term or 5 lease term or 5
years years
lives prescribed lives prescribed t h e rates the r a t e s lives prescribed lives prescribed
under the under the prescribed under prescribed under under the under the
Useful lives or depreciation rates
schedule II to the schedule II to the the schedule II to the schedule II to schedule II to the schedule II to
tangible assets Companies Act, Companies Act, the Companies the Companies Companies Act, the Companies
2013. 2013. Act, 2013. Act, 2013. 2013. Act, 2013.
[201100] Notes - Intangible assets
Disclosure of intangible assets [Table] ..(1)

Company total intangible assets
Classes of intangible assets [Axis]
[Member]
Internally generated and other than
Sub classes of intangible assets [Axis] internally generated intangible assets
[Member]
Carrying amount accumulated amortization and impairment and gross carrying amount [Axis] Carrying amount [Member]
31/03/2017 31/03/2016
Disclosure of intangible assets [Abstract]
Disclosure of intangible assets [LineItems]
Reconciliation of changes in intangible assets [Abstract]
Intangible assets at end of period 0 0
105
[200400] Notes - Non-current investments
Details of non-current investments [Table] ..(1)

Classification of non-current investments [Axis] Column 1 Column 2
01/04/2016 01/04/2015 01/04/2016 01/04/2015
to to to to
31/03/2017 31/03/2016 31/03/2017 31/03/2016
Non-current investments [Abstract]
Disclosure of details of non-current investments
[Abstract]
Details of non-current investments [LineItems]
Investment in Investment in Investment in Investment in
Type of non-current investments subsidiaries equity subsidiaries equity subsidiaries equity subsidiaries equity
instruments instruments instruments instruments
Class of non-current investments Trade investments Trade investments Trade investments Trade investments
Unquoted Equity Unquoted Equity Unquoted Equity Unquoted Equity
Nature of non-current investments Instruments Instruments Instruments Instruments
Non-current investments 149,94,51,300 149,94,51,300 23,00,00,000 23,00,00,000
Optival Health Optival Health Ritemed Pharma
Name of body corporate in whom investment has Ritemed Pharma
Solutions Private Solutions Private Retail Private
been made Retail Private Limited
Limited Limited Limited
Details of whether such body corporate is
subsidiary, associate, joint venture or Subsidiary Subsidiary Subsidiary Subsidiary
controlled special purpose entity
Details of non-current investments [Table] ..(2)

Classification of non-current investments [Axis] Column 3 Column 4
01/04/2016 01/04/2015 01/04/2016 01/04/2015
to to to to
31/03/2017 31/03/2016 31/03/2017 31/03/2016
Non-current investments [Abstract]
Disclosure of details of non-current investments
[Abstract]
Details of non-current investments [LineItems]
Investment in Investment in Investment in Investment in
Type of non-current investments subsidiaries equity subsidiaries equity subsidiaries equity subsidiaries equity
instruments instruments instruments instruments
Class of non-current investments Trade investments Trade investments Trade investments Trade investments
Unquoted Equity Unquoted Equity Unquoted Equity Unquoted Equity
Nature of non-current investments Instruments Instruments Instruments Instruments
Non-current investments 99,980 99,980 4,36,00,000 4,36,00,000
M H S PanIndia Pharma PanIndia Pharma
Name of body corporate in whom investment has MHS Pharmaceuticals
Pharmaceuticals Distributors Private Distributors Private
been made Private Limited
Private Limited Limited Limited
Details of whether such body corporate is
subsidiary, associate, joint venture or Subsidiary Subsidiary Subsidiary Subsidiary
controlled special purpose entity

31/03/2017 31/03/2016
Disclosure of notes on non-current investments explanatory [TextBlock]
Aggregate amount of quoted non-current investments 0 0
Market value of quoted non-current investments 0 0
Aggregate amount of unquoted non-current investments 177,31,51,280 177,31,51,280
Aggregate provision for diminution in value of non-current investments 0 0
106
[200600] Notes - Subclassification and notes on liabilities and assets
Loans and advances [Table] ..(1)

Security deposits
Classification of loans and advances [Axis] Loans and advances [Member]
[Member]
Unsecured
Classification of assets based on security [Axis] Unsecured considered good [Member] considered good
[Member]
01/04/2016
31/03/2017 31/03/2016 31/03/2015 to
31/03/2017
Subclassification and notes on liabilities and assets
[Abstract]
Loans and advances notes [Abstract]
Loans and advances [Abstract]
Disclosure of loans and advances [LineItems]
Loans and advances, gross 4,35,99,107 4,15,00,339 4,15,00,339 9,73,800
Allowance for bad and doubtful loans and
0 0 0 0
advances
Loans and advances 4,35,99,107 4,15,00,339 4,15,00,339 9,73,800
Nature of other loans and advances Deposits - others
Details of loans and advances due by
directors, other officers or others
[Abstract]
Loans and advances due by directors 0 0 0 0
Loans and advances due by other officers 0 0 0 0
Loans and advances due by others 0 0 0 0
Total loans and advances due by
0 0 0 0
Details of loans and advances due by firms
or companies in which any director is
partner or director [Abstract]
Loans and advances due by firms in
0 0 0 0
which any director is partner
Loans and advances due by private
companies in which any director is 0 0 0 0
director
member
Total loans and advances due
by firms or companies in which
0 0 0 0
any director is partner or
director
107

Classification of loans and advances [Axis] Security deposits [Member] Other loans and advances [Member]
Classification of assets based on security [Axis] Unsecured considered good [Member] Unsecured considered good [Member]
01/04/2015
to 31/03/2015 31/03/2017 31/03/2016
31/03/2016
[Abstract]
Loans and advances, gross 11,94,195 11,94,195 4,26,25,307 4,03,06,144
0 0 0 0
advances
Loans and advances 11,94,195 11,94,195 4,26,25,307 4,03,06,144
Nature of other loans and advances Deposits - others Deposits - others
[Abstract]
0 0 0 0
0 0 0 0
director
member
0 0 0 0
director
108

Other loans and
Classification of loans and advances [Axis] Advance tax [Member]
advances [Member]
Unsecured
Classification of assets based on security [Axis] considered good Unsecured considered good [Member]
[Member]
01/04/2016 01/04/2015
31/03/2015 to to 31/03/2015
31/03/2017 31/03/2016
[Abstract]
Loans and advances, gross 4,03,06,144 0 4,02,07,420 4,02,07,420
0 0 0 0
advances
Loans and advances 4,03,06,144 0 4,02,07,420 4,02,07,420
Advance income tax Advance income tax Advance income tax
Nature of other loans and advances (including TDS (including TDS (including TDS
receivable) receivable) receivable)
[Abstract]
0 0 0 0
0 0 0 0
director
member
0 0 0 0
director
109

Deposits with
statutory
Classification of loans and advances [Axis] Advance income tax paid [Member]
authorities
[Member]
Unsecured
[Member]
01/04/2016 01/04/2015 01/04/2016
to to 31/03/2015 to
31/03/2017 31/03/2016 31/03/2017
[Abstract]
Loans and advances, gross 0 4,02,07,420 4,02,07,420 4,26,25,307
0 0 0 0
advances
Loans and advances 0 4,02,07,420 4,02,07,420 4,26,25,307
Balances with
Advance income tax Advance income tax Advance income tax
statutory /
Nature of other loans and advances (including TDS (including TDS (including TDS
government
receivable) receivable) receivable)
authorities
[Abstract]
0 0 0 0
0 0 0 0
director
member
0 0 0 0
director
110

Classification based on time period [Axis] Long-term [Member] Short-term [Member]
Deposits with statutory authorities
Classification of loans and advances [Axis] Loans and advances [Member]
[Member]
01/04/2015
to 31/03/2015 31/03/2017 31/03/2016
31/03/2016
[Abstract]
Loans and advances, gross 98,724 98,724 8,02,415 26,23,886
0 0 0 0
advances
Loans and advances 98,724 98,724 8,02,415 26,23,886
Balances with
Balances with
statutory /
Nature of other loans and advances government
statutory / government
authorities
authorities
[Abstract]
0 0 0 0
0 0 0 0
director
member
0 0 0 0
director
111

Classification based on time period [Axis] Short-term [Member]
Loans and
Classification of loans and advances [Axis] Loans and advances to related parties [Member]
advances [Member]
Unsecured
[Member]
31/03/2015 31/03/2017 31/03/2016 31/03/2015
[Abstract]
Loans and advances, gross 26,23,886 23,642 19,57,742 19,57,742
0 0 0 0
advances
Loans and advances 26,23,886 23,642 19,57,742 19,57,742
[Abstract]
0 0 0 0
0 0 0 0
director
member
0 0 0 0
director
112

Loans advances
Classification of loans and advances [Axis] Loans advances given other related parties [Member] given employees
[Member]
Unsecured
[Member]
01/04/2016 01/04/2015 01/04/2016
to to 31/03/2015 to
31/03/2017 31/03/2016 31/03/2017
[Abstract]
Loans and advances, gross 23,642 19,57,742 19,57,742 650
0 0 0 0
advances
Loans and advances 23,642 19,57,742 19,57,742 650
Loans and advances Loans and advances Loans and advances to Advances to
Nature of other loans and advances to related parties to related parties related parties employees
[Abstract]
0 0 0 0
0 0 0 0
director
member
0 0 0 0
director
113

Loans advances given employees Loans advances value be received
Classification of loans and advances [Axis]
[Member] [Member]
01/04/2015 01/04/2016 01/04/2015
to 31/03/2015 to to
31/03/2016 31/03/2017 31/03/2016
[Abstract]
Loans and advances, gross 89,474 89,474 5,65,245 3,01,353
0 0 0 0
advances
Loans and advances 89,474 89,474 5,65,245 3,01,353
Advances
Advances recoverable
Advances to Advances to recoverable in cash
Nature of other loans and advances employees employees or kind or for value
in cash or kind or for
value to be received
to be received
[Abstract]
0 0 0 0
0 0 0 0
director
member
0 0 0 0
director
114

Loans advances
Classification of loans and advances [Axis] value be received Other loans and advances [Member]
[Member]
Unsecured
[Member]
31/03/2015 31/03/2017 31/03/2016 31/03/2015
[Abstract]
Loans and advances, gross 3,01,353 2,12,878 2,75,317 2,75,317
0 0 0 0
advances
Loans and advances 3,01,353 2,12,878 2,75,317 2,75,317
Advances
recoverable in cash
Nature of other loans and advances or kind or for value
to be received
[Abstract]
0 0 0 0
0 0 0 0
director
member
0 0 0 0
director
115

Classification of loans and advances [Axis] Prepaid expenses [Member]
Classification of assets based on security [Axis] Unsecured considered good [Member]
01/04/2016 01/04/2015
to to 31/03/2015
31/03/2017 31/03/2016
Subclassification and notes on liabilities and assets [Abstract]
Loans and advances, gross 2,12,878 2,75,317 2,75,317
Allowance for bad and doubtful loans and advances 0 0 0
Loans and advances 2,12,878 2,75,317 2,75,317
Nature of other loans and advances Prepaid expenses Prepaid expenses Prepaid expenses
Details of loans and advances due by directors, other
officers or others [Abstract]
Loans and advances due by directors 0 0 0
Loans and advances due by other officers 0 0 0
Loans and advances due by others 0 0 0
Total loans and advances due by directors, other officers
0 0 0
or others
Details of loans and advances due by firms or
companies in which any director is partner or
director [Abstract]
Loans and advances due by firms in which any director is
0 0 0
partner
Loans and advances due by private companies in which any
0 0 0
director is director
Loans and advances due by private companies in which any
0 0 0
director is member
Total loans and advances due by firms or companies
0 0 0
in which any director is partner or director
Disclosure of breakup of provisions [Table] ..(1)

Classification based on time period
[Member]
31/03/2017 31/03/2016 31/03/2017 31/03/2016
[Abstract]
Provisions notes [Abstract]
Disclosure of breakup of provisions [Abstract]
Disclosure of breakup of provisions [LineItems]
Provisions [Abstract]
Provisions for employee benefits
[Abstract]
Provision gratuity 6,42,226 6,16,085 3,56,600 4,06,601
Provision leave encashment 21,77,492 21,60,897
Total provisions for employee benefits 28,19,718 27,76,982 3,56,600 4,06,601
CSR expenditure provision 0 0 0 0
Total provisions 28,19,718 27,76,982 3,56,600 4,06,601
116
Disclosure of breakup of provisions [Table] ..(2)

31/03/2017 31/03/2016
Subclassification and notes on liabilities and assets [Abstract]
Provisions notes [Abstract]
Disclosure of breakup of provisions [Abstract]
Disclosure of breakup of provisions [LineItems]
Provisions [Abstract]
Provisions for employee benefits [Abstract]
Provision gratuity 2,85,626 2,09,484
Provision leave encashment 21,77,492 21,60,897
Total provisions for employee benefits 24,63,118 23,70,381
CSR expenditure provision 0 0
Total provisions 24,63,118 23,70,381
Subclassification of trade receivables [Table] ..(1)

Classification of assets based on security
Classification of assets based on security [Axis] Unsecured considered good [Member]
[Member]
31/03/2017 31/03/2016 31/03/2017 31/03/2016
[Abstract]
Trade receivables notes [Abstract]
Trade receivables [Abstract]
Subclassification of trade receivables
[Abstract]
Subclassification of trade receivables
[LineItems]
Breakup of trade receivables [Abstract]
Trade receivables, gross 8,42,053 17,96,940 8,42,053 17,96,940
Allowance for bad and doubtful debts 0 0 0 0
Total trade receivables 8,42,053 17,96,940 8,42,053 17,96,940
Details of trade receivables due by
[Abstract]
Trade receivables due by directors 0 0
Trade receivables due by other officers 0 0
Trade receivables due by others 0 0
Total trade receivables due by
directors, other officers or 0 0
others
Details of trade receivables due by
firms or companies in which any director
is partner or director [Abstract]
Trade receivables due by firms in
0 0
Trade receivables due by private
companies in which any director 0 0
is director
Trade receivables due by private
companies in which any director 0 0
is member
Total trade receivables due by firms
or companies in which any director is 0 0
partner or director
117
Classification of inventories [Table] ..(1)

Classification of inventories [Axis] Company total inventories [Member] Stores and spares [Member]
01/04/2016 01/04/2015 01/04/2016 01/04/2015
to to to to
31/03/2017 31/03/2016 31/03/2017 31/03/2016
[Abstract]
Inventories notes [Abstract]
Inventories [Abstract]
Classification of inventories [Abstract]
Details of inventories [LineItems]
Inventories 13,19,968 13,01,792 13,19,968 13,01,792
Goods in transit 0 0 0 0
Mode of valuation NA NA NA NA

01/04/2016 01/04/2015
to to
31/03/2017 31/03/2016
Disclosure of subclassification and notes on liabilities and assets
explanatory [TextBlock]
Trade payables, long-term 0 0
Others long-term, others (A) 37,77,16,054 (B) 19,79,26,906

Total others, long-term 37,77,16,054 19,79,26,906
Total other long-term liabilities 37,77,16,054 19,79,26,906
Interest accrued but not due on borrowings 0 0
Interest accrued and due on borrowings 0 0
Interest accrued but not due on public deposits 0 0
Interest accrued and due on public deposits 0 0
Debentures claimed but not paid 0 0
Unpaid dividends 0 0
Application money received for allotment of securities and
0 0
due for refund, principal
Unpaid matured deposits and interest accrued thereon 0 0
Unpaid matured debentures and interest accrued thereon 0 0
Public deposit payable, current 0 0
Advance received from customers 2,71,649 1,04,130
Current liabilities portion of share application money pending
0 0
allotment
Other current liabilities, others (C) 9,78,266 (D) 9,63,323
Total other current liabilities 12,49,915 10,67,453
Other non-current assets, others 75,000 75,000
Total other non-current assets 75,000 75,000
Nature of other non-current assets, others NA NA
Aggregate amount of trade receivables outstanding for period
0 0
exceeding six months
Fixed deposits with banks 0 0
Other balances with banks 26,07,402

(E) 1,72,67,483
Total balance with banks 26,07,402 1,72,67,483
Cash on hand 65,275 1,84,670
Total cash and cash equivalents 26,72,677 1,74,52,153
Total cash and bank balances 26,72,677 1,74,52,153
Total balances held with banks to extent held as
margin money or security against borrowings, 0 0
guarantees or other commitments
Bank deposits with more than twelve months maturity 0 0
Other current assets, others (F) 82,931 (G) 1,12,052

Total other current assets 82,931 1,12,052
118
Footnotes
(A) Premium payable on redemption of non - convertible debentures (refer note a ) Rs. 294,388,685 Premium payable on redemption of
redeemable preference shares (refer note a ) Rs. 83,327,369
(B) Premium payable on redemption of non - convertible debentures (refer note a )Rs.154343512 Premium payable on redemption of
redeemable preference shares (refer note a ) Rs.43583394
(C) Statutory liabilities
(D) statutory liabilities
(E) Balances with scheduled banks - On current accounts Rs.2267483 - Deposits with original maturity of less than 3 months
Rs.15000000
(F) Interest accrued on fixed deposits
(G) Non-current bank balances (refer note no. 16) Rs.0.00 Interest accrued on fixed depositsRs.112052
[200700] Notes - Additional disclosures on balance sheet

01/04/2016 01/04/2015
to to
31/03/2017 31/03/2016
Disclosure of additional balance sheet notes explanatory [TextBlock]
Total contingent liabilities and commitments 0 0
Amount of dividends proposed to be distributed to equity shareholders 0 0
Amount of per share dividend proposed to be distributed to equity
[INR/shares] 0 [INR/shares] 0
shareholders
Deposits accepted or renewed during period 0 0
Deposits matured and claimed but not paid during period 0 0
Deposits matured and claimed but not paid 0 0
Deposits matured but not claimed 0 0
Interest on deposits accrued and due but not paid 0 0
Share application money received during year 0 0
Share application money paid during year 0 0
Amount of share application money received back during year 0 0
Amount of share application money repaid returned back during year 0 0
Number of person share application money paid during year [pure] 0 [pure] 0
Number of person share application money received during year [pure] 0 [pure] 0
Number of person share application money paid as at end of year [pure] 0 [pure] 0
Number of person share application money received as at end of year [pure] 0 [pure] 0
Whether maintenance of cost records by company has been
mandated under Companies (Cost Records and Audit) Rules, No No
2014
Unclaimed share application refund money 0 0
Unclaimed matured debentures 0 0
Unclaimed matured deposits 0 0
Interest unclaimed amount 0 0
Number of warrants converted into equity shares during period [pure] 0 [pure] 0
Number of warrants converted into preference shares during period [pure] 0 [pure] 0
Number of warrants converted into debentures during period [pure] 0 [pure] 0
Number of warrants issued during period (in foreign currency) [pure] 0 [pure] 0
Number of warrants issued during period (INR) [pure] 0 [pure] 0
[200800] Notes - Disclosure of accounting policies, changes in accounting policies and estimates
01/04/2016 01/04/2015
to to
31/03/2017 31/03/2016
Disclosure of accounting policies, change in accounting policies and Textual information (36) Textual information (37)
changes in estimates explanatory [TextBlock] [See below] [See below]
119
Disclosure of accounting policies, change in accounting policies and changes in estimates explanatory [Text Block]
MedPlus Health Services Private Limited
CIN - U85110TG2006PTC051845
Notes to financial statements for the year ended March 31, 2017
(All amounts in Indian Rupees, except as otherwise stated)
Corporate
1.
information
MedPlus Health Services Private Limited (the ‘Company’) is a private

company domiciled in India. The Company has foreign direct investment of
49%. The Company is in the business of pathological laboratory testing.
Basis of
2.
preparation
The financial statements of the company have been prepared in accordance

with the generally accepted accounting principles in India (Indian GAAP).
The company has prepared these financial statements to comply in all
material respects with the accounting standards notified under section 133
of the Companies Act 2013, read together with paragraph 7 of the
Companies (Accounts) Rules 2014 and Companies (Accounting Standards)
Amendment Rules, 2016. The accounting policies adopted in the preparation
of financial statements are consistent with those of previous year.
Summary
of
2.1. significant
accounting
policies
(a) Use of estimates
The preparation of financial statements in conformity with Indian GAAP

requires the management to make judgments, estimates and assumptions
that affect the reported amounts of revenues, expenses, assets and
liabilities and the disclosure of contingent liabilities, at the end of the
reporting period. Although these estimates are based on the management’s
best knowledge of current events and actions, uncertainty about these
assumptions and estimates could result in the outcomes requiring a material
adjustment to the carrying amounts of assets or liabilities in future periods.
(b) Property, Plant and Equipment
Property, plant and equipment, capital work in progress are stated at cost,
net of accumulated depreciation and accumulated impairment losses, if any.
The cost comprises purchase price, borrowing costs if capitalization criteria
are met, directly attributable cost of bringing the asset to its working
condition for the intended use and initial estimate of decommissioning,
restoring and similar liabilities. Any trade discounts and rebates are
deducted in arriving at the purchase price. Such cost includes the cost of
replacing part of the plant and equipment. When significant parts of plant
and equipment are required to be replaced at intervals, the Company
depreciates them separately based on their specific useful lives. Likewise,
when a major inspection is performed, its cost is recognised in the carrying
amount of the plant and equipment as a replacement if the recognition
criteria are satisfied. All other repair and maintenance costs are recognised
in profit or loss as incurred.
120
121
Items of stores and spares that meet the definition of property, plant and
equipment are capitalized at cost and depreciated over their useful life.
Otherwise, such items are classified as inventories.
Gains or losses arising from derecognition of property, plant and equipment

are measured as the difference between the net disposal proceeds and the
carrying amount of the asset and are recognized in the statement of profit
and loss when the asset is derecognized.
The company identifies and determines cost of each component/ part of the
asset separately, if the component/ part has a cost which is significant to the
total cost of the asset and has useful life that is materially different from that
of the remaining asset.
Property, plant and equipment held for sale is valued at lower of their
carrying amount and net realizable value. Any write-down is recognized in
the statement of profit and loss.
(c) Depreciation on property, plant and equipment
Depreciation on property, plant and equipment other than leasehold

improvements is calculated on a straight-line basis using the following rates
arrived at based on the useful lives estimated by the management which
coincide with the lives prescribed under the schedule II to the Companies
Act, 2013:
Useful lives
estimated by
Asset class the
management
(years)
Furniture and fixtures 10
Vehicles 10
3
Data Processing Equipment -
6
Plant and equipment 5 - 10
Depreciation on leasehold improvements is provided over the lease term or

5 years, whichever is shorter, which is higher than the rates prescribed
under the schedule II to the Companies Act, 2013.
The residual values, useful lives and methods of depreciation of property,

plant and equipment are reviewed at each financial year end and adjusted
prospectively, if appropriate.
(d) Intangible assets
Intangible assets acquired separately are measured on initial recognition at

cost. Following initial recognition, intangible assets are carried at cost less
accumulated amortization and accumulated impairment losses, if any.
Intangible assets are amortized on a straight line basis over a period of five
years or estimated useful life whichever is lower.
(e) Impairment of fixed assets
The Company assesses at each reporting date whether there is an
122
indication that an asset may be impaired. If any indication exists, or when

annual impairment testing for an asset is required, the Company estimates
the asset’s recoverable amount. An asset’s recoverable amount is the higher
of an asset’s net selling price and its value in use. The recoverable amount
is determined for an individual asset, unless the asset does not generate
cash inflows that are largely independent of those from other assets or
groups of assets. Where the carrying amount of an asset exceeds its
recoverable amount, the asset is considered impaired and is written down to
its recoverable amount. In assessing value in use, the estimated future cash
flows are discounted to their present value using a pre-tax discount rate that
reflects current market assessments of the time value of money and the
risks specific to the asset. In determining net selling price, recent market
transactions are taken into account, if available. If no such transactions can
be identified, an appropriate valuation model is used.
Impairment losses, including impairment on inventories, are recognized in

the statement of profit and loss.
After impairment, depreciation is provided on the revised carrying amount of

the asset over its remaining useful life.
An assessment is made at each reporting date as to whether there is any

indication that previously recognized impairment losses may no longer exist
or may have decreased. If such indication exists, the company estimates the
asset’s or cash-generating unit’s recoverable amount. A previously
recognized impairment loss is reversed only if there has been a change in
the assumptions used to determine the asset’s recoverable amount since
the last impairment loss was recognized. The reversal is limited so that the
carrying amount of the asset does not exceed its recoverable amount, nor
exceed the carrying amount that would have been determined, net of
depreciation, had no impairment loss been recognized for the asset in prior
years. Such reversal is recognized in the statement of profit and loss unless
the asset is carried at a revalued amount, in which case the reversal is
treated as a revaluation increase.
(f) Leases
Leases, where the lessor effectively retains substantially all the risks and
benefits of ownership of the leased item, are classified as operating leases.
Operating lease payments are recognized as an expense in the statement of
profit and loss on a straight-line basis over the lease term.
(g) Investments
Investments, which are readily realizable and intended to be held for not
more than one year from the date on which such investments are made, are
classified as current investments. All other investments are classified as
long-term investments.
On initial recognition, all investments are measured at cost. The cost

comprises purchase price and directly attributable acquisition charges such
as brokerage, fees and duties. If an investment is acquired, or partly
acquired, by the issue of shares or other securities, the acquisition cost is
the fair value of the securities issued. If an investment is acquired in
exchange for another asset, the acquisition is determined by reference to
the fair value of the asset given up or by reference to the fair value of the
investment acquired, whichever is more clearly evident.
Current investments are carried in the financial statements at lower of cost

and fair value determined on an individual investment basis. Long-term
investments are carried at cost. However, provision for diminution in value is
made to recognize a decline other than temporary in the value of the
investments.
On disposal of an investment, the difference between its carrying amount

and net disposal proceeds is charged or credited to the statement of profit
and loss.
(h) Inventories
123
Inventories comprise of stores and spares and are valued at lower of cost
and net realizable value. Cost is determined on first in first out basis. Net
realizable value is the estimated selling price in the ordinary course of
business reduced by the estimated costs to affect the sale.
(i) Revenue recognition
Revenue is recognized to the extent that it is probable that the economic

benefits will flow to the Company and the revenue can be reliably measured.
The following specific recognition criteria must also be met before revenue is
recognized:
Income from services
Revenue from pathological laboratory services and running of clinics are

recognised as and when services are rendered.
Interest
Interest is recognized on a time proportion basis taking into account the

amount outstanding and the rate applicable.
(j) Foreign currency translation
Initial recognition
Foreign currency transactions are recorded in the reporting currency, by

applying to the foreign currency amount the exchange rate between the
reporting currency and the foreign currency at the date of the transaction.
Conversion
Foreign currency monetary items are retranslated using the exchange rate
prevailing at the reporting date. Non-monetary items, which are measured in
terms of historical cost denominated in a foreign currency, are reported
using the exchange rate at the date of the transaction. Non-monetary items,
which are measured at fair value or other similar valuation denominated in a
foreign currency, are translated using the exchange rate at the date when
such value was determined.
Exchange differences
Exchange differences arising on settlement of monetary items or on

reporting such monetary items of the Company at rates different from those
at which they were initially recorded during the year, or reported in previous
financial statements, are recognised as income or as expenses in the year in
which they arise.
(k) Retirement and other employee benefits
Retirement benefit in the form of provident fund is a defined contribution

scheme. The contributions to the provident fund are charged to the
statement of profit and loss for the year when the contributions are due. The
Company has no obligation, other than the contribution payable to the
provident fund.
The Company operates a defined benefit plan for its employees, viz.,
gratuity. The costs of providing benefits under the plan are determined on
the basis of actuarial valuation at each year-end using the projected unit
credit method. Actuarial gains and losses for the defined benefit plan are
recognized in full in the period in which they occur in the statement of profit
and loss.
Accumulated leave, which is expected to be utilized within the next 12

months, is treated as short-term employee benefit. The Company measures
the expected cost of such absences as the additional amount that it expects
to pay as a result of the unused entitlement that has accumulated at the
reporting date.
124
The Company treats accumulated leave expected to be carried forward

beyond twelve months, as long-term employee benefit for measurement
purposes. Such long-term compensated absences are provided for based on
the actuarial valuation using the projected unit credit method at the
year-end. Actuarial gains/losses are immediately taken to the statement of
profit and loss and are not deferred. The company presents the entire leave
as a current liability in the balance sheet, since it does not have an
unconditional right to defer its settlement for 12 months after the reporting
date.
(l) Employee stock compensation cost
Employees (including senior executives) of the company receive

remuneration in the form of share based payment transactions, whereby
employees render services as consideration for equity instruments.
In accordance with the Guidance Note on Accounting for Employee

Share-based Payments, the cost of equity-settled transactions is measured
using the intrinsic value method and recognized, together with a
corresponding increase in the “Stock options outstanding account” in
reserves. The cumulative expense recognized for equity-settled transactions
at each reporting date until the vesting date reflects the extent to which the
vesting period has expired and the company’s best estimate of the number
of equity instruments that will ultimately vest. The expense or credit
recognized in the statement of profit and loss for a period represents the
movement in cumulative expense recognized as at the beginning and end of
that period and is recognized in employee benefit expenses.
(m) Income taxes
Tax expense comprises current and deferred tax. Current income-tax is

measured at the amount expected to be paid to the tax authorities in
accordance with the Income-tax Act, 1961 enacted in India. The tax rates
and tax laws used to compute the amounts are those that are enacted or
substantively enacted, at the reporting date.
Deferred income taxes reflects the impact of timing differences between

taxable income and accounting income originating during the current year
and reversal of timing differences for the earlier years. Deferred tax is
measured using the tax rates and the tax laws enacted or substantively
enacted at the reporting date.
Deferred tax liabilities are recognized for all taxable timing differences.
Deferred tax assets are recognized for deductible timing differences only to
the extent that there is reasonable certainty that sufficient future taxable
income will be available against which such deferred tax assets can be
realized. In situations where the company has unabsorbed depreciation or
carry forward tax losses, all deferred tax assets are recognized only if there
is virtual certainty supported by convincing evidence that they can be
realized against future taxable profits.
At each reporting date, the company re-assesses unrecognized deferred tax

assets. It recognizes unrecognized deferred tax asset to the extent that it
has become reasonably certain or virtually certain, as the case may be, that
sufficient future taxable income will be available against which such deferred
tax assets can be realized.
(n) Earnings per share
Basic earnings per share are calculated by dividing the net profit or loss for
the period attributable to equity shareholders by the weighted average
number of equity shares outstanding during the period.
For the purpose of calculating diluted earnings per share, the net profit or
loss for the period attributable to equity shareholders and the weighted
average number of shares outstanding during the period are adjusted for the
effects of all dilutive potential equity shares.
125
(o) Provisions
A provision is recognized when the company has a present obligation as a

result of past event, it is probable that an outflow of resources embodying
economic benefits will be required to settle the obligation and a reliable
estimate can be made of the amount of the obligation. Provisions are not
discounted to their present value and are determined based on the best
estimate required to settle the obligation at the reporting date. These
estimates are reviewed at each reporting date and adjusted to reflect the
current best estimates.
(p) Contingent liabilities
A contingent liability is a possible obligation that arises from past events

whose existence will be confirmed by the occurrence or non-occurrence of
one or more uncertain future events beyond the control of the company or a
present obligation that is not recognized because it is not probable that an
outflow of resources will be required to settle the obligation. A contingent
liability also arises in extremely rare cases where there is a liability that
cannot be recognized because it cannot be measured reliably. The company
does not recognize a contingent liability but discloses its existence in the
financial statements.
(q) Cash and cash equivalents
Cash and cash equivalents for the purposes of cash flow statement
comprise cash at bank and in hand and short-term investments with an
original maturity of three months or less.
126
Disclosure of accounting policies, change in accounting policies and changes in estimates explanatory [Text Block]
Corporate
1.
information
MedPlus Health Services Private Limited (the ‘Company’) was incorporated on November
13, 2006 and is a company registered under Indian Companies Act, 1956. The Company
has foreign direct investment of 49%. The Company is in the business of pathological
laboratory testing.
Basis of
2.
preparation
The financial statements of the company have been prepared in accordance with the
generally accepted accounting principles in India (Indian GAAP). The company has
prepared these financial statements to comply in all material respects with the accounting
standards notified under section 133 of the Companies Act 2013, read together with
paragraph 7 of the Companies (Accounts) Rules 2014. The accounting policies adopted in
the preparation of financial statements are consistent with those of previous year.
Summary
of
2.1. significant
accounting
policies
(a) Use of estimates
The preparation of financial statements in conformity with Indian GAAP requires the
management to make judgments, estimates and assumptions that affect the reported
amounts of revenues, expenses, assets and liabilities and the disclosure of contingent
liabilities, at the end of the reporting period. Although these estimates are based on the
management’s best knowledge of current events and actions, uncertainty about these
assumptions and estimates could result in the outcomes requiring a material adjustment to
the carrying amounts of assets or liabilities in future periods.
(b) Tangible fixed assets
Fixed assets are stated at cost, less accumulated depreciation and impairment losses, if
any. The cost comprises purchase price and directly attributable cost of bringing the asset
to its working condition for the intended use. Any trade discounts and rebates are deducted
in arriving at the purchase price.
Subsequent expenditure related to an item of fixed asset is added to its book value only if it
increases the future benefits from the existing asset beyond its previously assessed
standard of performance. All other expenses on existing fixed assets, including day-to-day
repair and maintenance expenditure and cost of replacing parts, are charged to the
statement of profit and loss for the period during which such expenses are incurred.
Gains or losses arising from derecognition of fixed assets are measured as the difference
between the net disposal proceeds and the carrying amount of the asset and recognized in
the statement of profit and loss when the asset is derecognized.
(c) Depreciation on tangible fixed assets
Depreciation on fixed assets other than leasehold improvements is calculated on a

straight-line basis using the rates arrived at based on the useful lives estimated by the
management which coincide with the lives prescribed under the schedule II to the
Depreciation on leasehold improvements is provided over the lease term or 5 years,

whichever is shorter, which is higher than the rates prescribed under the schedule II to the
127
(d) Intangible assets
Intangible assets acquired separately are measured on initial recognition at cost. Following
initial recognition, intangible assets are carried at cost less accumulated amortization and
accumulated impairment losses, if any.
Intangible assets are amortized on a straight line basis over a period of five years or
estimated useful life whichever is lower.
(e) Impairment of tangible assets and intangible assets
The Company assesses at each reporting date whether there is an indication that an asset
may be impaired. If any indication exists, or when annual impairment testing for an asset is
required, the Company estimates the asset’s recoverable amount. An asset’s recoverable
amount is the higher of an asset’s net selling price and its value in use. The recoverable
amount is determined for an individual asset, unless the asset does not generate cash
inflows that are largely independent of those from other assets or groups of assets. Where
the carrying amount of an asset exceeds its recoverable amount, the asset is considered
impaired and is written down to its recoverable amount. In assessing value in use, the
estimated future cash flows are discounted to their present value using a pre-tax discount
rate that reflects current market assessments of the time value of money and the risks
specific to the asset. In determining net selling price, recent market transactions are taken
into account, if available. If no such transactions can be identified, an appropriate valuation
model is used.
Impairment losses, including impairment on inventories, are recognized in the statement of

profit and loss.
After impairment, depreciation is provided on the revised carrying amount of the asset over
its remaining useful life.
An assessment is made at each reporting date as to whether there is any indication that
previously recognized impairment losses may no longer exist or may have decreased. If
such indication exists, the company estimates the asset’s or cash-generating unit’s
recoverable amount. A previously recognized impairment loss is reversed only if there has
been a change in the assumptions used to determine the asset’s recoverable amount since
the last impairment loss was recognized. The reversal is limited so that the carrying amount
of the asset does not exceed its recoverable amount, nor exceed the carrying amount that
would have been determined, net of depreciation, had no impairment loss been recognized
for the asset in prior years. Such reversal is recognized in the statement of profit and loss
unless the asset is carried at a revalued amount, in which case the reversal is treated as a
revaluation increase.
(f) Leases
Leases, where the lessor effectively retains substantially all the risks and benefits of
ownership of the leased item, are classified as operating leases. Operating lease payments
are recognized as an expense in the statement of profit and loss on a straight-line basis
over the lease term.
(g) Investments
Investments, which are readily realizable and intended to be held for not more than one
year from the date on which such investments are made, are classified as current
investments. All other investments are classified as long-term investments.
On initial recognition, all investments are measured at cost. The cost comprises purchase
price and directly attributable acquisition charges such as brokerage, fees and duties. If an
investment is acquired, or partly acquired, by the issue of shares or other securities, the
acquisition cost is the fair value of the securities issued. If an investment is acquired in
exchange for another asset, the acquisition is determined by reference to the fair value of
the asset given up or by reference to the fair value of the investment acquired, whichever is
more clearly evident.
Current investments are carried in the financial statements at lower of cost and fair value
determined on an individual investment basis. Long-term investments are carried at cost.
128
However, provision for diminution in value is made to recognize a decline other than
temporary in the value of the investments.
On disposal of an investment, the difference between its carrying amount and net disposal
proceeds is charged or credited to the statement of profit and loss.
(h) Inventories
Inventories comprise of stores and spares and are valued at lower of cost and net
realizable value. Cost is determined on first in first out basis. Net realizable value is the
estimated selling price in the ordinary course of business reduced by the estimated costs to
affect the sale.
(i) Revenue recognition
Revenue is recognized to the extent that it is probable that the economic benefits will flow
to the Company and the revenue can be reliably measured. The following specific
recognition criteria must also be met before revenue is recognized:
Income from services
Revenue from pathological laboratory services and running of clinics are recognised as and
when services are rendered.
Interest
Interest is recognized on a time proportion basis taking into account the amount
outstanding and the rate applicable.
(j) Foreign currency translation
Initial recognition
Foreign currency transactions are recorded in the reporting currency, by applying to the
foreign currency amount the exchange rate between the reporting currency and the foreign
currency at the date of the transaction.
Conversion
Foreign currency monetary items are retranslated using the exchange rate prevailing at the
reporting date. Non-monetary items, which are measured in terms of historical cost
denominated in a foreign currency, are reported using the exchange rate at the date of the
transaction. Non-monetary items, which are measured at fair value or other similar
valuation denominated in a foreign currency, are translated using the exchange rate at the
date when such value was determined.
Exchange differences
Exchange differences arising on settlement of monetary items or on reporting such

monetary items of the Company at rates different from those at which they were initially
recorded during the year, or reported in previous financial statements, are recognised as
income or as expenses in the year in which they arise.
(k) Retirement and other employee benefits
Retirement benefit in the form of provident fund is a defined contribution scheme. The
contributions to the provident fund are charged to the statement of profit and loss for the
year when the contributions are due. The Company has no obligation, other than the
contribution payable to the provident fund.
The Company operates a defined benefit plan for its employees, viz., gratuity. The costs of
providing benefits under the plan are determined on the basis of actuarial valuation at each
year-end using the projected unit credit method. Actuarial gains and losses for the defined
benefit plan are recognized in full in the period in which they occur in the statement of profit
and loss.
Accumulated leave, which is expected to be utilized within the next 12 months, is treated as
short-term employee benefit. The Company measures the expected cost of such absences
as the additional amount that it expects to pay as a result of the unused entitlement that
129
has accumulated at the reporting date.
The Company treats accumulated leave expected to be carried forward beyond twelve
months, as long-term employee benefit for measurement purposes. Such long-term
compensated absences are provided for based on the actuarial valuation using the
projected unit credit method at the year-end. Actuarial gains/losses are immediately taken
to the statement of profit and loss and are not deferred. The company presents the entire
leave as a current liability in the balance sheet, since it does not have an unconditional right
to defer its settlement for 12 months after the reporting date.
(l) Employee stock compensation cost
Employees (including senior executives) of the company receive remuneration in the form
of share based payment transactions, whereby employees render services as consideration
for equity instruments.
In accordance with the Guidance Note on Accounting for Employee Share-based

Payments, the cost of equity-settled transactions is measured using the intrinsic value
method and recognized, together with a corresponding increase in the “Stock options
outstanding account” in reserves. The cumulative expense recognized for equity-settled
transactions at each reporting date until the vesting date reflects the extent to which the
vesting period has expired and the company’s best estimate of the number of equity
instruments that will ultimately vest. The expense or credit recognized in the statement of
profit and loss for a period represents the movement in cumulative expense recognized as
at the beginning and end of that period and is recognized in employee benefit expenses.
(m) Income taxes
Tax expense comprises current and deferred tax. Current income-tax is measured at the
amount expected to be paid to the tax authorities in accordance with the Income-tax Act,
1961 enacted in India. The tax rates and tax laws used to compute the amounts are those
that are enacted or substantively enacted, at the reporting date.
Deferred income taxes reflects the impact of timing differences between taxable income
and accounting income originating during the current year and reversal of timing differences
for the earlier years. Deferred tax is measured using the tax rates and the tax laws enacted
or substantively enacted at the reporting date.
Deferred tax liabilities are recognized for all taxable timing differences. Deferred tax assets
are recognized for deductible timing differences only to the extent that there is reasonable
certainty that sufficient future taxable income will be available against which such deferred
tax assets can be realized. In situations where the company has unabsorbed depreciation
or carry forward tax losses, all deferred tax assets are recognized only if there is virtual
certainty supported by convincing evidence that they can be realized against future taxable
profits.
At each reporting date, the company re-assesses unrecognized deferred tax assets. It
recognizes unrecognized deferred tax asset to the extent that it has become reasonably
certain or virtually certain, as the case may be, that sufficient future taxable income will be
available against which such deferred tax assets can be realized.
(n) Earnings per share
Basic earnings per share are calculated by dividing the net profit or loss for the period
attributable to equity shareholders by the weighted average number of equity shares
outstanding during the period.
For the purpose of calculating diluted earnings per share, the net profit or loss for the period
attributable to equity shareholders and the weighted average number of shares outstanding
during the period are adjusted for the effects of all dilutive potential equity shares.
(o) Provisions
A provision is recognized when the company has a present obligation as a result of past
event, it is probable that an outflow of resources embodying economic benefits will be
required to settle the obligation and a reliable estimate can be made of the amount of the
130
obligation. Provisions are not discounted to their present value and are determined based
on the best estimate required to settle the obligation at the reporting date. These estimates
are reviewed at each reporting date and adjusted to reflect the current best estimates.
(p) Contingent liabilities
A contingent liability is a possible obligation that arises from past events whose existence
will be confirmed by the occurrence or non-occurrence of one or more uncertain future
events beyond the control of the company or a present obligation that is not recognized
because it is not probable that an outflow of resources will be required to settle the
obligation. A contingent liability also arises in extremely rare cases where there is a liability
that cannot be recognized because it cannot be measured reliably. The company does not
recognize a contingent liability but discloses its existence in the financial statements.
(q) Cash and cash equivalents
Cash and cash equivalents for the purposes of cash flow statement comprise cash at bank
and in hand and short-term investments with an original maturity of three months or less.
[201700] Notes - Government grants

01/04/2016 01/04/2015
to to
31/03/2017 31/03/2016
Disclosure of notes on government grants explanatory [TextBlock]
Capital subsidies or grants received from government authorities 0 0
Revenue subsidies or grants received from government authorities 0 0
[201200] Notes - Employee benefits

01/04/2016 01/04/2015
to to
31/03/2017 31/03/2016
Textual information (38) Textual information (39)
Disclosure of employee benefits explanatory [TextBlock] [See below] [See below]
131
Disclosure of employee benefits explanatory [Text Block]

Employee
19. benefits
expense
March 31, March 31,

2017 2016
Salaries, wages
and bonus [net
of
reimbursement
14,379,133 12,795,649
of Rs.21,517,065
(March 31, 2016:
Rs.20,151,185)]
Contribution to
provident fund 1,197,439 1,098,797
Gratuity expense
(refer note no.
375,768 275,747
24)
Staff welfare
expenses [net of
reimbursement
of
606,288 667,081
Rs.79,490(March
31, 2016:
Rs.96,098)]
Amortisation of
employees stock
compensation - 13,061,452
expenses
16,558,628 27,898,72
132
Disclosure of employee benefits explanatory [Text Block]

Employee
19. benefits
expense
March 31, March 31,

2016 2015
Salaries, wages and bonus [net of

reimbursement of Rs.20,151,185
12,795,649 12,382,571
(March 31, 2015: Rs.18,310,330)]
Contribution to provident fund

1,098,797 907,490
Gratuity expense (refer note no.

24) 275,747 591,999
Staff welfare expenses [net of

reimbursement of
Rs.96,098(March 31, 2015: 667,081 493,920
Rs.79,447)]
Amortisation of employees stock

compensation expenses 13,061,452 13,258,815
27,898,726 27,634,795
133
[201600] Notes - Related party
Disclosure of relationship and transactions between related parties [Table] ..(1)

Categories of related parties [Axis] Column 1 Column 2
01/04/2016 01/04/2015 01/04/2016 01/04/2015
to to to to
31/03/2017 31/03/2016 31/03/2017 31/03/2016
Disclosure of relationship and transactions
between
related parties [Abstract]
Disclosure of relationship and
transactions between
related parties [LineItems]
OPTIVAL HEALTH OPTIVAL HEALTH RITEMED PHARMA RITEMED PHARMA
Name of related party SOLUTIONS PRIVATE SOLUTIONS PRIVATE RETAIL PRIVATE RETAIL PRIVATE
LIMITED LIMITED LIMITED LIMITED
Country of incorporation or residence
of related India India India India
party
CIN of related party U85110TG2005PTC046821 U85110TG2005PTC046821 U52399TG2009PTC064130 U52399TG2009PTC064130
Description of nature of related party
Subsidiary company Subsidiary company Subsidiary company Subsidiary company
relationship
Description of nature of transactions
with related Multiple Transactions Multiple Transactions Multiple Transactions Multiple Transactions
party
Related party transactions [Abstract]
Purchases of tangible assets related
party 4,63,946 4,63,946
transactions
Revenue from rendering of services
related 1,64,70,852 1,64,70,852 37,76,671 37,76,671
party transactions
Advances given during year related
party 0 0
transactions
Advances taken during year related
party 0 0
transactions
Interest paid during year related party
0 0
transactions
Reimbursement of expenses incurred
on
behalf of company during year 0 0
related
party transactions
Reimbursement of expenses incurred
by
related party during year related party 3,72,254 3,72,254 10,504 10,504
transactions
Transfers under finance agreements
related
party transactions [Abstract]
Equity contributions made under
finance
23,00,00,000 23,00,00,000
agreements related party
transactions
Provision of guarantees or collateral
to 105,00,00,000 105,00,00,000 18,00,00,000 18,00,00,000
enterprise related party transactions
Other related party transactions
9,23,990 9,23,990 86,339 86,339
expense
3,25,523 3,25,523
income
134

contribution 0 0
made
Amount written off during period in
respect 0 0 0 0
of debts due from related parties
Amount written back during period in
respect 0 0 0 0
of debts due to related parties

01/04/2016 01/04/2015 01/04/2016 01/04/2015
to to to to
31/03/2017 31/03/2016 31/03/2017 31/03/2016
Disclosure of relationship and transactions
between
Disclosure of relationship and
transactions between
M H S M H S PANINDIA PHARMA PANINDIA PHARMA
Name of related party PHARMACEUTICALS PHARMACEUTICALS DISTRIBUTORS DISTRIBUTORS
PRIVATE LIMITED PRIVATE LIMITED PRIVATE LIMITED PRIVATE LIMITED
of related India India India India
party
CIN of related party U24233TG2008PTC059624 U24233TG2008PTC059624 U24232TG2007PTC055895 U24232TG2007PTC055895
Description of nature of related party
Subsidiary company Subsidiary company Subsidiary company Subsidiary company
relationship
Description of nature of transactions
with related Multiple Transactions Multiple Transactions Multiple Transactions Multiple Transactions
party
Revenue from rendering of services
related 3,39,186 3,39,186
party transactions
Transfers under finance agreements
related
Equity contributions made under
finance
1,70,00,000 1,70,00,000
agreements related party
transactions
Amount written off during period in
respect 0 0 0 0
Amount written back during period in
respect 0 0 0 0
135

01/04/2016 01/04/2015 01/04/2016 01/04/2015
to to to to
31/03/2017 31/03/2016 31/03/2017 31/03/2016
Disclosure of relationship and transactions between
MEDSUPPLY MEDSUPPLY
G Madhukar
Name of related party DISTRIBUTORS DISTRIBUTORS
Reddy
G Madhukar Reddy
PRIVATE LIMITED PRIVATE LIMITED
Country of incorporation or residence of related
party
Permanent account number of related party AJEPG8481E AJEPG8481E
CIN of related party U24239TG2007PTC052676 U24239TG2007PTC052676
Key Management Key Management
Description of nature of related party relationship Subsidiary company Subsidiary company
Personnel Personnel
Description of nature of transactions with related
Multiple Transactions Multiple Transactions Remuneration Remuneration
party
Revenue from rendering of services related
0 0
party transactions
Reimbursement of expenses incurred by
related party during year related party 7,66,708 7,66,708
transactions
Transfers under finance agreements related
Equity contributions made under finance
agreements related party transactions, 0.00% 0.00%
percentage
Other related party transactions expense 0 0
Transaction relating to key management personnel
[Abstract]
Remuneration for key managerial personnel 40,00,000 40,00,000
Amount written off during period in respect
0 0 0 0
Amount written back during period in respect
0 0 0 0
136

01/04/2016 01/04/2015 01/04/2016 01/04/2015
to to to to
31/03/2017 31/03/2016 31/03/2017 31/03/2016
IL & FS Trust IL & FS Trust
Company Limited Company Limited (As
Name of related party C Bhaskar Reddy C Bhaskar Reddy (As trustee of India trustee of India
Venture Trust - Venture Trust - Fund-
Fund- I) I)
party
Permanent account number of related party AFKPC5689Q AFKPC5689Q
AAATI6554P AAATI6554P
Enterprises which
Enterprises which are
are owned, or have
owned, or have
significant influence
Key Management Key Management of or are partners
Description of nature of related party relationship Personnel Personnel with Key
of or are partners with
Key management
management
personnel and their
personnel and their
relatives
relatives
Description of nature of transactions with related Multiple
Remuneration Remuneration Multiple Transactions
party Transactions
0 0
transactions
Other related party transactions contribution
0 0
made
Transaction relating to key management personnel
[Abstract]
Remuneration for key managerial personnel 53,36,100 53,36,100
0 0 0 0
0 0 0 0
137

01/04/2016 01/04/2015 01/04/2016 01/04/2015
to to to to
31/03/2017 31/03/2016 31/03/2017 31/03/2016
IL & FS Trust IL & FS Trust IL & FS Trust
IL & FS Trust
Company Limited Company Limited Company Limited (As
Company Limited (As
Name of related party (As trustee of TVS
trustee of TVS Sriram
(As trustee of India trustee of India
Sriram Growth Fund Venture Trust - Venture Trust - Fund-
Growth Fund I)
I) Fund- II) II)
party
Permanent account number of related party AABTT5582H AABTT5582H AABTI1118C AABTI1118C
Enterprises which Enterprises which
Enterprises which are Enterprises which are
are owned, or have are owned, or have
owned, or have owned, or have
significant influence significant influence
significant influence significant influence
of or are partners of or are partners
Description of nature of related party relationship with Key
with Key
Key management Key management
management management
personnel and their personnel and their
personnel and their personnel and their
relatives relatives
relatives relatives
Description of nature of transactions with related Multiple Multiple
Multiple Transactions Multiple Transactions
party Transactions Transactions
0 0
transactions
Other related party transactions contribution
0 0 0 0
made
0 0 0 0
0 0 0 0

Categories of related parties [Axis] Column 11
01/04/2016 01/04/2015
to to
31/03/2017 31/03/2016
Disclosure of relationship and transactions between related parties [Abstract]
Disclosure of relationship and transactions between related parties [LineItems]
MKCP Institutional MKCP Institutional
Name of related party Inve s tor s Inve s tor s
(Mauritius) III Ltd (Mauritius) III Ltd
Country of incorporation or residence of related party MAURITIUS MAURITIUS
Enterprises which
Enterprises which are
are owned, or have
owned, or have
of or are partners
Description of nature of related party relationship with Key
Key management
management
personnel and their
personnel and their
relatives
relatives
Multiple
Description of nature of transactions with related party Transactions
Multiple Transactions

Interest paid during year related party transactions 428 428
Other related party transactions contribution made 0 0
Amount written off during period in respect of debts due from related parties 0 0
Amount written back during period in respect of debts due to related parties 0 0
138

01/04/2016 01/04/2015
to to
31/03/2017 31/03/2016
Disclosure of notes on related party explanatory [TextBlock] [See below]
Whether there are any related party transactions during year Yes Yes
Whether company is subsidiary company No No
139
Disclosure of notes on related party explanatory [Text Block]

Related party
transactions
B.
during the year
ended
March 31,
2017
(i) Subsidiaries
1. Optival
Health Solutions
Private Limited
Investment in
share capital of - 230,000,000
Rental income
249,611
Rental
expenses
[including
service tax of
1,043,092 923,990
Rs.135,457
(March 31,2016
: Rs.113,080)]
Purchase of
Fixed Assets - 463,946
Purchase of
Stationery - 41,985
Reimbursement
of expenses by 273,019 372,254
Guarantee
given on behalf
of (refer note 1,050,000,000 1,050,000,000
no. 28)
Management
services
17,090,652 16,470,852
rendered
Pathological
Testing Services
150,600 738,450
rendered
2. Ritemed
Pharma Retail
Private Limited
Rent expense
[including
service tax of
Rs.16,968 130,568 86,339
(March 31,2016
: Rs.10,600)]
Reimbursement
140
of expenses by 2,676 10,504
Guarantee
given on behalf
of (refer note 180,000,000 180,000,000
no. 28)
Management
services
4,575,342 4,286,174
rendered
Pathological
Testing Services
123,000 487,050
rendered
3. MHS
Pharmaceuticals
Private Limited
Management
services
480,893 339,186
rendered
4. PanIndia
Pharma
Distributors
Private Limited
Investment in
share capital of - 17,000,000
5. MedSupply
Distributors
Private Limited
Reimbursement
of expenses by - 766,708
Reimbursement
of expenses to 23,642 -
Enterprises over
which
shareholders,
key
(ii) management
personnel
exercise control
or significant
influence
1. Hinshitsu
Manufacturing
Pvt Ltd
Purchase of
Fixed Assets 35,929 -
Key
(iii) Management
Personnel
G. Madhukar
Reddy
Managerial
141
remuneration 4,000,000 4,000,000
C. Bhaskar
Reddy
Managerial
remuneration 5,939,590 5,336,100
Note: The
remuneration to
the key
management
personnel does
not include the
provisions made
for gratuity and
leave benefits,
as they are
determined on
an actuarial
basis for the
company as a
whole.
Enterprises
under common
(iv) control with
regards to
Investing party
MKCP
Institutional
Investors
(Mauritius) III
Ltd
Interest
expense 428
Balances
C. outstanding as
at debit/(credit)
March 31,
2017
(i) Subsidiaries
1. Optival
Health Solutions
(61,173) 1,481,800
Private Limited
2. Ritemed
Pharma Retail
(12,979) 458,368
Private Limited
3. Ritecure
Pharma Private
629,876 629,876
Limited
4. MedSupply
Distributors
23,642 -
Private Limited.
5. MHS
142
Pharmaceuticals
Private Limited - 17,574
Enterprises
exercising
significant
(ii) influence over
the Company
("Investing
party")
1. IL & FS Trust
Company
Limited (As
trustee of India (40,000,000) (40,000,000)
Venture Trust -
Fund- I)*
2. Vistra ITCL
India Limited
[formerly known
as 'IL & FS (40,000,000) (40,000,000)
Trust Company
Limited'
(As trustee of
TVS Sriram
Growth Fund I)]*
Enterprises
under common
(iii) control with
regards to
Investing party
1. IL & FS Trust
Company
Limited (As
trustee of India (40,000,000) (40,000,000)
Venture Trust -
Fund- II)*
2. MKCP
Institutional
Investors
(428,470,000) (428,470,000)
(Mauritius) III
Ltd**
Enterprises over
which
shareholders,
key
(iv) management
personnel
exercise control
or significant
influence
1. Hinshitsu
Manufacturing
(35,929) -
Pvt Ltd
143
[201400] Notes - Leases

01/04/2016 01/04/2015
to to
31/03/2017 31/03/2016
Disclosure of leases explanatory [TextBlock]
Whether any operating lease has been converted to financial lease or
No No
vice-versa
[300300] Notes - Earnings per share

01/04/2016 01/04/2015 01/04/2014
to to to
31/03/2017 31/03/2016 31/03/2015
Disclosure of earnings per share explanatory [TextBlock]
Adjustments of numerator to calculate basic earnings per share [Abstract]
Adjustments of numerator to calculate diluted earnings per share [Abstract]
144
[202800] Notes - Subsidiary information
Details of subsidiaries [Table] ..(1)

Subsidiaries [Axis] Column 1 Column 2 Column 3 Column 4
01/04/2016 01/04/2016 01/04/2016 01/04/2016
to to to to
31/03/2017 31/03/2017 31/03/2017 31/03/2017
Details of subsidiaries [Abstract]
Details of subsidiaries [LineItems]
OPTIVAL HEALTH RITEMED PHARMA M H S PANINDIA PHARMA
Name of subsidiary SOLUTIONS PRIVATE RETAIL PRIVATE PHARMACEUTICALS DISTRIBUTORS
LIMITED LIMITED PRIVATE LIMITED PRIVATE LIMITED
INDIA INDIA INDIA INDIA
of subsidiary
CIN of subsidiary company U85110TG2005PTC046821 U52399TG2009PTC064130 U24233TG2008PTC059624 U24232TG2007PTC055895
Nature of issuing authority in country
of Ministry of Corporate Ministry of Corporate Ministry of Corporate Ministry of Corporate
incorporation or residence subsidiary Affairs Affairs Affairs Affairs
company
Section under which company became
Section 2(87)(ii) Section 2(87)(ii) Section 2(87)(ii) Section 2(87)(ii)
subsidiary
Whether subsidiary has filed balance
Yes Yes Yes Yes
sheet
SRN of filing of balance sheet by
G25094848 G25684176 G24282782 G25096496
subsidiary
Whether financial year of subsidiary
different from financial year of holding
No No No No
company
Financial year of subsidiary [Abstract]
Start date of accounting period of
01/04/2016 01/04/2016 01/04/2016 01/04/2016
subsidiary
End date of accounting period of
31/03/2017 31/03/2017 31/03/2017 31/03/2017
subsidiary
Percentage of shareholding in
99.98% 100.00% 99.98% 100.00%
subsidiary
Key information about subsidiary
[Abstract]
Reporting currency of subsidiary INR INR INR INR
Exchange rate as applicable for
NA NA NA NA
subsidiary
Share capital of subsidiary 141,54,40,000 23,00,00,000 1,00,000 4,36,00,000
Reserves and surplus of subsidiary 9,14,60,000 18,52,40,000 4,53,80,000 -43,40,000
Total assets of subsidiary 408,89,60,000 77,81,10,000 11,97,10,000 3,93,10,000
Total liabilities of subsidiary 408,89,60,000 77,81,10,000 11,97,10,000 3,93,10,000
Investment of subsidiary 0 5,00,000 0 3,86,50,000
Turnover of subsidiary 1,908,56,50,000 511,39,50,000 52,69,50,000 0
Profit before tax of subsidiary 28,76,40,000 18,50,70,000 2,60,60,000 -30,000
Provision for tax of subsidiary 6,10,10,000 2,72,10,000 7,30,000 0
Profit after tax of subsidiary 18,15,80,000 11,91,10,000 1,68,80,000 -30,000
Proposed dividend of subsidiary 0 0 0 0
145

Subsidiaries [Axis] Column 5 Column 6 Column 7 Column 8
01/04/2016 01/04/2016 01/04/2016 01/04/2016
to to to to
31/03/2017 31/03/2017 31/03/2017 31/03/2017
MEDSUPPLY VENKATA KRISHNA
RITECURE PHARMA DECCAN MEDISALES
Name of subsidiary PRIVATE LIMITED
DISTRIBUTORS ENTERPRISES PRIVATE
PRIVATE LIMITED
PRIVATE LIMITED LIMITED
INDIA INDIA INDIA INDIA
of subsidiary
CIN of subsidiary company U24232TG2008PTC058385 U24239TG2007PTC052676 U51909TG2010PTC071012 U51397KA2011PTC059204
Nature of issuing authority in country
of Ministry of Corporate Ministry of Corporate Ministry of Corporate Ministry of Corporate
incorporation or residence subsidiary Affairs Affairs Affairs Affairs
company
Section under which company became
Section 2(87)(ii) Section 2(87)(ii) Section 2(87)(ii) Section 2(87)(ii)
subsidiary
Whether subsidiary has filed balance
Yes Yes Yes Yes
sheet
SRN of filing of balance sheet by
G25097429 G24308918 G24313280 G24268872
subsidiary
Whether financial year of subsidiary
different from financial year of holding
No No No No
company
Start date of accounting period of
01/04/2016 01/04/2016 01/04/2016 01/04/2016
subsidiary
End date of accounting period of
31/03/2017 31/03/2017 31/03/2017 31/03/2017
subsidiary
Percentage of shareholding in
100.00% 100.00% 100.00% 100.00%
subsidiary
Key information about subsidiary
[Abstract]
Reporting currency of subsidiary INR INR INR INR
Exchange rate as applicable for
NA NA NA NA
subsidiary
Share capital of subsidiary 1,00,000 12,57,70,000 1,80,000 21,00,000
Reserves and surplus of subsidiary -8,60,000 -12,38,00,000 2,66,20,000 1,64,80,000
Total assets of subsidiary 0 24,50,000 5,74,80,000 3,80,30,000
Total liabilities of subsidiary 0 24,50,000 5,74,80,000 3,80,30,000
Investment of subsidiary 0 0 0 0
Turnover of subsidiary 0 0 171,09,30,000 109,48,10,000
Profit before tax of subsidiary -40,000 -3,70,000 1,14,10,000 96,80,000
Provision for tax of subsidiary 0 0 50,000 70,000
Profit after tax of subsidiary -40,000 -3,70,000 76,10,000 66,60,000
Proposed dividend of subsidiary 0 0 0 0
146

Subsidiaries [Axis] Column 9 Column 10 Column 11
01/04/2016 01/04/2016 01/04/2016
to to to
31/03/2017 31/03/2017 31/03/2017
SHRI BANASHANKARI SIDSON PHARMA
SAI SRIDHAR PHARMA
Name of subsidiary PRIVATE LIMITED
PHARMA PRIVATE DISTRIBUTORS
LIMITED PRIVATE LIMITED
Country of incorporation or residence of subsidiary INDIA INDIA INDIA
CIN of subsidiary company U24232TG2007PTC055902 U74900KA2014PTC074302 U74900TG2014PTC092145
Nature of issuing authority in country of incorporation or Ministry of Corporate Ministry of Corporate Ministry of Corporate
residence subsidiary company Affairs Affairs Affairs
Section under which company became subsidiary Section 2(87)(ii) Section 2(87)(ii) Section 2(87)(ii)
Whether subsidiary has filed balance sheet Yes Yes No
SRN of filing of balance sheet by subsidiary G24310641 G24266439
Reason if no filing has been made by subsidiary Inadvertent Delay
Whether financial year of subsidiary different from financial
No No No
year of holding company
Start date of accounting period of subsidiary 01/04/2016 01/04/2016 01/04/2016
End date of accounting period of subsidiary 31/03/2017 31/03/2017 31/03/2017
Percentage of shareholding in subsidiary 100.00% 100.00% 99.99%
Key information about subsidiary [Abstract]
Reporting currency of subsidiary INR INR INR
Exchange rate as applicable for subsidiary NA NA NA
Share capital of subsidiary 2,40,000 21,00,000 2,01,00,000
Reserves and surplus of subsidiary 2,63,10,000 2,10,000 -2,20,10,000
Total assets of subsidiary 6,97,10,000 1,28,10,000 2,28,40,000
Total liabilities of subsidiary 6,97,10,000 1,28,10,000 2,28,40,000
Investment of subsidiary 0 0 0
Turnover of subsidiary 131,65,00,000 26,42,10,000 38,09,20,000
Profit before tax of subsidiary 77,50,000 10,10,000 -54,20,000
Provision for tax of subsidiary 5,90,000 0 0
Profit after tax of subsidiary 49,50,000 8,90,000 -54,20,000
Proposed dividend of subsidiary 0 0 0

01/04/2016
to
31/03/2017
Disclosure of subsidiary information explanatory [TextBlock]
Whether company has subsidiary companies Yes
Number of subsidiary companies [pure] 11
Whether company has subsidiary companies which are yet to commence
No
operations
Whether company has subsidiary companies liquidated or sold during year No
[202400] Notes - Investments in associates

01/04/2016
to
31/03/2017
Disclosure of notes on investment in associates explanatory [TextBlock]
Whether company has invested in associates No
Whether company has associates which are yet to commence operations No
Whether company has associates liquidated or sold during year No
147
[202500] Notes - Financial reporting of interests in joint ventures

01/04/2016
to
31/03/2017
Disclosure of notes on interests in joint ventures explanatory [TextBlock]
Whether company has invested in joint ventures No
Whether company has joint ventures which are yet to commence operations No
Whether company has joint ventures liquidated or sold during year No
[202700] Notes - Cash flow statements

01/04/2016 01/04/2015
to to 31/03/2015
31/03/2017 31/03/2016
Disclosure of cash flow statement explanatory [TextBlock]
Cash and cash equivalents if different from balance sheet [Abstract]
Cash and cash equivalents cash flow statement 26,72,677 1,74,52,153 30,07,59,063
Total cash and cash equivalents 26,72,677 1,74,52,153
Income taxes paid (refund) [Abstract]
Income taxes paid (refund), classified as operating activities 23,27,232 61,30,124
Total income taxes paid (refund) 23,27,232 61,30,124
148
[100200] Statement of profit and loss

01/04/2016 01/04/2015 01/04/2014
to to to
31/03/2017 31/03/2016 31/03/2015
Statement of profit and loss [Abstract]
Disclosure of revenue from operations [Abstract]
Disclosure of revenue from operations for other than finance company
[Abstract]
Revenue from sale of products 0 0
Revenue from sale of services 2,16,48,642 2,24,39,160
Total revenue from operations other than finance company 2,16,48,642 2,24,39,160
Total revenue from operations 2,16,48,642 2,24,39,160
Other income 37,28,021 1,00,61,274
Total revenue 2,53,76,663 3,25,00,434
Expenses [Abstract]
Cost of materials consumed 0 0
Changes in inventories of finished goods, work-in-progress and
0 0
stock-in-trade
Employee benefit expense 1,65,58,628 2,78,98,726
Finance costs 430 1,957
Depreciation, depletion and amortisation expense [Abstract]
Depreciation expense 39,01,848 28,55,139
Amortisation expense 0 0
Total depreciation, depletion and amortisation expense 39,01,848 28,55,139
CSR expenditure 0 0
Other expenses 2,44,14,302 4,47,80,371
Total expenses 4,48,75,208 7,55,36,193
Total profit before prior period items, exceptional items, extraordinary
-1,94,98,545 -4,30,35,759
items and tax
Exceptional items before tax 0 0
Total profit before extraordinary items and tax -1,94,98,545 -4,30,35,759
Total profit before tax -1,94,98,545 -4,30,35,759
Tax expense [Abstract]
Total tax expense 0 0
Total profit (loss) for period from continuing operations -1,94,98,545 -4,30,35,759
Total profit (loss) for period before minority interest -1,94,98,545 -4,30,35,759
Total profit (loss) for period -1,94,98,545 -4,30,35,759 -4,30,35,759
Earnings per equity share [Abstract]
Basic earning per equity share [INR/shares] -115.9 [INR/shares] 0
Diluted earnings per equity share [INR/shares] -115.9 [INR/shares] 0
149
[300500] Notes - Subclassification and notes on income and expenses

01/04/2016 01/04/2015
to to
31/03/2017 31/03/2016
Subclassification and notes on income and expense explanatory [TextBlock]
Disclosure of revenue from sale of products [Abstract]
Revenue from sale of products [Abstract]
Total revenue from sale of products 0 0
Disclosure of revenue from sale of services [Abstract]
Revenue from sale of services [Abstract]
Revenue from sale of services, gross 2,16,48,642 2,24,39,160
Total revenue from sale of services 2,16,48,642 2,24,39,160
Disclosure of other income [Abstract]
Interest income [Abstract]
Total interest income 0 0
Dividend income [Abstract]
Total dividend income 0 0
Other non-operating income [Abstract]
Miscellaneous other non-operating income 37,28,021
(A) 1,00,61,274
Total other non-operating income 37,28,021 1,00,61,274
Total other income 37,28,021 1,00,61,274
Disclosure of finance cost [Abstract]
Interest expense [Abstract]
Other interest charges 430
(B) 1,957
Total interest expense 430 1,957
Total finance costs 430 1,957
Employee benefit expense [Abstract]
Salaries and wages 1,43,79,133 1,27,95,649
Managerial remuneration [Abstract]
Remuneration to directors [Abstract]
Total remuneration to directors 0 0
Total managerial remuneration 0 0
Contribution to provident and other funds [Abstract]
Contribution to provident and other funds for others 11,97,439 10,98,797
Total contribution to provident and other funds 11,97,439 10,98,797
Gratuity 3,75,768 2,75,747
Staff welfare expense 6,06,288 6,67,081
Other employee related expenses 0

(C) 1,30,61,452
Total employee benefit expense 1,65,58,628 2,78,98,726
Breakup of other expenses [Abstract]
Consumption of stores and spare parts 78,40,368 82,90,271
Power and fuel 0 0
Rent 27,91,461 26,13,254
Repairs to building 0 0
Repairs to machinery 7,72,151 8,86,716
Insurance 1,51,120 1,32,074
Rates and taxes excluding taxes on income [Abstract]
Other cess taxes 10,35,501
(D) 1,90,870
Total rates and taxes excluding taxes on income 10,35,501 1,90,870
Electricity expenses 6,37,451 10,58,096
Telephone postage 6,00,144 5,97,844
Printing stationery 6,34,984 3,79,719
Travelling conveyance 10,94,013 15,69,009
Legal professional charges 38,92,853 2,24,74,797
Directors sitting fees 0 0
Advertising promotional expenses 3,08,756 18,55,752
Provision bad doubtful debts created 5,44,685 4,04,293
150
Provision bad doubtful loans advances created 0 0

Write-off assets [Abstract]
Miscellaneous expenditure written off [Abstract]
Total miscellaneous expenditure written off 0 0
Bad debts written off 0 0
Bad debts advances written off 47,989 11,482
Total write-off assets 47,989 11,482
Loss on disposal of intangible asset 0 0
Loss on disposal, discard, demolishment and destruction of depreciable
0 4,951
tangible asset
Payments to auditor [Abstract]
Payment for audit services 7,08,180 7,19,548
Total payments to auditor 7,08,180 7,19,548
Miscellaneous expenses 33,54,646 35,91,695
Total other expenses 2,44,14,302 4,47,80,371
Footnotes
(A) bank deposits Rs.8403972 others Rs.315209 Rental income Rs.325523 Liabilities/provisions no longer required written back
Rs.614043 Miscellaneous income Rs.402527
(B) Interest Rs.430 Bank charges Rs.1527
(C) Amortisation of employees stock compensation expenses
(D) rates and taxes
[300600] Notes - Additional information statement of profit and loss

01/04/2016 01/04/2015
to to
31/03/2017 31/03/2016
Additional information on profit and loss account explanatory [TextBlock]
Total changes in inventories of finished goods, work-in-progress and
0 0
stock-in-trade
Exceptional items before tax 0 0
Total exceptional items 0 0
Total exceptional and extraordinary items 0 0
Revenue domestic contracts 2,16,48,642 2,24,39,160
Total revenue contracts 2,16,48,642 2,24,39,160
Total gross income from services rendered 2,16,48,642 2,24,39,160
Expenditure on dividend paid 0 0
Total expenditure in foreign currency 0 0
Total amount of dividend remitted in foreign currency 0 0
Total earnings in foreign currency 0 0
Total revenue from sale of products 0 0
Domestic revenue services 2,16,48,642 2,24,39,160
Total revenue from sale of services 2,16,48,642 2,24,39,160
Gross value of transaction with related parties as per AS-18 0 0
Bad debts of related parties as per AS-18 0 0
[300100] Notes - Revenue

01/04/2016 01/04/2015
to to
31/03/2017 31/03/2016
Textual information (41) Textual information (42)
Disclosure of revenue explanatory [TextBlock] [See below] [See below]
151
Disclosure of revenue explanatory [Text Block]

Revenue from
17.
operations
March 31, March 31,

2017 2016
Sale of services
21,648,642 22,439,160
Net revenue from

operations 21,648,642 22,439,160
Details of service
rendered
March 31, March 31,

2017 2016
Pathological testing
services 21,419,123 22,074,124
Diagnostic Income
229,519 365,036
21,648,642 22,439,160
152
Disclosure of revenue explanatory [Text Block]

Revenue from
17.
operations
March 31, March 31,

2016 2015
Sale of services
22,439,160 23,924,860
Net revenue from

operations 22,439,160 23,924,860
Details of service
rendered
March 31, March 31,

2016 2016
Pathological testing
services 22,074,124 23,614,206
Diagnostic Income
365,036 310,654
22,439,160 23,924,860
153
[300700] Notes - Key managerial personnels and directors remuneration and other information
Disclosure of key managerial personnels and directors and remuneration to key managerial personnels and directors [Table] ..(1)
Key managerial personnels and directors [Axis] Column 1 Column 2
01/04/2016 01/04/2016
to to
31/03/2017 31/03/2017
Disclosure of key managerial personnels and directors and remuneration to key
managerial personnels and directors [Abstract]
Disclosure of key managerial personnels and directors and remuneration to key
managerial personnels and directors [LineItems]
GANGADI
CHERUKUPALLI
Name of key managerial personnel or director MADHUKAR
BHASKAR REDDY
REDDY
Director identification number of key managerial personnel or director 00098097 00926550
Date of birth of key managerial personnel or director 20/09/1967 13/06/1968
Designation of key managerial personnel or director Managing Director Director
MBBS from
Kurnool Medical MS (General
Qualification of key managerial personnel or director College and a MBA Surgeon), FRCS
from the Wharton (Edinburgh).
School of Business
Shares held by key managerial personnel or director [shares] 33,280 [shares] 0
Key managerial personnel or director remuneration [Abstract]
Gross salary to key managerial personnel or director [Abstract]
Salary key managerial personnel or director 40,00,000 53,36,100
Perquisites key managerial personnel or director 0 0
Profits in lieu of salary key managerial personnel or director 0 0
Gross salary to key managerial personnel or director 40,00,000 53,36,100
Sitting fees key managerial personnel or director 0 0
Stock option key managerial personnel or director 0 0
Sweat equity key managerial personnel or director 0 0
Commission as percentage of profit key managerial personnel or director 0 0
Other commission key managerial personnel or director 0 0
Other compensation key managerial personnel or director 0 0
Total key managerial personnel or director remuneration 40,00,000 53,36,100
[301000] Notes - Corporate social responsibility

01/04/2016
to
31/03/2017
Disclosure of corporate social responsibility explanatory [TextBlock]
Whether provisions of corporate social responsibility are applicable on
No
company
154

Annual Report

Uploaded by

Document Information

Original Description:

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Annual Report

Uploaded by

Copyright:

Available Formats

MEDPLUS HEALTH SERVICES PRIVATE LIMITED

Standalone Financial Statements for period 01/04/2016 to 31/03/2017

[400100] Disclosure of general information about company

Disclosure of principal product or services [Table] ..(1)

[400400] Disclosures - Directors report

Details of directors signing board report [Table] ..(1)

Unless otherwise specified, all monetary values are in INR

Details of significant and material orders passed by

Textual information (1)

Disclosure in board of directors report explanatory [Text Block]

MedPlus Health Services Private Limited

Amount (In Rs)

Particulars 31st March, 2017 31st March, 2016

Income from Operations (Including other Income) 21,648,642 22,439,160

Total Expenses 44,875,208 75,536,193

Profit/Loss before Tax (19,498,545) (43,035,759)

Profit/Loss after Tax (19,498,545) (43,035,759)

Balance carried to Balance sheet (19,498,545) (43,035,759)

1.1 PERFORMANCE AND FINANCIAL HIGHLIGHTS:

1.2 FUTURE OUTLOOK:

3 CHANGE IN THE NATURE OF BUSINESS, IF ANY:

S. No. Date of Board Meetings

1. 22nd April, 2016

2. 28th May, 2016

3. 06th September, 2016

4. 14th November, 2016

5. 14th March, 2017

S. No. Name of Director Designation No. of Board Meetings attended

1. Mr. G. Madhukar Reddy Managing Director 5

2. Mr. Cherukupalli Bhaskar Reddy Director 5

3. Mr. Roy Edwin Campbell II Nominee Director 1

4. Ms. Sudha Ravi Nominee Director 2

The following is the Committee constituted by the Company:

Composition Designation No. of Meetings entitled to attend No. of Meetings attended

Mr. G. Madhukar Reddy Member 3 3

Mr. Roy Edwin Campbell II Member 3 1

Ms. Sudha Ravi Member 3 2

*Mr. C. Bhaskar Reddy Member 1 1

8 DIRECTORS AND KEY MANAGERIAL PERSONNEL:

S. No. Name of Director Designation

i. Mr. G. Madhukar Reddy Managing Director

ii. Mr. Cherukupalli Bhaskar Reddy Director

iii. Mr. Roy Edwin Campbell II Nominee Director

iv. Ms. Sudha Ravi Nominee Director

v. Mr. Atul Kumar Agarwal Chief Financial Officer

vi. Mr. Parag Kumar Jain Company Secretary

9 STATEMENT ON DECLARATION GIVEN BY THE INDEPENDENT DIRECTORS:

10 CHANGES IN SHARE CAPITAL:

11 DIRECTOR’S RESPONSIBILITY STATEMENT:

12 NAMES OF THE SUBSIDIARIES/ASSOCIATES/JOINT VENTURES:

The following are the Subsidiaries of your Company:

· Optival Health Solutions Private Limited

· Ritemed Pharma Retail Private Limited

· MHS Pharmaceuticals Private Limited

· PanIndia Pharma Distributors Private Limited

· Ritecure Pharma Private Limited

· Medsupply Distributors Private Limited

The following are the step subsidiaries of your Company:

· Sai Sridhar Pharma Private Limited

· Venkata Krishna Enterprises Private Limited

· Shri Banashankari Pharma Private Limited

· Deccan Medisales Private Limited